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Abstract 
The biopharmaceutical industry is becoming increasingly reliant on recombinant 
proteins as therapeutic agents. The work presented here details the development of 
rapid mammalian expression systems and novel capture methods for use in early 
recombinant protein development.  
A key aim was to investigate expression of recombinant proteins via cost effective 
production methods and to compare the resultant products at small scales of 
manufacture. A model single chain variable fragment Fc conjugate (scFv-Fc) targeted 
against a clinically relevant glycoprotein, the carcinoembryonic antigen (CEA), was 
expressed and characterised using both transient and stable-based expression of 
transgenic DNA. Transient gene expression in suspension HEK293 cells produced a 
maximum scFv-Fc level of 72µg/mL, which was used for initial protein 
characterisation. A stable pool of transfected CHO cells was also generated using a 
ubiquitous chromatin opening element (UCOE)-based vector achieving increased 
protein expression and culture periods when combined with a fed-batch regimen. 
Characterisation of the resulting proteins showed that stability and effector function 
was maintained across transient and stable production methods at all scales, indicating 
that preliminary data generated from transient expression in HEK293F cells could be 
generalised to predict that of protein stably expressed in CHO cell populations.   
A significant bottleneck in harvesting and purifying proteins from cell containing feed 
streams is the requirement for solid-liquid separation prior to capture. Therefore, a 
technique was proposed for direct capture of recombinant protein from unclarified 
feed streams that can integrate directly into the bioreactor harvest line. The process 
was demonstrated using immobilised metal affinity chromatography (IMAC) capture 
of recombinant CEA with a polyhistidine (His6) tag from a bioreactor culture. This 
provides a basis for direct primary capture of recombinant proteins from unclarified 
mammalian cell feed streams that could be generalized to other capture methods and 
proteins.  
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Chapter 1 Introduction 
1.1 Recombinant proteins as therapeutics 
Proteins are macromolecules formed of amino acid chains folded into three-
dimensional structures. They play a dynamic role in almost every cellular function 
from receptor signalling and motility to catalytic reactions and cellular differentiation 
(Leader et al., 2008).  
This functional variety of protein activities and the advent of recombinant DNA 
technology have combined to provide vast opportunities for the commercial 
development of recombinant proteins as production means become more efficient. 
Enzymes are now used routinely for biocatalytic reactions in industry enabling their 
use in everything from agriculture and bioremediation to medicine and food 
preparation (Demain and Vaishnav, 2009). Further exploitation and manipulation of 
recombinant protein structure and function for therapeutic uses has brought about the 
rise of the biopharmaceutical industry.  
Some therapeutic proteins can be purified and utilised in their natural state from 
donors e.g. pancreatic enzymes or human growth hormone, or alternative sources 
such as native proteins from plants and microbes. However isolation of protein coding 
genes via recombinant DNA technology has facilitated movement of DNA into 
transgenic host cells for improved production. Transgenic expression of these proteins 
achieves reduced associated costs and improves the safety and quality of the product. 
Molecular and synthetic biology has also allowed the precise engineering of DNA 
sequences in order to create novel therapeutic proteins targeted for specific 
indications.  
The list of licensed recombinant therapeutics currently includes hormones, enzymes 
and immunoglobulins amongst others. The year on year sales of biologics has 
outpaced many predictions as technology has advanced enabling improved protein 
engineering, product safety and yield (Figure 1.1 Growth in sales of biologics and 
antibodies in the US from 2002-2012. Data collated from (Aggarwal, 2014, 2012, 
2011, 2010, 2008,; Chames et al., 2009; Dimitrov and Marks, 2009).  
 21 
Monoclonal antibodies (mAbs) and antibody derivatives in particular have emerged 
as a class leader in the treatment of many diseases, with successes in oncology and 
autoimmune disorders. In 2012 the market for biologics was $63.6 billion, of which 
antibodies generated $24.6 billion (Elvin et al., 2011, Aggarwal, 2014). The number 
of potential targets for immunotherapy is ever increasing thanks to improved 
understanding of disease (Pillay et al., 2011)  and the FDA approved biologics list has 
seen a rapid increase over the last 10-15 years with a total of around 90 now in use 
(Kinch, 2015). Still, biologics development continues at a rapid rate with commercial 
pipelines around the world highly dependent on them for new growth. The percentage 
increase of biologics and antibody sales have closely followed each other over the last 
10 years with 70% and 78% increases in sales respectively.  
 
Figure 1.1 Growth in sales of biologics and antibodies in the US from 2002-2012. 
Data collated from (Aggarwal, 2014, 2012, 2011, 2010, 2008,; Chames et al., 2009; 
Dimitrov and Marks, 2009). 
Whilst the general use of recombinant therapeutic proteins has increased, the time and 
costs associated with their development remains exceptionally high, primarily due to 
the challenges encountered during rapid expression and characterisation of large 
numbers biologics from host systems and the high risk of product failure at clinical 
stages.  
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Microbial expression systems have significant advantages over mammalian cells for 
expression and processing purposes, however mammalian expression of complex 
proteins remains a costly necessity adding significant challenges to the industry. 
Improved mammalian cell specific productivity, feeding strategies and protein 
engineering have combined to produce cell densities in excess of 1x107cells/mL and 
yields of up to 8g/L (Farid, 2007; Hacker et al., 2009). However these advances have 
in turn created new challenges for downstream processing, leading to a focus on 
development of high capacity methods for the primary capture of protein from high 
cell density feeds. 
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1.2 Antibodies 
1.2.1 Structure and function of antibodies 
The immunoglobulin protein superfamily contains many proteins that share subunit 
structures and binding properties including cell surface receptors and soluble proteins. 
Antibodies are immunoglobulins that consist of two polypeptide chains of 55 kDa 
each and two of 22 kDa known as the heavy and light chains respectively. Disulphide 
bridges and non-covalent bonds hold these chains together forming a Y-shaped 
protein of approximately 155 kDa (Figure 1.2 Antibody IgG1 Structure). 
 
Figure 1.2 Antibody IgG1 Structure. Two light and two heavy chains of 22 kDa 
and 55 kDa respectively make up a whole antibody. These can be separated into the 
Fab and Fc regions that are linked by the hinge region. The three complementarity 
determining regions are located in the variable region of each chain (adapted from 
Natsume et al., 2009).  
The molecule can be divided into two regions as characterised by observed 
fragmentation after proteolytic cleavage by the enzymes papain and pepsin (Porter, 
1959; Nisonoff et al., 1960). Cleavage via papain produces a set of three fragments, 
two of which display antigen-binding properties (Fragment Antigen Binding- Fab) 
and contain highly variable regions responsible for specificity of an antibody to its 
epitope (Jones and Gellert, 2004). The third fragment is termed the Fc or Fragment 
crystalline after its crystallisable structure. Antibody isotypes can be classified into 
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five groups (IgG, IgM, IgA, IgE and IgD) depending on the type of heavy chain 
constant regions. 
1.2.2 Glycosylation of recombinant proteins and antibodies 
Glycosylation of recombinant proteins is the covalent addition of an oligosaccharide 
sugar group to specific amino acid residues, occurring in the endoplasmic reticulum 
and Golgi apparatus. Interactions between oligosaccharides via hydrogen bonding 
contribute to the overall folding and structure of the protein, hence glycosylation 
affects many properties including electrical charge (pI), solubility, mass, size and 
effector function (Jefferis, 2012, 2008).  
Oligosaccharide attachment can be in either N-linked or O-linked forms. N- linked 
glycosylation is the attachment of branched mannose and glucose containing 
oligosaccharides to an asparagine in the amino acid sequence asp-X-ser/thr. In 
mammalian cells enzymatic removal of various residues from the high mannose 
structure enables protein folding, with assistance from chaperones, before further 
reduction of the oligosaccharide and transit to the Golgi apparatus where final 
adjustments form a complex diantennary structure (Figure 1.3 Glycosylation of 
antibody CH2 domainand Figure 1.5 Examples of yeast, plant, insect and human 
glycosylation structures). N-linked additions can be extended in a branched fashion 
whilst O-linked glycosylation is extended in a single chain at serine or threonine 
residues and the oligosaccharide chains are capped by sialic acid or phosphate group 
addition. For a full review of antibody glycosylation structure and mechanism see 
Jefferis, 2008.  
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Figure 1.3 Glycosylation of antibody CH2 domain. Correct glycosylation of 
antibody CH2 domains at Asn297 is required for proper effector function and to 
reduce immune response in patients.  
 
1.2.3 Effector function 
Antibodies function as immune effector proteins with specific affinity for molecular 
targets known as antigens based on their variable domain CDR regions. The Fc region 
has multiple effector functions enabling coupling of antigen recognition and immune 
response as well as moderating pharmacokinetics (Zalevsky et al., 2010). Once bound 
to an antigen, antibodies can stimulate the innate immune system to destroy the target 
either via antibody dependant cell-mediated cytotoxicity (ADCC) or by a system of 
protein cascades known as complement dependant cytotoxicity (CDC) (Gelderman et 
al., 2004). ADCC involves initiation of cytotoxic action against targets via Fc binding 
to FcγR (CD16) receptors on cytotoxic cells called natural killers to induce 
degranulation (Woof and Burton, 2004). These innate properties enable the use of 
antibodies as therapeutic agents to target a number of diseases.  
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1.2.4 Therapeutic applications 
Paul Ehrlich originally described an ideal ‘magic bullet’ therapy that could directly 
bind to a single specific target in the early 1900’s. Kohler and Milstein realised this 
concept in 1975 by pioneering hybridoma technology allowing the identification, 
isolation and in vitro culture of a clonal population of antibody-producing B-cells.  
Hybridoma technology uses a mouse model to produce antibodies of interest after 
exposure to an antigen. Once an immune response has developed, differentiated B-
cells can be removed and fused to an immortalised myeloma cell line to produce a 
clonal hybridoma that can be cultured in vitro (Köhler	   and	   Milstein,	   1975). 
Hybridoma cells can then be selected via screening for expression of the desired 
antibody. 
During the 1980’s the first monoclonal antibodies (mAbs) were developed for 
treatment of cancerous diseases, allowing highly specific targeting of molecules on 
cells, known as markers. Early in vitro and in vivo experiments with mAbs were 
encouraging, however the results in human patients were less spectacular. Clinical 
trials resulted in immunogenic responses as patients developed Human Anti-Mouse 
Antibodies (HAMA) resulting in rapid clearance from the body and reduction in 
efficacy (Tjandra et al., 1990). The need to make antibodies less recognisable to the 
immune system was established by the reduction in immune system activity in 
response to humanised antibodies (Mirick et al., 2004). Antibody engineering 
Recombinant DNA technology enabled manipulation of genetic regions to construct 
and combine regions of antibodies into new proteins.  The HAMA response was over 
come by replacing mouse constant regions with those of a human antibody creating a 
chimeric molecule that reduced the exposure of foreign regions to the immune 
system.  
Biogen IDEC (Massachusetts, USA) produced the first chimeric antibody, Rituximab, 
which was licensed by the FDA in 1997. Rituximab is a mouse-human chimeric 
antibody targeted at CD20 for B-cell destruction, a therapy for non-Hodgkin’s 
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lymphoma and other autoimmune disorders (McLaughlin et al., 1998; Reff and 
Heard, 2001).  
Further advances in humanisation of antibodies include CDR grafting, where the 
affinity defining CDR regions from mouse antibodies are grafted onto a human 
antibody scaffold leaving a final product with only 5-10% murine sequence compared 
to around 65% in chimeric antibodies (Winter and Harris, 1993). The first fully 
humanised antibody was trastuzumab from Roche in 1998, an anti-HER2 breast 
cancer treatment, that has since become one of the most successful treatments 
available (Bryant, 2006). 
Therapeutic applications of monoclonal antibodies now include the recruitment of the 
immune system for cytotoxic action, receptor and ligand interaction blocking and as 
vehicles for drug delivery (Reff and Heard, 2001; Berger et al., 2002; Filpula, 2007; 
Weiner et al., 2010; Alley et al., 2010; Beck et al., 2010; Pillay et al., 2011; Redman 
et al., 2015). Conjugations of mAbs to cytotoxic, enzymatic or radiolabelled drugs 
maximises target specific treatment whilst reducing non-specific cell death (bystander 
effect). A table containing examples of conjugated antibodies can found in Parakh et 
al., 2016 and Scott et al., 2012. 
Aside from their use in therapeutic applications, antibodies have been used in research 
to track, detect, label and alter targets. However the majority of research purposed 
antibodies are polyclonal, originating from a range of B-cells after animal 
immunisation or from hybridoma cells often leading to irreproducible data. Hence, 
there is a concerted effort amongst the research community to use recombinant 
antibodies, which are fully characterised and sequence defined where possible 
(Bradbury and Plückthun, 2015). This will have a significant effect on the number of 
recombinant antibodies in use reinforcing the need for rapid production and 
characterisation.  
1.2.5 Antibody fragments 
Recombinant DNA technology has provided the potential to define antibody affinity 
contributing significantly to their success in both analytical and medical applications. 
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Phage display libraries, in particular, have been successful in producing antibodies 
specific to almost any target (McCafferty et al., 1990). This technology uses probing 
of a library of 107-1010 protein coding combinations with varying diversity (Qin et al., 
2007), for affinity to the chosen molecule and can be carried out using DNA 
recombination, human naïve or semi-synthetic libraries. Phage display can be used to 
develop novel binding fragments out of a library of around 10-100 fold the diversity 
of a naïve library. Thus screening of phage libraries can generate many potential 
candidates with antigen-binding properties (Hoogenboom and Chames, 2000).  
Although the scFv products of phage display can be manufactured as whole 
antibodies, there are often advantages of using antibody-based derivative proteins 
instead. For instance initial manufacture and characterisation of proteins is more 
easily carried out in different formats including scFv-Fcs.  
Antibody derivatives are formed of rearranged polypeptide chains to make novel 
antibody fragments such as single chain variable fragments (scFv) and diabodies 
amongst others (see Figure 1.4 Antibody Fragments). These retain the specific antigen 
binding properties of a whole antibody but may provide an improved bio-distribution 
in vivo (Holliger and Hudson, 2005). Whilst the large majority of regulatory 
submissions remain for whole antibodies, fragments are also entering clinical trials 
with increasing frequency (Nelson, 2010; Reichert, 2015), and as such antibody based 
therapies are expected to continue as one of the most profitable areas of the 
pharmaceutical industry in the next decade (Beck et al., 2010; Aggarwal, 2014), 
without necessarily remaining based on whole antibodies.  
 Fab fragments and single chain variable fragments (scFv) are the most common small 
antibody molecules used. Advantages of these smaller molecules include simple 
synthesis that can be achieved using bacteria and thus a reduced cost of production. 
The smaller size and weight of the fragments also changes the pharmacokinetics once 
in the body, essential when penetration of solid tumours is required. For a 
comprehensive review of single chain variable fragments and other antibody 
derivatives used as therapeutics see Gebauer and Skerra, 2015 or Holliger and 
Hudson, 2005.  
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Figure 1.4 Antibody Fragments. Left to right – a whole IgG antibody, a single chain 
variable fragment-Fc fusion protein (scFv-Fc) and a single chain variable fragment 
(scFv). Complementarity determining regions are marked as in Figure 1.2.  
 
Applications of antibody fragments include conjugation to toxins, radioactive labels 
and bioactive components such as enzymes. Using this set of conjugative payloads 
antibody fragments can be used to image, diagnose and treat disease with increased 
efficacy. However those antibody structures without an Fc region lose activation of 
FcyR or complement and thus immunomodulation of the cytotoxic cells of the innate 
immune system. Engineered multivalent antibody fragments can specifically bind to 
more than one antigen, with different target affinities at each variable region. There 
are many different formats of multivalent antibody fragments; some of which are 
designed to address the lack of an Fc using specificity to an antigen of choice and to 
innate immune cells. Multivalent antibody fragments can also be used to bring other 
cells and molecules into close proximity (Morrison, 2007). 
Dual variable antibodies along with a range of multivalent antibodies have two or 
more antigen specificities on a single variable region achieved by insertion of a 
polypeptide loop into a CDR region or antibody variable domain linking. Advantages 
of this include increased avidity for antigen targets and improved cell targeting (Gu 
and Ghayur, 2012; Wu et al., 2007). 
Conjugation of an scFv to an Fc fragment can reinstate immunomodulatory properties 
and provides a convenient cloning platform for scFv fragments produced via phage 
display libraries. However conjugation to an Fc also increases the size and complexity 
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of the molecule making mammalian expression necessary due its glycosylation 
requirements. 
1.3 Bioprocessing 
Bioprocessing of recombinant proteins is the procedure whereby a transgenic cellular 
expression system is grown under fermentation conditions to produce a protein and its 
subsequent recovery and purification. The process can be broadly split into upstream, 
fermentation and downstream stages. Upstream stages include protein engineering, 
expression plasmid design and transgene integration into host cells whilst 
fermentation is the growth of the host system and expression of the recombinant 
protein. Downstream processing is concerned with separation and recovery of the 
product through to polishing and formulation of the final product.  
Expression systems used to produce proteins using recombinant DNA technology 
include simple microorganisms, mammalian cells, transgenic plants, insects cells and 
animals (Andersen and Krummen, 2002; Assenberg et al., 2013). Suspension-based 
microbial and mammalian cell culture is particularly well suited to large-scale 
fermentation that can be scaled up from laboratory research to meet industrial 
demands. 
The cost of manufacture of recombinant proteins in mammalian cell expression 
systems is exceptionally high compared to those from microbial sources. However 
COG (Cost of Goods)/g is reducing thanks to improvements in upstream technology 
and feeding providing mammalian cell densities in excess of 1-1.5x107cells/mL and 
yields of 8g/L, (Farid, 2007; Hacker et al., 2009). The cost of mammalian cell culture, 
lengthy production times and complex down stream processing combine to increase 
costs for patients (Birch and Racher, 2006). 
Addressing these issues is a priority for industry. Synthetic approaches to 
manipulating metabolic and biosynthetic pathways have already provided 
improvements in antibody production and alternative expression systems are also 
being explored (Wurm, 2004, Durocher and Butler, 2009). Downstream processing 
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and recovery techniques have also improved by utilising novel solid-liquid separation 
and chromatographic recovery steps (Warikoo et al., 2012).  
1.4 Expression of recombinant proteins  
Expression of recombinant proteins has for many years been carried out in a number 
of host systems including yeasts, bacteria, plants, transgenic animals and both 
cultured insect and mammalian cells. The advantages and disadvantages of the main 
expression systems are listed in Table 1.1 Expression system advantages and 
disadvantages. The decision on which expression system to use is often dictated by 
the eventual function of the protein and therefore it’s necessary quality, production 
speed or scale and its cost.  
Microbial expression systems are used to produce the majority of recombinant 
proteins at industrial and laboratory scale thanks to their simple and low cost 
requirements for growth. Strains of Escherichia coli and Bacillus subtillis are widely 
used bacterial expression systems (Demain and Vaishnav, 2009). They are very well 
characterised and many fully sequenced strains are available that can be easily 
manipulated using synthetic and molecular biology approaches. Yeast expression 
systems are also widely used, especially Saccharomyces cerevisiae and Pichia 
pastoris, as they are capable of exceptionally high yield and can perform some 
glycosylation on more complex proteins (Cregg et al., 2000; Miller et al., 2005; 
Mattanovich et al., 2012). 
 Microbes remain ideal expression systems as they are highly cost effective, allow for 
simple, high yield fermentation systems and grow to very high cell densities (Demain 
and Vaishnav, 2009). However not all systems are appropriate for the production of 
complex proteins such as antibodies and Fc conjugates due to their size and complex 
nature (Buck et al., 2013; Jacobs et al., 2008).  
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Transgenic 
expression system 
Advantages Limitations Reference 
Bacteria  Rapid expression, 
yield, simplicity, 
cost effective and 
well suited to mass 
production 
(scalable).  
Disulphides hard to 
express, no 
glycosylation, 
endotoxins, inclusion 
bodies require 
refolding.  
Terpe, 2006 
Yeast Yield, cost effective, 
high cell density, 
rapid growth, some 
glycosylation, stable 
strains, and good 
approval rate.  
High mannose type 
glycosylation limits 
complex protein 
expression, very high 
cell density for DSP. 
Mattanovich et 
al., 2012 
Insect PTM, proper folding, 
strong promoters, 
yield, approval rate, 
large proteins 
possible, scale up.  
Different 
oligosaccharide chain 
extension, inactive 
cleavage sites, high 
O2 demand.  
Cox, 2012 
Mammalian Large complex 
proteins, yield, scale 
up, convenience for 
approval. 
Cost of media, time 
for stable cell 
selection, limited cell 
density, process 
implications (shear). 
Matasci et al., 
2008; Wurm, 
2004; Zhu, 
2011 
Plant Cost effective, scale 
out, PTM, low safety 
risk, some complex 
proteins produced, 
simple DSP. 
Space and control of 
transgenic plants, 
limited PTM, 
immature technology.  
Franconi et al., 
2010; Pogue et 
al., 2010 
Animals Yield, processing in 
place (e.g. dairy), 
approval.  
Cost, time and 
potential safety 
concerns 
Wang et al., 
2013 
Table 1.1 Expression system advantages and disadvantages. Many cell types can 
be used for recombinant protein expression, however some are not currently 
applicable for production of therapeutic proteins for in vivo use.  
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1.4.1 Expression system glycosylation 
Unlike translation of a polypeptide from mRNA, the glycoprofile of a protein is not 
DNA template driven. Considerable differences can be found in the glycoprofile of 
recombinant proteins, as glycosylation can be dependant on expression system and 
environment. This heterogeneity is termed either macroheterogeneity (i.e. whether a 
residue is/ is not glycosylated), or microheterogeneity (i.e. which oligosaccharide 
structure has been attached to a site) (Potgieter et al., 2009). 
The necessity for correct protein glycosylation, especially in therapeutic use, can be 
demonstrated by the reduction in effector function or even immune reaction to some 
glycosylated proteins. This can range from non-functional proteins resulting from 
bacterial expression, where no glycosylation is present (Buck et al., 2013), to patient 
immune response to high mannose or xylose containing oligosaccharides from yeast 
and plants (Demain and Vaishnav, 2009; Jacobs et al., 2008; Jefferis, 2012). An 
example of the different host glycosylation structures are illustrated in Figure 1.5 
Examples of yeast, plant, insect and human glycosylation structures.  
Hence, although microbial expression systems are used to produce the majority of 
industrial recombinant proteins, those requiring glycosylation for correct structure and 
function, such as Fc containing proteins, are preferentially expressed in mammalian 
host systems (Wurm, 2004; Zhu, 2011; Lai et al., 2013; Dean and Reddy, 2013).  
This challenge is being addressed using synthetic glycoengineering of expression 
systems in order to create human-like glycosylation structures as discussed by 
Durocher and Butler, 2009 and Potgieter et al., 2009 including successes such as 
Novozymes (Denmark) recombinant human albumin S. cerevisiae expression system. 
Further glycoengineering of recombinant proteins has been demonstrated by altering 
antibody effector function after reduction of fucosylation present on the CH2 domain 
of the Fc region of IgGs for improved ADCC (Okazaki et al., 2004; Shields et al., 
2002).  
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Figure 1.5 Examples of yeast, plant, insect and human glycosylation structures.  
Adapted from Jefferis, 2008 and Jacobs and Callewaert, 2009. Glycosylation 
structures vary substantially between species types. These differences can have 
significant impacts on immunogenicity and therefore host system of choice during 
protein expression. NGNA- N-Glycolylneuraminic acid. 
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1.5 Mammalian cells as expression hosts 
Mammalian cells are used to produce the majority of biopharmaceuticals. The 
popularity of mammalian expression systems stems from the relative ease of product 
approval, complex posttranslational glycoprotein modifications and a large base of 
methodology to support their use (Wurm, 2004; Zhu, 2011; Lai et al., 2013). The 
average amount of recombinant protein produced in mammalian cells has increased 
100 fold since the 1980s (Wurm, 2004). These increases in productivity are owed to 
several factors including the generation and selection of cell lines with high viability, 
improvements in fermentation techniques and improved expression plasmid design. 
Mammalian expression systems that meet today’s industrial scale protein demands 
became a reality after adherent cells were adapted to growth in a suspended state. 
Adherent cells are inefficient for mass cell culture, as they require high surface areas 
and maintenance. Microcarrier based cell culture expands the available surface area 
for cell cultivation of anchorage dependant cells using small particle spheres of 
around 500 µm diameter (Justice et al., 2009). However adaptation of anchorage 
dependant cell lines to growth in suspension can be achieved making the use of micro 
carriers redundant, saving costs and simplifying downstream processing of material at 
industrial scale.  
Cells rely on signals and nutrients provided in serum for proper growth. In 
mammalian cell culture foetal bovine serum (FBS) is used as a substitute for the 
natural serum that surrounds a cell. However serum from bovine sources has potential 
for viral contamination and remains expensive therefore is unsuitable for large 
recombinant therapeutic production. Cells adapted to growth in serum free media 
remove the problems associated with animal based products for therapeutic use. 
Sequential adaption of cells can be achieved by gradually swapping serum-based 
media for serum free media over a period of passages (Sinacore et al., 2000).  
Suspension adapted mammalian cells are grown in shaken flasks at laboratory scale 
and fermentations can now be carried out at 20,000L capacity in stirred tank 
bioreactors for industrial production of recombinant proteins. There are multiple 
platforms for mammalian cell culture aiming to increase productivity and cost 
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efficiency whilst reducing reactor downtime e.g. disposable reactors such as the Wave 
bioreactor (GE Healthcare) or continuous perfusion feeding strategies.   
1.5.1 Common mammalian expression hosts 
A number of mammalian cells are in common use for protein expression taking 
advantage their unique properties. Cells from human, Chinese Hamster, monkey and 
murine donors are used regularly (See Table 1.2). However CHO cells remain the 
dominant expression system, currently used to express over 70% of recombinant 
therapeutics (F. Li et al., 2010). There are a number of reasons for the popularity of 
CHO cells including their yield, high cell density, regulatory familiarity and 
established production protocols (Durocher and Butler, 2009; Kunert and Reinhart, 
2016). Although not human cells they can achieve glycosylation more similar to 
humans than murine cells (see Figure 1.6)  
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Figure 1.6 Comparison on human, CHO and NSO glycosylation (Adapted from 
Fliedl et al., 2014 and Butler, 2005). Glycosylation structures remain relatively 
constant across recombinant protein production mammalian host systems.  
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Expression host  References 
Chinese Hamster Ovary 
(CHO) 
Clincke et al., 2013; Kim 
et al., 2013; Wernicke and 
Will, 1992; Ye et al., 2009 
Human Embryonic 
Kidney (HEK293) 
Backliwal et al., 2008a; 
Cervera et al., 2011; 
Durocher et al., 2002; 
Thomas and Smart, 2005 
Murine Myeloma (NS0, 
SP2/0) 
Dietmair et al., 2012; 
Wurm, 2004 
Human Embryonic 
Retinoblast (PERC.6) 
Lewis et al., 2006; Pau et 
al., 2001; Zhu, 2011 
African Monkey Kidney 
(COS, VERO) 
Fliedl and Kaisermayer, 
2011 
Table 1.2 Mammalian expression hosts. Multiple expression host system have been 
generated from mammalian cells of different species however CHO cells remain the 
standard industrial cell line for recombinant protein expression. Further descriptions 
of cell lines can be found in Khan, 2013. 
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1.5.2 Expression plasmid design 
Non-viral vectors are most often used for the expression of recombinant therapeutic 
proteins over retroviral vectors. Expression of recombinant proteins in mammalian 
cells is generally driven using strong, constitutive promoters. Popular viral promoters 
include the cytomegalovirus (CMV), human T-cell leukaemia virus (HTLV) or the 
simian virus 40 (SV40). These viral promoters can be combined with cellular 
equivalents such as constituents of the elongation factor 1 alpha (E1Fα). Composites 
of viral and cellular promoters are often used to drive particularly strong expression 
often combined with elements designed to effect mRNA transcription and half-life.  
Transcriptional elements involved in mRNA processing involve the inclusion introns 
that have been shown to play significant role in the increased protein expression 
during (pre) mRNA splicing (Le Hir et al., 2003). Translation initiation can be 
improved using elements such as the Kozak sequence, a consensus sequence that is 
present at the region immediately before translation. This has been shown to differ 
according to expression system (Nakagawa et al., 2008).  
The posttranslational modifications (PTM) and fate of proteins can also be modified 
in the design of plasmids. These include the addition of polyadenylation and secretion 
signal sequences that control the location of recombinant proteins. Further protein 
engineering at this stage includes the addition of affinity tags and selection markers as 
discussed in 1.7.4 Affinity tags and 1.6.5 Stable transgene integration.  
1.5.3 Transfection 
Recombinant protein expression in mammalian cells is achieved by the introduction 
of transgenic DNA. There are a number of techniques available that move DNA into 
the nucleus including mediation by transduction (viral delivery) or transfection 
(chemical or physical methods) (see Figure 1.7). Introducing foreign nucleic acids 
into mammalian cells can be used for analysis of gene and protein function, knocking 
out genetic elements as well as recombinant protein production.   
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Figure 1.7 Introducing DNA into mammalian cells. Examples of three methods for 
DNA integration into mammalian cells including electroporation induced pore 
formation, viral mediated transduction and cationic liposome mediated transfection. 
All three methods can be used for transient or stable cell generation, however this 
diagram is far from exhaustive.  
        
Whilst transduction is an excellent gene delivery system, it is limited by its nucleic 
acid payload capacity and potential safety concerns in therapeutic use. In contrast 
transfection via chemical methods, such as cationic liposome formation, are the most 
widely used, as they are simple and effective. The range of available transfection 
reagents can also be expensive and in many cases have cytotoxic effects. Physical 
methods often rely on transient membrane pore formation e.g. electroporation 
(Ehrhardt et al., 2006), however these techniques can be reliant on expensive 
equipment. A full discussion of the advantages and disadvantages of gene delivery 
methods can be found in Kim and Eberwine, 2010. 
The exact methods of nucleic acid entry and translocation into cells is not yet fully 
characterised with conflicting evidence in the literature (Akinc et al., 2005; 
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Benjaminsen et al., 2013). However it has been shown that cell passage through 
mitosis is a prerequisite for transfection (Mortimer et al., 1999) using popular cationic 
polymers such as polyethylenimine (Durocher et al., 2002; Ehrhardt et al., 2006). 
Hence cell cultures under going rapid division are necessary for successful 
transfections of recombinant protein expression systems. Translocation of DNA to the 
nucleus or episomal space for transcription and translation is necessary for protein 
expression (Jäger et al., 2013).  
1.5.4 Transient transgene expression  
Transient gene expression (TGE) is widely used for cell research (Elias et al., 2003) 
and rapid production of recombinant proteins in mammalian cells (Wurm, 2004). 
Advantages of TGE include simple methodology and speed of expression; purified 
recombinant protein can be obtained within a few days, whilst stable gene expression 
(SGE) requires a laborious, time consuming selection process often taking weeks to 
months (Backliwal et al., 2008c). Transient gene expression therefore lends itself 
particularly well to early stage expression of proteins such as biotherapeutic for 
preclinical characterisation and low quantity assays. 
Transgenes that are not integrated into the genome are removed from the cell within a 
matter of days or diluted during cell division (Matasci et al., 2008). As well as 
providing valuable material for preclinical performance studies, TGE has also been 
utilised in the analyses of manufacturability of candidates.  
Transient gene expression can be used to predict the expression characteristics of 
recombinant proteins in given expression systems expression characteristics of similar 
recombinant proteins are not necessarily the same (Bentley et al., 1998; Pybus et al., 
2014b). Ye et al., 2009 showed that there was no difference in glycosylation profile 
between transient and stabley expressed proteins therefore TGE is often used to 
produce the first quantities of novel proteins for use preclinical and early in vivo 
experimental work prior to committing to stable cell selection (Agrawal and Bal, 
2012).  
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The high transfection efficiency and yield of the human embryonic kidney (HEK293) 
cell line has meant it has been widely adopted over CHO cells (Sun et al., 2008). 
However as the majority of industrial scale culture uses CHO cells in stable form 
there is also a demand for high expressing transient systems in CHO to improve 
modelling of protein activity from stable cells (Derouazi et al., 2004). Although ideal 
for laboratory scale expression, transient transfection has limited usage in large-scale 
production due to difficulties in producing consistently homogenous products, 
requirements for large amounts of DNA (>mgs) and repeated transfections to continue 
production. 
The lack of selection requirements simplifies vector construction for transient systems 
however expression performance can be improved via design of transgene vectors to 
increase the expression of the DNA. Examples include incorporation of transcription 
factor X-Box binding protein 1 (XBP1) to improve secretion (Codamo et al., 2011), 
the cytomegalovirus (CMV) promoter that is commonly used (Boscolo et al., 2011; 
Zhu, 2011) and by optimisation of transfection cell densities and methods (Backliwal 
et al., 2008b; Durocher et al., 2002).  Using these systems transient protein expression 
can produce up to 1g/L quantities of protein in HEK293s (Backliwal et al., 2008a).  
1.5.5 Stable transgene integration  
Transgenic DNA integrated into the genome via homologous recombination provides 
long term, defined expression of a transgene in a cell. Once a transgene is integrated 
into the genome it is expressed constituently as part of the cells proteome removing 
the need for further transfections. The advantages of stable cell integration include 
constitutive expression, high yields and genomic heritage of daughter cells enabling 
high cell density fermentation and cryopreservation of cell lines. 
Stable genomic integration of transgenes is a rare event; hence cells are selected using 
a marker that confers a selection advantage on those cells. As such transgene 
constructs destined for stable cell generation contain markers, antibiotic resistance 
genes or metabolic enzymes, included in the expression vector. Cell selection using 
antibiotic resistance markers employs growth in selective media to kill those cells 
without the corresponding resistance gene, similar to bacterial selection. Problems 
 43 
with antibiotic selection occur when multiple resistance vectors are used with a single 
cell line (i.e. co-transfection) and the need to include unnecessary genetic elements in 
the cell.  
Alternative selection methods used in CHO cells utilise knockout cell strains that are 
deficient for enzymes involved in key metabolic reactions such as nucleotide 
synthesis (dihydrofolate reductase (DHFR)) or glutamine synthesis (glutamine 
synthetase (GS)). In both instances inclusion of DNA coding for the missing 
metabolic enzyme in the expression vector confers a selection advantage on stably 
integrated cells. Metabolic selection involves culturing transfected cells in a media 
negative for the enzyme product i.e. glutamine or the nucleotide pre-requisites 
hypoxanthine and thymidine (Wernicke and Will, 1992). For an in depth description 
of selection markers see (F. Li et al., 2010).  
A comparison of transient and stable gene expression can be found in Table 1.3 
Transient and stable gene expression.  
Table 1.3 Transient and stable gene expression 
 Time 
period 
Expression 
system 
Yield Scale Application 
Transient 
Expression 
 48hrs – 
14 days 
HEK293 and 
CHO 
10mg-
100mg/L 
<100L Preclinical and 
research  
Stable 
Expression 
3 
Months+ 
CHO g/L Up to 
20,000L 
Large scale for 
therapeutic use 
 
1.5.6 Mammalian cell fermentation 
Shake flask and bioreactor growth of suspension-adapted cells enables very high cell 
density cultures at large and small-scale operation. Key factors in the ability to gain 
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high cell density include the design and optimisation of media and feeding strategies, 
environmental control in bioreactors and cell engineering approaches.  
Media composition for suspension cell culture purposes uses chemically defined 
media for most batch production processes. This contains a mixture of glucose, 
specific lipids, vitamins, inorganic salts, amino acids, growth factors and trace 
elements without the need for animal sourced products. Additionally concentrated 
feed can be used to replenish spent media components in fed-batch approaches that 
extend cell culture periods and therefore increase productivity (Lu et al., 2013; Sauer 
et al., 2000). The optimisation of feeding strategies and constituents can be carried out 
using a multifactorial design of experiments approach. Semi-continuous cultures 
using perfusion systems that replace media whilst retaining cells can be used to 
increase culture period and viable densities significantly however perfusion reactors 
remain costly compared to current fed-batch processes (Pollock et al., 2013).  
Stirred tank bioreactors are the most commonly used mammalian cell culture platform 
however the need for reactor sterilisation and cleaning of these reactors adds down 
time and requires validation or cGMP processes. A range of single-use reactors are 
now in use that can be used with most suspension cultures including roller bottles the 
WAVE bag (Singh, 1999), pneumatic bioreactors (Kim et al., 2013) and singe-use 
stirred tanks (Odeleye et al., 2013).  
Cell engineering strategies can be employed to attain improved viability, and 
therefore productivity through tolerance to stresses such as shear, osmotic pressure 
and toxic accumulation. Inhibition of apoptotic pathways can be achieved by 
engineering strains to over express bcl-2 or inhibition of caspase 9 and 3 by addition 
of active site blocking peptides or bacilovirus p35 insertion (Vives et al., 2003). 
Alternatively chemical inhibition of caspase 9 and 3 has been shown to increase cell 
viability by up to 33% and improve antibody production titre by 20% in CHO cells 
(Arden et al., 2007). Metabolic engineering such as lactate dehydrogenase (LDH) 
deficient strains can produce as high as a 50% reduction in lactate synthesis and a cell 
density increase of 30% (Chen et al., 2001). 
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These methods have successfully increased culture viability and enhanced resistance 
to stresses such as toxic accumulation, nutrient and oxygen limitation or shear. 
However the overall protein production from these genetically modified (GM) cell 
lines is not as great as was anticipated A combination approach to improving cell 
viability has been suggested that could incorporate multiple modifications (Dinnis and 
James 2005; Dixit et al., 2003).    
1.5.7 Measurements of protein expression 
Fermentation and feeding strategies are designed to balance the need to promote cell 
growth and maintain volumetric productivity of a cell culture (Dean and Reddy, 
2013). Calculating specific parameters, such as the specific and volumetric 
productivity, allows the comparison of protein expression cells on a like for like basis. 
Recombinant protein yield is dependent on individual production rate of cells and the 
number of viable cells in culture; the function of these elements is the volumetric 
productivity see Equation 1 Volumetric productivity 
  U x qP= volumetric productivity 
Equation 1 Volumetric productivity 
U= cell density, qP= single cell (specific) productivity. 
Equation 2 Specific productivity of a cell culture in picograms per cell per day 
(pg/cell/day), also known as single cell productivity; 
𝑞!"#!  !!"#!"#  
Equation 2 Specific productivity 
qmAb = Specific productivity, MmAb = Mass of antibody in supernatant, ICA = 
Integral cell area  
Where mmAb is the total mass of antibody in the cell supernatant and (ICA) integral 
cell area is calculated as described in Equation 3 ICA (Integral Cell Area); 
 46 
𝐼𝐶𝐴 = 𝑁 − 𝑁! ×𝑡𝑙𝑜𝑔!  (𝑁𝑁!)  
Equation 3 ICA (Integral Cell Area) 
ICA = Integral Cell Area, N = number of cells at time point 2, N0 = No of cells at time 
point 1, t = Time.  
Where N and N0 are the number of viable cells at the end and start of the culture 
period and t is culture time.  
Maintaining a high specific yield along with a high viable cell count over an extended 
time period delivers optimum productivity for industrial cell culture.  
However the volumetric productivity of a cell culture can also be significantly 
affected by a number of factors such as cell cycle, temperature and nutrition. 
Therefore these factors must be tightly controlled. Glucose is the main source of 
energy for cells yielding lactate as a waste product that, if accumulated, can cause a 
reduction in cell growth and protein productivity (Eibl et al., 2009). Glutamine 
metabolism is also a key factor in cell growth contributing up to 30% of cell energy 
via TCA cycle oxidation with the excretion of ammonia as a waste product. Ammonia 
is particularly important as high concentrations (>5mM) can affect glycosylation of 
proteins (Xie and Zhou, 2005). Measuring the consumption of glucose and excretion 
of lactate allows for appropriate cell feeding strategies to be designed based on the 
state of cell metabolism. 
The effect of temperature on recombinant protein expression and growth of cells can 
be significant. Strategies for enhanced protein production include a temperature 
reduction to induce mild hypothermic conditions resulting in an increased portion of 
cells in G1 phase and a significant increase in protein yield compared to cultures kept 
at 37C. The glycosylation profiles of proteins from cell cultures can also be affected.  
(Agrawal and Bal, 2012; Sunley and Butler, 2010) 
In large-scale mammalian bioprocessing of antibodies a significant amount of glyco-
heterogeneity is found due to affects of environmental factors on glycosylation e.g. 
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temp, ph (Zhu, 2011). Glycosylation of antibodies produced at large scale is therefore 
an area of intense research with the aim of producing a uniform product across 
multiple batches of antibody using environmental and genetic manipulation (Hossler 
et al., 2009). 
1.5.8 Improving protein expression 
Recombinant protein expression can be improved by tackling the challenges of 
unequal genome expression, gene silencing and transcriptional control. The genome is 
not expressed equally (e.g. heterochromatin and euchromatin) thus DNA integrated at 
areas of high expression will be translated at a greater rate, this is the position effect 
(Feng et al., 2001). To gain increased volumetric productivity from a culture a clone 
with high transgene expression can be selected and cultured however this process can 
be time consuming. 
Site-specific integration is a method of targeting the locus of transgene integration to 
a transcriptionally active site allowing rapid generation of stable cells with high 
expression of a transgene. These genomic ‘hotspots’ can be targeted using 
recombinase specific DNA integration sites that are transfected into the genome and 
assayed for high expression. Subsequent co-transfection of a vector containing the 
corresponding recombinase and the recombinant DNA of interest is then integrated 
via site-specific recombination (Liu et al., 2005). 
As the sites of integration are genetically identical in the cell population, transfection 
results in an isogenic population that can be easily screened using selectable markers. 
Site-specific integration removes many of the key challenges in screening for high-
expressing stable cells.  
Alternatively incorporation of specific promoters and epigenetic modifications into a 
transgenic vector can ensure high expression at any site of integration. The universal 
chromatin-opening element is a region of DNA that has a set of promoters usually 
used for housekeeping genes allowing constitutive high expression of recombinant 
proteins. Heterochromatin formation can reduce or silence transcription of a gene. 
Non-methylated CpG vectors can be used to successfully reduce heterochromatin 
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formation around an integration site allowing expression of transgenic DNA without 
the risk of gene silencing to improve stable cell expression (Boscolo et al., 2011).  
Expression ratios of some constructs such as antibodies rely on co-transfection of 
multiple plasmids in many cases as antibody heavy and light chains are expressed at 
different rates from the genome. The optimum ratio of transgene insertion is therefore 
not an equal 1:1 heavy chain (Hc) – light chain (Lc) ratio. It has been shown 
previously that whilst heavy chain expression is a limiting factor in productivity, light 
chain expression is expressed at 2.25-fold that rate. However during folding and 
secretion of antibodies, light chain availability becomes the limiting factor. The 
highest expression and secretion rates have been found at a Hc:Lc ratio of  3:2 in 
CHO cells (Schlatter et al., 2005).  
1.6 Downstream processing and primary recovery of recombinant proteins for 
therapeutic application  
Recombinant proteins, as discussed in section 1.1, have a wide range of applications 
from therapeutic use to food processing and bioremediation. As such the techniques 
involved in purification and storage of proteins varies as much as the products 
themselves ranging from simple protein recovery through to cGMP-compliant 
processes. Proteins destined for therapeutic use have the most stringent controls on 
downstream processing protocols requiring validation to the highest levels ensuring 
product quality and sterility.  
In the past a substantial percentage of the high costs of mammalian derived proteins 
has come from fermentation however, recently production costs have become more 
heavily weighted toward downstream processing (González et al., 2003). The same 
advances that have improved cell growth and protein expression have therefore in 
turn created new challenges for downstream processing, leading to a focus on 
developing high capacity methods for the primary capture of protein from high cell 
density feeds.  
Bioreactor based fermentation of expression hosts generates a liquid feed stream of 
varying viscosity dependent on expression host. The industrialisation of recombinant 
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protein production has meant increased bioreactor capacity with feed streams in 
excess of 20,000L now routinely processed.  
Some feeds such as mammalian cells require a carefully considered approach to 
downstream processing, as they are more susceptible to cell disruption when 
compared to other host systems such as yeast and bacterial cells. Disrupted cells can 
introduce increased levels of feed contaminants such as DNA and proteases that effect 
protein quantity and further downstream processes.  
1.6.1 General outline of downstream process unit operations 
Process scale, expression system of choice and recombinant protein structure all 
affect the decisions made in downstream processing of these high value molecules 
however there are general unit operations are performed in most processing cases. 
Generally feed streams consist of both solid and liquid components that must be 
separated prior to protein capture via affinity, ion exchange or size-exclusion 
chromatography. After elution of the target protein a series of downstream processes 
are applied to further purify and reformulate the protein into its final state. Here the 
initial harvest and primary recovery strategies for a mammalian cell feed stream are 
discussed up to the point of primary product capture (Figure 1.8 General mammalian 
cell process flow diagram. A simplified process flow diagram for expression and 
capture of a recombinant protein from mammalian cells including upstream 
expression system engineering, fermentation and DSP through to clean up 
(polishing) and formulation. 
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Figure 1.8 General mammalian cell process flow diagram. A simplified process 
flow diagram for expression and capture of a recombinant protein from mammalian 
cells including upstream expression system engineering, fermentation and DSP 
through to clean up (polishing) and formulation.  
 
1.6.2 Solid-liquid separation 
Recombinant proteins are usually secreted by mammalian cells into growth media via 
one of many available secretion tags (Kober et al., 2013) included in protein 
engineering stages. Solids typically make up around 40-50% of the feed in high cell 
density fermentation (Marichal-Gallardo and Álvarez, 2012), hence the first stage in 
product recovery is the segregation of solid and liquid elements. Primary processing 
of high cell density feed streams requires particular consideration to avoid cell 
stresses and shearing that could result in protein aggregation and cell lysis 
(Hutchinson et al., 2006; Kiese et al., 2008). The latter affecting the quantity and 
quality of product by host cell proteins (HCP) and host DNA contamination 
(Sandberg et al., 2006).  
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Typically solid-liquid separation consists of centrifugation and depth/micro filtration 
steps to remove cells and cell debris from feed streams (Marichal-Gallardo and 
Álvarez, 2012).  
1.6.2.1 Centrifugation 
At industrial scale batch processing reduces efficiency therefore a semi-continuous 
sedimentation approaches are widely used. Tubular bowl centrifuges accumulate 
solids against the wall of a rotating bowl whilst enabling liquid discharge in a 
continuous manner through the end. Although the technology is effective the disc 
stack centrifuge thanks to its partial discharge function allowing continuous operation 
as well as a reduced shear effect on the feed stream has largely superseded it. The disc 
stack centrifuge consists of a set of plates arranged in a conical fashion, as feed enters 
liquids pass through the plates whilst solids accumulate on the underside and exterior 
of the bowl (for diagram see Marichal-Gallardo and Álvarez, 2012). As with the 
tubular bowl the liquid portion of the feed is discharged through the top of the 
centrifuge whilst the solids are separated to the underside of the plates. However disk 
stacks enable removal of these solids during operation in either partial or full 
discharge modes via opening of the bowl sleeve, enabling a continuous flow during 
the process.  
1.6.2.2 Filtration 
In order to prevent fouling of high expense chromatography resins, feed should be 
fully clarified prior to column application. Microfiltration has historically been used 
in biologics recovery as it enables separation of recombinant protein from both large 
and small remaining after centrifugation. Filtration can occur either via dead-end or 
tangential flow. Microfiltration units operate via exclusion of particles to form a 
caking layer on the surface of the membrane. However fouling via pore blockage or 
cake formation significantly affects membrane flux, requiring filter cleaning and 
replacement at regular intervals.  
Depth filters, unlike membrane filters, utilise a porous medium that is able to retain 
particles throughout its matrix not just its surface. Depth filters for bioprocess 
operations generally come in disposable units and are constructed of diatomaceous 
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earth (DE), perlite and cellulose fibres. Filtration based on particle exclusion and 
internal adhesion enables removal of different size particles and can be combined 
with a more traditional membrane filter as the bottommost layer to ensure 
clarification. The combination of centrifugation and depth-filtration is now the 
industry standard for processing of mammalian-expressed proteins prior to 
chromatography (Marichal-Gallardo and Álvarez, 2012). Both depth and microfilters 
are available in single-use cassette systems that avoid validation challenges and make 
process integration simple. 
Factors affecting the clarity of feed streams from these processes include the feeds 
turbidity and its flow rate. Both of these factors can be significantly affected by cell 
lyses during bioreactor fermentation, centrifugation or filtration. The shear affects 
experienced by cells have been shown previously to impact the protein yield and filter 
area required or feeds in scale down models (Hutchinson et al., 2006). 
1.6.3 Affinity tags 
Recombinant protein purification relies on affinity chromatography for primary 
recovery in most cases. In terms of antibody purification, protein A from S. aureus 
has affinity for the junction between the CH2 and CH3 domains (Figure 1.2 Antibody 
IgG1 Structure Protein A based chromatography is used in the purification of two 
thirds of antibodies (Vunnum et al., 2009). However products without natural 
affinities are less easily purified, hence recombinant protein purification has long 
relied on utilisation of engineered affinity tags which can be used to facilitate capture 
in addition to improving expression and solubility (Young et al 2012). A large 
selection of affinity tags are in use as described in (Arnau et al., 2011). The 
polyhistidine repeat tag however, remains the major workhorse for affinity tag 
purification due to the simplicity of N or C terminal fusion and purification via IMAC 
(Terpe, 2003). Protein capture via a polyhistidine repeat tag is often achieved using 
repeated histidine residues at the C-terminal region of proteins, most commonly with 
a 6 residue repeat, although the number of histidine residues and tags (i.e. dual 
polyhistidine tags) can vary.  
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1.6.4 Chromatography and primary protein capture 
Primary recovery strategies are highly dependent on the characteristics of the protein 
and cell type used to express them.  
Affinity chromatography makes use of highly specific, reversible interactions 
between molecules to selectively retain mobile proteins on an immobilised ligand. 
Once a target protein has been captured altering conditions within the column reduces 
affinity and the product is eluted. These interactions can be based on native protein 
properties such as antibody Fc ot via the addition of purification tags engineered into 
a protein (e.g. histidine repeat tag) that allows protein capture based on immobilised 
metal affinity chromatography (IMAC) (see section 1.7.4).  
Purification ligands are immobilised on a stable material such as Sepharose to form a 
chromatography resin, usually in bead form that is then packed into a static bed. The 
height and density parameters of this bed are adjusted dependant on scale of 
purification. Traditionally chromatography beads are formed into solid phase beds 
averaging around 80-100µm in diameter. A feed stream that is applied to a packed 
bed column cannot contain a large number of particles due to blocking and eventual 
cake build up on the bed.  
Expanded bed adsorption (EBA) resins are packed at a reduced density sometimes 
referred to as a fluidized bed. Bead sizes in EBA vary but are often between 200-
1000µm. Unlike packed bed chromatography, mixtures of particulate matter and 
target protein can be applied to EBA resins due to increases in pore sizes and reduced 
density of packing.  
1.6.5 Advances in protein recovery 
As upstream processing technology has improved the associated cost has come down 
whilst the cost of DSP has remained relatively constant. Overall, the cost 
considerations have become more weighted towards downstream processing as 
protein titres and cell densities increase (González et al., 2003). This has affected the 
demands of primary recovery and alternative primary recovery techniques are now 
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being harnessed including both resin and column designs that require less stringent 
clarification of media prior to column passage. 
Large bead diameter chromatography resin utilises stationary phase agarose beads 
typically between 300-500µm in diameter creating a semi-porous bed that allows 
particles to flow through it.  
Unlike typical axial flow systems, radial flow chromatography (RFC) consists of two 
concentric cylindrical porous frits holding a stationary phase between them. In RFC 
feed flows from the outer to the inner surface across the radius of the column 
providing a minimal pressure drop, improved elution peak resolution due to 
trapezoidal column geometry and greater operational flow rates (Besselink et al., 
2013)(Fig 2.1, Table 1.4). RFC columns can be packed with many resins depending 
on frit design, including ion exchange (IEX), immobilized metal affinity 
chromatography (IMAC) or protein A/G.  
Table 1.4 Pros and Cons of Radial and Axial flow based chromatography 
systems. 
Radial Flow Axial Flow 
Scalability  - bed height does not change 
with increased scale, rather the column is 
expanded in length.  
Industry standard – Axial flow is the 
industrial standard for chromatography 
therefore is well optimized and efficient.  
Pressure drop – Radial flow columns have 
a reduced pressure drop  
High capture rates – Simple to run 
sequentially to obtain improved capture.  
Concentration - radial concentric shape of 
the solid phase within the column 
facilitates a concentration effect of the 
product upon elution. 
Scale down– Easy to reduce in size for 
small scale purifications. 
Flow rate – due to the reduced pressure 
drop the flow rate can be increased 
compared to axial columns.  
 
Flexible - Both column types can be used with multiple different types of resins 
including bead type (affinity, Ionic exchange etc) or solid phase type (Expanded bed, 
fluidized bed or large bead).  
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1.7  Motivation and rationale  
This thesis aims to develop and compare methods for simple, cost effective and rapid 
expression and recovery of recombinant proteins for early screening of novel drugs. 
Transient and stable gene expression in mammalian systems was carried out using a 
novel scFv-Fc and its clinically relevant target, CEA, as model proteins. A process for 
primary capture of protein from unclarified mammalian cell feed streams was 
developed and characterized allowing protein recovery directly from bioreactors 
during harvest. Together these techniques aim to dramatically reduce the cost and 
time associated with production, purification and screening of recombinant protein 
therapeutics, including both the antigen target and binding antibody.  
Firstly, the anti-CEA scFv-Fc was expressed via transient transfection of HEK293F 
cells and stable expression in CHO cell pools. The resulting yield and protein quality 
was compared between the two systems. 
Secondly, a process was developed using a scale down radial flow chromatography 
system packed with large bead diameter resin to obtain an integrated primary capture 
step with IMAC for unclarified mammalian cell fermentation feed streams. This 
removed the need for centrifugation and filtration of feeds prior to primary capture. 
The results form the basis of an interfaced primary recovery step applicable to the 
recovery of many recombinant proteins from unclarified mammalian cell feed 
streams.  
Chapter Aims: 
Aim 1) Develop a mammalian system for rapid, scalable and cost effective production 
of recombinant proteins for use in laboratory scale production. 
Aim 2) Investigate methods to generate stable cell pools for high expression of a 
model protein and to compare scFv-Fc produced in stable and transient systems  
Aim 3) Develop a process for protein recovery directly from unclarified mammalian 
cell feed streams and demonstrate reactor harvest integration.  
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Chapter 2 Materials and Methods 
2.1 Cell lines 
2.1.1 Cell line storage and recovery 
Unless otherwise stated all cell lines were stored in liquid nitrogen at a density of 
1x107 cells/mL in standard media, as defined below, supplemented with 10% 
dimethyl sulphoxide (DMSO) (Sigma-Aldrich, Gillingham, UK). Suspension adapted 
cell lines were thawed from a single vial in a 37 °C water bath before addition to 
directly to 29mL of pre-warmed media in a 125ml Erlenmeyer vented conical flask 
with a 0.22µm filter from Corning Limited (Union City, CA) and placed in incubation 
conditions. Adherent cell lines were also thawed in a 37 °C water bath but were added 
to 5 mL of pre-warmed media and centrifuged at 500xg and re-suspended in fresh 
media before seeding tissue culture plates as described below and placing in 
incubation conditions.  
2.1.2 Human embryonic kidney-293F 
The HEK293F cell line was purchased from Life Technologies, Paisley, UK. Cells 
were maintained in Freestyle serum-free media also from Life Technologies (12338-
018) at a density of 0.5x106 in 125ml Erlenmeyer vented conical flasks with a 0.22µm 
filter from Corning. Cell culture conditions were 37°c, 125 RPM and 5% CO2 for all 
suspension shake flask cultures in an Stuit Orbital SJL1 incubator using a shaken 
platform from RS Biotech R+ (Ayrshire, UK).  
2.1.3 Hela 
Hela cells were obtained from Dr Darren Nesbeth at UCL Biochemical Engineering 
(University College London, UK). Cells were maintained in 5 mL of DMEM 
supplemented as above in T25 tissue culture flasks (Corning). H2Z-Hela cells, stably 
expressing flp recombinase targeting sites (FRT), were also obtained from Dr Darren 
Nesbeth and were maintained as above with the addition of 150 µg/mL zeocin (Life 
Technologies), (Cat. Num R250-01) to maintain selection pressure.  
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2.1.4 CHO-S and stably transfected CHO-S cells 
Suspension and serum free adapted Chinese Hamster Ovary cells (CHO-S) (Life 
Technologies, Paisley, UK) or stably transfected CHO-S cells were seeded at a 
density of 0.3 million viable cells (MVC)/mL in 300mL of a 1:1 (v/v) mix of CD-
CHO (Life Technologies, Paisley, UK) and EX-CELL CD-CHO 3 (Sigma Aldrich, 
St. Louis, MO) in 125mL Erlenmeyer flasks (Corning Limited, Union City, CA) with 
0.22µm vented caps to a maximum cell density of 3x106 cells/mL unless otherwise 
specified. All incubation conditions were 125rpm, 8% CO2 and 37°C. A master and 
working cell bank was stored at low passage number (p2/p3) in liquid nitrogen and all 
cell stocks were maintained below 3-4x106 cells/mL during regular passage.  
2.1.5 Cell line maintenance  
2.1.5.1 Adherent cells 
Media was aspirated from adherent cell cultures and an equal amount of pre-warmed 
PBS solution was added and aspirated to remove residual serum. Pre-warmed 0.25% 
Trypsin solution (Sigma Aldrich) was added sufficient to cover the surface of the 
flask. The flask was returned to incubation conditions for 5 minutes before cells were 
dislodged by pipetting and re-suspended in fresh supplemented media for counting 
using a haemocytometer and a Motic AE 2000  (Wetzlar, Germany) microscope 
before subsequent dilution and plate seeding.  
2.1.5.2 Suspensions cells 
Cells in suspension were removed from culture flasks (30µL) by pipette and mixed 
with Trypan Blue stain (Sigma Aldrich) at an appropriate ratio dependent on cell 
concentration. Cell density and viability were determined by visualisation using a 
microscope with 10 µL of Trypan Blue and cell culture solution loaded onto a 
haemocytometer. Cell suspensions were diluted in the appropriate amount of pre-
warmed media as calculated via the equation C1V1=C2V2. Where C1 is the current 
concentration, C2 is the desired concentration and V2 the desired volume. Culture 
flasks were returned to incubation conditions immediately after cell passaging. After 
cell passaging flasks were returned to incubation conditions.  
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2.2 Plasmid DNA 
2.2.1 Plasmid origins 
Plasmids stocks were obtained from UCL, Invivogen or Novogen, unless cloned in 
house. All plasmid DNA concentrations were analysed using a nanodrop 
spectrophotometer (Thermo Scientific, Loughborough, UK). DNA coding for the 
scFv SM3E was obtained from Dr Enrique Miranda Rota (UCL Cancer Institute, 
London, UK). Table 2.1 shows the derivation of the construct and related literature.  
Table 2.1 MFE-23 development, descriptions and associated mutations. 
Protein Name Mutations Reference 
MFE-23 scFv generated via phage 
display library against CEA. 
(Chester et al., 1994) 
hMFE-23 Humanised MFE-23: 28 
residues altered to produce 
humanised resurfaced form. 
(Boehm et al., 2000; Graff et 
al., 2004) 
shMFE-23 Stabilised humanised MFE-
23; Mutations in VL N20T, 
S31P, W47L, M78V. 
(Graff et al., 2004) 
SM3E Affinity matured and 
stabilised shMFE-23; 
Mutations in VL N20T, S31P, 
F36L, W47L, S50L, M78V. 
(Graff et al., 2004) 
2.2.2 Restriction enzyme digestion  
Restriction enzyme digestion of plasmid DNA for analysis or cloning purposes was 
carried out using enzymes from New England Biolabs (NEB) (MA, USA). Restriction 
digests were carried out using digestion buffers and conditions as recommended in the 
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manufactures instructions (see table 2.1). Unless otherwise stated digestions were 
incubated for one hour at 37°C in total reaction volumes of 25 µL.  
2.2.3 Agarose gel electrophoresis 
Unless otherwise specified agarose gel electrophoresis was carried out using 50 mL of 
1% agarose (Sigma Aldrich) in 1x TAE (see appendices Buffers and Reagents). The 
solution was heated in a microwave until fully dissolved before addition of 3 µL of 
ethidium bromide and pouring into a Bio-Rad gel system and allowing to set. Gels 
were covered in TAE buffer before DNA loading buffer at 10x concentrate was added 
to DNA to make a 1x solution prior to gel loading. The running conditions were 
10V/cm for 1 h and a molecular weight marker was included dependent on expected 
band size. 
2.3 Plasmid amplification and purification  
2.3.1 Plasmid amplification 
DNA was transformed via electroporation using a Bio-Rad Micro Pulser 
electroporater. Top10 electrocompetent Escherichia coli stocks were thawed on ice 
for 10 min before 1 µL of pDNA was added and transferred to an electroporation 
cuvette, also on ice. Electroporation was carried out using on the EC2 setting. Room 
temperature 2TY media (See appendices Buffers and Reagents) with 1% glucose was 
added (1mL) immediately after electroporation and the cuvette transferred to 
incubation conditions at 37°c for 1 hr. Transformed Top10 E. coli cultures were 
streaked onto 2TY agar plates supplemented with 100 µg/mL ampicillin before a 24hr 
incubation at 37°C. Electroporation of TG1 electrocompetent E. coli was carried out 
as above.  
2.3.2 Selection, amplification and purification of plasmid DNA 
A single bacterial colony was selected from an inoculated 2TY agar plate 
supplemented with 100 µg/mL ampicillin using a sterile inoculation loop and used to 
inoculate 5 mL of 2TY media supplemented with 1% (v/v) glucose and 100µg/mL 
ampicillin in a 15ml falcon tube and incubated at 37°C for 24hrs with 225rpm 
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agitation in an Innova 4230 incubator (New Brunswick, Arlington, UK). A 100 µL/L 
inoculation was then added to an appropriate amount of ampicillin 2TY media and 
incubated at 37°C, 225rpm for 24 hrs. Plasmid DNA was purified using endotoxin-
free gigaprep, midiprep or mini-prep kits from Qiagen (Manchester, UK).  
2.3.3 Polymerase chain reaction (PCR) 
PCR amplification of template DNA was carried out using Phusion Polymerase 
(NEB, Hertfordshire, UK) unless otherwise stated. Reaction mixture contained 4 µL 
of Phusion HF (5x) buffer, 0.4 µL of 10mM dNTPs 1 µL of both forward and reverse 
primers at 10µM, <1µg of template DNA, 0.2 µL of Phusion Polymerase and 
nuclease free ddH2O to a final volume of 20 µL. Reaction conditions were 98°C for 
30 s, 35 cycles of; 68-72°C for 20-30 s (dependent on primers) followed by 30 s per 
kb of DNA extension with a final extension of 5 min at 72°C and an infinite hold at 
4°C.  
2.3.4 Preparation of bacterial glycerol stocks  
A 0.5mL aliquot of overnight culture of transformed bacterial was added to 0.5mL of 
autoclaved 50% glycerol before storage immediately at -80°C. Glycerol stocks were 
thawed on ice and streaked on selection plates for overnight incubation for further 
use.  
2.4 Transient transfection of suspension adapted HEK293F and CHO cells 
2.4.1 Preparation of 25 kDa linear polyethylenimine 
Polyethylenimine (PEI) (25 kDa, linear form) was obtained from Poysciences 
(Eppelheim, Germany). 100mg was added to 80 mL autoclaved ddH20. A 4M 
solution of HCL was added to reduce the pH to <3 and the solution allowed to stir 
using a magnetic stirrer for 1 h at room temperature. Once the solution was colourless 
a 4M solution of NaOH was added to return the solution to pH 7.2 and ddH20 added 
to make a final volume of 100 mL at 1 mg/mL of PEI. The solution was filter 
sterilised using a 0.22 µm syringe filter (Millipore, Darmstadt, Germany) in a sterile 
tissue culture hood and aliquoted into 1 mL Eppendorf tubes for storage at -80 °C. 
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After thawing, PEI solution was either used immediately or kept at 4°C for up to 1 
week before disposal.  
2.4.2 Preparation of branched 25 kDa polyethylenimine 
Branched form 25 kDa polyethylenimine was obtained from Sigma Aldrich in viscous 
liquid form. Branched form PEI was dissolved in an appropriate amount of ddH20 to 
obtain a 1mg/mL solution (1 mL/L). The solution was heated to 60°C for 1 h with 
magnetic stirring, allowed to cool to room temperature and filter sterilised using a 
0.22 µm filter (Millipore) before storage at 4°C.  
2.4.3 Cell culture prior to transfection 
HEK293F and CHO cells were seeded 24hrs prior to transfections in pre-warmed 
Freestyle serum-free media at a density of 0.5x106 cells/mL. Transfections were 
carried out in either 30 mL media in 125 mL vented conical flasks and for large-scale 
transfections cells were seeded in 300 mL media in 1L vented conical flasks. Once 
cell densities reached 1x106 cells/mL with over 90% viability and good single cell 
dispersion as determined via the Trypan Blue exclusion assay transfection was carried 
out.  
2.4.4 Transient transfection 
293Fectin-mediated transfection 
In a 2 mL eppendorf 60 µL of 293fectin was added to 940 µL of Optimem and mixed 
by inversion. In a second eppendorf 30 µg of plasmid DNA (minimum DNA 
concentration 100 ng/µL) was added to Optimem to a final volume of 1 mL, mixed 
once by inversion and incubated at room temperature for 5 minutes.  
After incubation the pDNA–Freestyle media solution was added drop wise to the 
293Fectin solution, mixed once by inversion and incubated at room temperature for 
20 minutes before being added drop wise directly to the cell culture whilst gently 
swirling the flask. The flask was returned to incubation conditions as described above.  
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25 kDa linear Polyethylenimine –mediated transfection 
Freestyle media (to final volume 2 mL) was added to a 1.5 mL eppendorf followed by 
30 µg of plasmid DNA via pipette. The solution was mixed twice by inversion and 60 
µL of a 1mg/mL linear 25 kDa PEI solution was added drop wise via pipette. The 
transfection solution was vortexed briefly and incubated at room temperature for 10 
minutes. The transfection solution was then added drop wise directly to the cell 
culture whilst swirling the flask gently. The culture was then returned to incubation 
conditions.  
2.4.5 Transient transfection of HEK293F cells in PBS 3L reactor 
A PBS3L SUT reactor vessel containing 2.4L of Freestyle media was allowed to 
equilibrate to 37°C before being seeded with from HEK293F cells at a density of 
3x106 cells/mL cultured in shake flasks as described in section 2.1.5.2. Initial seeding 
density was 0.3x106 cells/mL with a typical four-day expansion time before 
transfection at 1x106 cells/mL. Culture samples were removed using the PBS Biotech 
sample manifold. Reactor conditions were set at 37°C with 25RPM agitation, pH7.2 
and >30% DO2 maintained via PID control (Kim et al., 2013).  
2.5 Hela cell transfection  
2.5.1 Transfection for random integration into Hela cells 
Hela cell culture (1x106 cells/mL) was seeded in 5 mL of supplemented DMEM at a 
density of 1x105 cells/mL in T25 Tissue culture flasks 24 hours prior to transfection 
to attain 70% confluency on the day of transfection. When cells reached 70% 
confluency they were transfected. 
Plasmid DNA (pFUSE-SM3E-Fc) (5 µg) was added to 5 mL of DMEM supplemented 
with 2mM L-glutamine only in a 15 mL Falcon tube. The solution was vortexed 
briefly and incubated at room temperature for 5 minutes. 20 µL of a 1 mg/mL 
branched 25 kDa polyethylenimine was added to the solution before vortexing briefly 
and a further 5-minute incubation at room temperature.  
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The media in the cell culture flasks was aspirated and replaced with the transfection 
solution and cells were returned to incubation conditions. Control flasks were treated 
with 5mL DMEM supplemented with 2mM L-glutamine and 20µl of branched PEI as 
above. After 24 hours the media was aspirated and replaced with DMEM 
supplemented with 10% FCS, 1% penicillin and streptomycin (PenStrep) antibiotic, 
2mM L-Glutamine and 150 µg/mL zeocin.  
2.6 Stable transgene integration in CHO-F cells 
Stable cell selection was carried out after transfection with pUCOE-SM3E-Fc using 
FreestyleMAX (Life Technologies, Paisley, UK) transfection reagent as per the 
manufacturer’s instructions. Antibiotic selection was carried out using addition of 
12.5 µg/mL puromycin (Invivogen, Toulouse, France) to media 48 hrs after 
transfection unless otherwise stated. Cells were maintained under selection conditions 
until untransfected control cells reached <10% viability and transfected cells 
recovered to >90% viability as determined by daily Trypan blue staining and 
counting. After selection, stable cells were stored in liquid nitrogen at a density of 
1x107 cells/mL.  
2.7 Fed-batch fermentation of CHO cells  
Fed-Batch culture of CHO cells was performed using either 1L shake flask culture 
flasks (Corning) or single-use pneumatic bioreactor from PBS Biotech Inc (CA, USA) 
with a working volume of 3L was used for scaled up cell culture.  
2.7.1 PBS 3L Bioreactor fed-batch fermentation of CHO cells 
Sterile polycarbonate gamma-irradiated SUT 3L units (PBS Biotech Inc, CA, USA) 
were seeded with CHO cells at a density of 0.3x106cells/mL. Reactor conditions were 
set at 37°C with 25RPM pneumatic vertical wheel agitation, pH7.2 and >30% DO2 
maintained via PID control (Kim et al., 2013). Cells were maintained in a fed-batch 
mode of operation with 3%  (v/v) EfficientFeed B (Life Technologies, Paisley, UK) 
daily from Day 4. Once cells reached the end of exponential growth phase 
temperature and agitation were reduced to 35°C and 20RPM respectively (Nam et al., 
2008). Cells were harvested when viability dropped below 80% or after day 14.  
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2.7.2 Fed-batch shake flask culture of CHO cells 
Shake flasks cultures (300mL) in 1L flasks with 0.22µM vented caps (Corning) were 
seeded at a density of 0.3-0.5x106 cells/mL in 50% CD-CHO/ 50% Excel CHO. 
Feeding was carried out from day 4 as above (1.7.2). 
2.8 Media Bioprofiling   
Media composition and cell culture metabolites were analysed by ion selective 
electrode potentiometry, amperometry, and enzymatic reaction-dependent biosensors 
in 1mL aliquots immediately after sample removal (BioProfile 400, Nova Biomedical, 
Inc., Waltham, MA). 
2.9 Cell analysis and imaging 
2.9.1 Automated cell counting  
Where automatic cell counting was used a Vi-CELL XR automated cell counter 
(Beckman Coulter, High Wycombe, UK) was used to determine cell density and 
viability via the Trypan blue exclusion method. Vi-CELL parameters were min/max 
size 6-50µm and 50 repeated counts. Cell cultures were diluted in phosphate buffered 
saline (PBS) were necessary to ensure counting accuracy. 
2.9.2 Particle size distribution 
Particle size distribution was analyzed using the CASY Cell Counter Analyzer 
System (Roche, Basal, Sweden) with cell analyses parameters set to min/max 3-
40µm, particles greater than 40µm where deemed to be cell and protein aggregates. 
Cell culture was diluted in phosphate buffered saline where appropriate to ensure 
accuracy in cell counting and particle distribution analyses.  
2.9.3 Cell and fluorophore imaging 
Green fluorescent protein (GFP) and red fluorescent protein (DS-RFP) expression 
was analysed using fluorescent microscopy on an Aiovert100 microscope and 
Axiocam from Carl Ziess limited. Briefly, a 10 µL solution of 1x105cells/mL was 
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added to a microscope slide chamber. Cell and fluorescence imaging was carried out 
using the appropriate filters to excite fluorophores (RFP – 554nm and GFP- 498nm.  
Antibody localisation staining was carried out using SM3EL-Fc (1µg/mL) added to 
either Capan-1 cells or A375 CEA negative cells cultured in 6cm2 tissue culture 
plates. The plates were incubated at 4°C for 1 h to prevent internalisation. Secondary 
staining of the scFv-Fc was achieved using an anti-murine IgG conjugated Alexaflour 
488 (green) whilst the nucleus is stained using DAPI (blue). Images were captured 
using a Leica TCS SP Confocal Microscope (Leica, Milton Keynes, UK) and image 
analysis performed using ImageJ (with help from Dr Enrique Miranda Rota).  
2.9.4 Flow cytometry 
The CyAn ADP Flow Cytometer (Beckman Coulter, High Wycombe, UK) was used 
to determine transfection efficiency of reagents using a red fluorescent protein. 
HEK293 or CHO cells at a viable cell density of 2x106 cells/mL were removed from 
culture, centrifuged at 350g and re-suspended in PBS twice before a third re-
suspension in chilled 70% ethanol and incubation on ice for 30 min. After fixing cells 
were re-suspended in PBS prior to loading onto the flow cytometer. Un-transfected 
control cells were loaded to achieve gating of flow cytometry data before analysis of 
DS-RED fluorescence at 558nm (R1) and 583nm (R2) of transfected culture samples. 
Flow cytometry data was analysed using FlowJo analysis software.  
2.9.5 MTS Tetrazolium Assay (MTT Assay) 
CEA-expressing capan-1 cells and CEA-negative Hela cells were plated out in a 96-
well tissue culture plate (10,000 cells/well). After 24 hrs 1µg of SM3EL-Fc was 
added to each well and the plate was incubated at 4°C for 1 hr. Rabbit complement 
(AbD Sertech) was added (11µL/well) and the plate incubated for a further 1 h at 
37°C followed by MTS solution (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Cell Titre 96 Aqueous 
One Solution, Promega) assay substrate (12µL/well) and an incubation for 30min at 
37°C. Analysis of developed colour was performed using a Varioskan Flash plate 
reader (Life Technologies, Paisley, UK) at 490nm.  
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2.9.6 Quantification of protease activity in supernatants 
Protease activity in cell culture supernatant and flow-through from column-based 
chromatography was determined using the fluorescence resonance energy transfer 
(FRET) protease assay (Life Technologies, Paisley, UK) according to the 
manufactures instructions. Briefly, 100µL of fluorescein labeled casein stock solution 
(10mg/mL) or assay buffer as blank was added to each well of a black Nunc 96-well 
plate (Thermo Scientific). Supernatant (50µL) was added to wells in triplicate and 
incubated for 20-30min at room temperature before addition of 50µL 5% 
(v/v) trinitrobenzene sulfonic acid (TNBSA) solution in methanol and a further 
incubation of 20min at room temperature to allow color to develop.  The assay plate 
was read in a Varioskan Flash plate reader in fluorescence mode at 485/538nm. 
Activity was quantified against a standard curve of trypsin with known proteolytic 
activity, 15525 Unit/mg (1 Unit defined as a change in absorbance at 253 nm of 0.001 
per minute at 25 °C, pH 7.6 in a reaction volume of 3.2 mL of Na-Benzoyl-L-
Arginine Ethyl Ester Solution (BAEE) (Papaioannou and Liener, 1968). 
2.9.7 β-Galactosidase activity  
β-Galactosidase activity was analysed using the β-Gal Assay Kit from Invitrogen 
(K1455-01 Version F) according to the manufactures instructions. In brief, the media 
was aspirated from T25 flasks of transfected cells followed by washing with 1xPBS 
and trypsinising into PBS solution. The cells were counted and normalised to 1x105 
cells/mL in 1 mL. The solution was centrifuged at 250g for 5 min, the supernatant 
aspirated and the cells re-suspended in 100µL lysis buffer.  Cells were lysed by 
freeze-thawing on dry ice and heating to 37°C twice and the cell debris pelleted at 
4122g for 5 min. 20µl of the soluble lysed cell material was added to a fresh tube 
along with 70µL of ONPG substrate and 200µL of cleavage buffer before incubating 
at 37°C. Once colour had developed (20-25min), 500µL of stop solution was added 
and 200µL of each sample added to each well of a 96-well plate for absorbance 
analysis at 420nm in a Varioskan Flash plate reader (Life Technologies) and 
compared to control conditions.  
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2.9.8 Quantitative qPCR for detection of CHO cell genomic DNA in 
supernatant.  
2.9.8.1 Genomic DNA isolation 
CHO cell culture (2 mL) at a cell density of ≥5x106 /mL were pelleted by 
centrifugation at 200g for 5 min and the supernatant aspirated. The cell pellet was re-
suspended in 1mL TRIzol reagent (Qiagen) /5x106 cells and lysed by aggressive 
pipetting. After homogenization the samples were incubated for 5 minutes at RT 
before 200 µL of chloroform was added per 1 mL of TRIzol reagent. The tubes were 
shaken vigorously for 15 seconds and incubated at 30°C for 2 minutes.  
The samples were separated into aqueous and organic phases by centrifugation at 
12,000g for 15 minutes at 4°C. The aqueous phase was removed by pipette and 
discarded. Absolute ethanol (300 µL/ 1 mL TRIzol) was added and incubated for 2 
min at room temperature before centrifugation at 2000g for 5 min to pellet DNA. The 
supernatant was decanted and the pellet washed twice using 100 mM sodium citrate in 
10% ethanol (2 mL) for 30 min at room temperature and subsequently pelleting by 
centrifugation before a final wash in 70% ethanol and re-suspension in TE buffer.  
2.9.8.2  qPCR analysis of genomic DNA contaminant in supernatant  
Contaminating DNA was quantified by real time PCR performed in a Realplex4 
Mastercycler EPgradient S (Eppendorf, Stevenage, UK) using the following 
conditions: initial heat denaturation at 50°C for 2 min, 95°C for 10 min, followed by 
40 cycles each of 95°C for 15s and 60°C for 1 min. Sample preparation required 
recovery of cell culture supernatant via centrifugation at <500g, followed by removal 
of the supernatant to a fresh tube and centrifugation at13000g for a further 5 min and 
0.22µm filtration. The supernatant was analyzed in 3µL samples using previously 
isolated and quantified genomic DNA. Unless otherwise stated the reaction mix 
contained 3µL of supernatant sample in a 25µL reaction mixture of ITAQ SYBR with 
a final concentration of 5 nM of each primer. Primers directed against genomic DNA 
isolated from Critcetulus griseus (CHO) were synthesized by IDT (Integrated DNA 
Technologies, Glasgow, UK). Primer sequences were: Sense 
5’ACAGGTTTCTGCTTCTGGCT and Anti-sense 
5’CATCAGCTGACTGGTTCACA. The reaction mix contained 3µL of sample in a 
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25µL reaction mixture of ITAQ SYBR with a final concentration of 5 nM of each 
primer.  
2.10 Chromatography 
2.10.1 Hightrap protein A chromatography 
Proteins with Fc fragments were captured from mammalian suspension cultures after 
solid liquid separation. Cultures of ≤300mL were centrifuged at 400xg for 5 min to 
remove cells/debris and the supernatant was removed and filtered via 0.22µm vacuum 
filtration. The filtrate was concentrated where appropriate and dialysed into 20mM 
sodium phosphate using tangential flow filtration (Labscale TFF, Millipore) with 
Pellicon filtration cassettes (Millipore) of an appropriate pore size. Two volumes of 
buffer exchange were used per total supernatant volume to gain full dialysis.  
Proteins were captured using a HiTrap rProtein A ff 1mL column from GE Healthcare 
(Cat. Num. 17-0402-01) and a Bio-Rad Econopump chromatography pump. Unless 
otherwise specified flow rates were set at 1 column volume (CV)/min. The column 
was washed using 10 column volumes of 20mM sodium phosphate and the dialysed 
supernatant was applied to the column. A 5 CV wash using binding buffer preceded 
elution in 0.1M sodium citrate (pH3) using 60µL/mL of Tris-HCL buffer (pH 8.4) to 
neutralise protein solutions.  Proteins were quantified by absorbance at 280nm using a 
nanodrop spectrophotometer.  
2.11 Radial flow chromatography operation 
A scale down RFC column with bed volume of 5 mL and height of 6cm was used 
with either 40µm or 200µm pore size frits (Proxcys, Nieuw-Amsterdam, Netherlands) 
(Fig 1.A). The column was packed with iminodiacetic acid (IDA) Chelating 
CellthruTM BigBead agarose resin (Sterogene, Carlsbad, CA) as per the 
manufacturer’s instructions. Column conditioning was performed to remove air 
bubbles with 6x column volumes (CV) PBS (pH 7.2). The resin was charged with 
5CV 100mM nickel sulphate and equilibrated with 0.5M NaCl/ 0.5x PBS/ 10mM 
imidazole. An operational flow rate of one CV/minute was used for column loading, 
achieved using a peristaltic pump (New MBR, Zurich, Switzerland). Whilst frit pore 
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sizes of both 200µm and 40µm were studied, the 200µm pore frit was used routinely. 
Non-specifically bound proteins were removed via wash buffer (40mM imidazole/ 
0.5X PBS/ 0.5M NaCl) before elution with 200mM imidazole/0.5X PBS/ 0.5M NaCl. 
The column was stripped and regenerated after each use using 50mM NA-EDTA and 
stored in 20% (v/v) ethanol. 
 
Figure 2.1 Cross section of microRFC 5mL radial flow column (image courtesy 
of Proxcys).  The microRFC column has a bed height of 6cm and volume of 5mL. 
 
2.12 Column-reactor integration and harvest 
In-line integration of RFC was achieved via welding the column tubing directly to the 
reactor harvest line using Masterflex C-FLEX tubing (Cole-Palmer, London, UK) 
with a sterile tube welder (GE Healthcare, Buckinghamshire, UK). Valve and pump 
operation was used to control flow from the reactor (Valves 1 and 3 open), followed 
by wash, elution and regeneration buffers (Valves 2 and either 3 or 4 open) (Fig 1.B). 
Cells were buffered to IMAC binding conditions by addition of 4x concentrated 
IMAC buffer to the reactor prior to passage directly through the column in 3x1L 
batches. The column was eluted and regenerated between batches as described above.  
2.13 Model His-tagged protein recovery  
A His-tagged scFv (SM3E) (Graff et al., 2004) was expressed and purified from 
Pichia pastoris as previously described (Tolner et al., 2006) and used as the test 
protein for recovery from cell culture media. Ultraviolet light absorbance and 
conductivity were analyzed by linking the RFC to an AKTA Prime Plus (GE 
Healthcare, Buckinghamshire, UK). Eluted fractions were resolved by 10% (v/v) 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), stained 
for 1 h with Coomassie Brilliant Blue (Sigma Aldrich, St. Louis, MO) and destained 
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until clear using a mixture of 10% (v/v) glacial acetic acid, 30% (v/v) methanol and 
60% (v/v) double distilled water (ddH2O). 
2.13.1 Fast Protein Liquid Chromatography (FPLC) separation of proteins. 
FPLC separation of recombinant proteins was carried out using a Superdex200 75mL 
column and an AKTA Prime Plus FPLC machine from Amersham Biosciences 
(Buckinghamshire, UK). Protein samples at a minimum concentration of 100µg/mL 
were loaded on to the column in maximum 2mL quantities using the manual loop 
injection mode. Running conditions were 1 mL/min and 1.5MPa pressure limit, 
optical density was measured at 280nm for protein detection and fraction collection 
was set at 1mL.  
2.14 Protein storage 
After elution from chromatographic capture proteins were dialysed into PBS 
overnight, aliquoted into appropriate volumes and stored at -80°C unless other wise 
specified. Protein dialysis was carried out using Slide-A-Lyzer dialysis cassettes 
(ThermoFisher) with pore size restricted to between 10X lower than the size of the 
target protein IE NMWC of 10000 for a protein of 100 kDa. Proteins were dialysed in 
5L of PBS solution overnight with magnetic stirring at 4°C. 
2.15 Biophysical analysis of recombinant proteins 
2.15.1 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE)  
SDS-PAGE gels were cast in a Bio-Rad Handcast dock using the reagents specified in 
Table 2.2. Protein solutions were diluted to 0.25 mg/mL with PBS where necessary 
prior loading. A 4X concentrated reducing buffer was added to samples prepared for 
SDS-PAGE under reducing conditions. Samples where heated in a PCR machine 
(Biometra Personal, Göttingen, Germany) for 5 min at 100°C. Reduced protein 
solutions were added to the gel and the electrophoresis carried out at 150V for 1 h.  
SDS-PAGE gels were washed with ddH2O and stained for 1 h with Coomassie 
Brilliant Blue (Sigma Aldrich, St. Louis, MO) with gentle agitation on a rocking 
platform. Coomassie stained gels were destained until clear using a mixture of 10% 
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(v/v) glacial acetic acid, 30% (v/v) methanol and 60% (v/v) double distilled water 
(ddH2O).  
Table 2.2 SDS-PAGE gel solutions 
Reagent 4% Stacking Gel 10% Resolving Gel 
ddH20 3.6 mL 3.2 mL 
30% Acrylamide 
(Protogel) 
0.67 mL 2.67 mL 
1.5M Tris-HCL pH 8.8 
1.0M Tris-HCL pH6.8 
na 
0.625 mL 
2 mL 
na 
10% SDS 50 µL 80 µL 
10% Ammonium 
Persulphate 
50 µL 80 µL 
TEMED 5 µL 8 µL 
2.15.2 Western Blotting 
Purified proteins were diluted to 1µg/mL prior to being resolved by SDS-PAGE as 
above and transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad, 
Hercules, CA) using 110V for 1 h. Positive control proteins included His-tagged CEA 
(R&D, Abingdon, UK). Membranes were blocked with 5% (w/v) skimmed milk 
powder in 0.1% (v/v) PBS and probed with murine anti-His tag (Qiagen, Limburg, 
Netherlands) or an anti-CEA antibody (Pedley et al., 1987). Bound antibodies were 
detected with HRP-linked secondary anti-mouse-HRP conjugated antibody (R&D, 
Abingdon, UK) and developed using Luminata Classico Western HRP substrate 
(Millipore, Darmstadt, Germany).  
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2.15.3 Differential scanning fluorimetry   
DSF was used to monitor IgG and scFv-Fc unfolding during exposure to a 
temperature gradient. A 96-white well PCR plate was used during DSF experiments 
(Bio-Rad Laboratories, Hercules, CA), with each well containing 22.5 µL of IgG or 
scFv-Fc sample in PBS and 2.5 µL of 10x SYPRO Orange solution (Life 
technologies) that had been diluted from the purchased 5000x stock in water. A 
Realplex4 Mastercycler EPgradient S RT-PCR machine (Eppendorf, Stevenage, UK)) 
was used to record fluorescence changes during DSF measurement in FRET scanning 
mode. Samples were incubated at 15 °C for 4 min before exposure to a temperature 
gradient of 20 to 95 °C in 0.5 °C increments, with an equilibration time of 30 s at each 
temperature followed by a fluorescence read. Protein unfolding was reported as the 
midpoint transition temperature at which hydrophobic regions become exposed (Tm). 
Mean Tm values were determined using first-order derivative curves of triplicate 
experiments with reference to a blank buffer as background.  
2.15.4 Enzyme Linked Immunosorbant Assays 
ELISA based quantification of CEA was carried out using a double antibody 
sandwich ELISA method. A 96-well plate (Life Technologies) was coated with 
10  µg/mL polyclonal rabbit anti-CEA (UCL Cancer Institute, London). After washing 
with PBS twice, wells were blocked with 200  µL of 5% (w/v) skimmed milk in PBS. 
Plates were washed as before and samples were added along with a serial dilution of 
His-tagged CEA (R&D, Abingdon, UK) to form a standard curve. After washing, 
1  µg/mL murine anti-CEA was added for 1  h and detected using anti-mouse-
horseradish peroxidase (HRP) conjugate (R&D, Abingdon, UK) diluted 1:4000 in 
PBS, using 0.5  mg/mL o-phenylenediamine dihydrochloride (Sigma–Aldrich) in 
phosphocitrate buffer for development. Intensity was analysed by absorbance at 
490  nm in a Varioskan Flash platereader (Life Technologies). All incubations were 
carried out at room temperature.  
ScFv-Fc concentrations and activity were analysed by either double antibody 
sandwich (DAS) or plate trapped antigen (PTA) ELSIA formats. In both cases 
purified and quantified recombinant protein was used as a standard curve.  
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2.15.4.1 DAS-ELISA format 
• A	  96-­‐plate	  was	  coated	  with	  100	  µL/well	  of	  a	  1/4000	  dilution	  in	  PBS	  of	  goat	   anti-­‐human	   IgG-­‐Fc	   (Jackson,	   109-­‐005-­‐098)	   for	   1	   h.	   The	   assay	  plate	  was	  flicked	  off	  and	  blocked	  for	  1	  h	  as	  above.	  Samples	  were	  added	  (100	   µL/well)	   and	   incubated	   at	   room	   temperature	   for	   1	   h	   before	  washing	   as	   above.	   A	   secondary	   anti-­‐mouse-­‐HRP	   conjugate	   as	  described	  above	  was	  used	  to	  report	  fluorescence	  quantification	  using	  a	   1/4000	   dilution	   with	   incubation	   for	   1	   h	   at	   room	   temperature	  followed	  by	  development	  using	  OPD	  and	  absorbance	  measurement	  as	  above.	  	  
2.15.4.2 PTA-ELISA format 
• A	  96-­‐well	  plate	  was	  coated	  overnight	  at	  4°C	  with	  a	  1	  µg/mL	  dilution	  of	  recombinant	  NA1	  (Produced	  in	  house	  accoding	  to	  Sainz-­‐Pastor	  et	  al.,	  2006;	  Tolner	  et	  al.,	  2013)	  in	  PBS.	  The	  plate	  was	  blocked	  as	  above	  and	  the	  assay	  samples	  added	  from	  a	  titration	  plate	  and	  incubated	  for	  1	  h	  at	  room	   temperature.	   The	   assay	   was	   detected	   and	   reported	   using	   the	  anti	  mouse	  Fc-­‐HRP	  conjugate	  as	  described	  above.	  	  	  
2.16 Surface Plasmon Resonance  
Surface plasmon resonance (SPR) spectroscopy was performed using a T200 
enhanced Biacore (GE Health Care Life Sciences, Amersham, UK). All solutions 
used were 0.22 µm filtered prior to use, however not degassed.  
Analysis of affinity and binding kinetics was carried out via immobilisation of the 
antibody as ligand where possible using CM5 chip (carboxymethylated dextran 
covalently attached to a gold surface) and 1-Ethyl-3-(3-dimethylaminopropyl)-
carbodiimide (EDC)/ N-Hydroxysuccinimide (NHS) based covalent amine coupling 
chemistry according to the manufactures instructions.  
In brief, the CM5 chip surface was activated using EDC/NHS prior to immobilisation 
of proteins prepared in solutions of 1-10 µM on single flow cells leaving flow cell one 
blank as reference. The ligand was past over the flow cell at a rate of 5-10 µL/min 
before 1M Ethanolamine hydrochloride-NaOH (pH 8.5) was used to deactivate excess 
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binding groups. See plate layout according to BIAcore CM5 immobilisation wizard 
(Figure 2.2 Biacore CM5 Chip immobilisation plate set up according to template 
protocol. 
 
Figure 2.2 Biacore CM5 Chip immobilisation plate set up according to template 
protocol. 
Kinetic affinity analysis was carried out using starting sample concentrations of 200-
400nM with ½ dilutions in 1HBS-EP+ (10mM HEPES, 150mM NaCl, 0.05% v/v 
Surfactant P20, pH 7.4 10mM HEPES, 150mM NaCl, 0.05% v/v Surfactant P20, pH 
7.4) to allow for multi-cycle kinetics. Flow rate was 30µL/min with association and 
disassociation times of 300s. The chip surface was regenerated using 10mM Glycine-
HCL, pH2.5. Affinity analysis was carried out using the BIAevaluate software with 
global model fitting via Boltzmann fitting.  
2.17 Design of Experiments 
A central composite design (CCD) was used for optimization of buffer conditions for 
His-tagged CEA Ni-IMAC binding. Three variables were investigated with 
parameters based on standard IMAC binding buffers; (A) pH, (B) NaCl concentration 
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(mM) and (C) imidazole concentration (mM). Clarified supernatant (100mL) 
containing His-tagged CEA was adjusted to the appropriate buffer composition and 
randomized using the design matrix prior to capture using a 5mL HisTrap column 
(GE Healthcare, Buckinghamshire, UK). CEA yield was assessed via ELISA and 
process interactions were analyzed using Design-Expert 8 (Stat-Ease, Inc, MN. USA).  
Table 2.3 General reagents and buffers 
Buffer/reagent name  
SDS-PAGE running buffer 
250mM Tris Base, 1.92M Glycine, 1% 
SDS solution, pH 8.3 
Western blot transfer buffer 
250mM Tris Base, 1.92M Glycine, 1% 
SDS solution, pH 8.3 
Protein A elution buffer 100mM Citric acid, pH 2.7 
Protein A binding buffer  20mM Sodium Phosphate, pH 7.2 
Protein A wash buffer 20mM Sodium Phosphate, pH 7.2 
Protein A Neutralisation buffer 1M Tris-HCL, pH 9.0 
IMAC binding buffer 0.5M NaCl/ 0.5x PBS/ 10mM imidazole. 
IMAC  100mM Nickel Sulphate 
IMAC elution buffer 200mM imidazole/0.5X PBS/ 0.5M NaCl 
IMAC wash buffer 0.5M NaCl/ 0.5x PBS/ 40mM imidazole 
ELISA development buffer 
0.1M sodium citrate, 40mg/100mL 
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Ortho-phenylenediamine 
HBS-EP+ 
0.1 M HEPES, 1.5 M NaCl and 0.5% v/v 
Surfactant P20 pH 7.4 
PBS-Tween 1x PBS, 0.05% (v/v) Tween 
Phosphate buffered saline (PBS) NaCl 137mM, KCL 2.7 mM, Na2HPO4 
10 mM, KH2PO4 1.8 mM 
Reducing buffer 2.5mL MilliQ, 2.5mL 1MTris-HCL 
(pH6.8), 4.0mL Glycerol, 0.8g SDS, 
0.8mL β-Mercapto-ethanol, 0.4mg 
Bromophenol Blue.  
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Chapter 3 Development of a rapid and cost effective recombinant 
protein expression system in mammalian cells using transient lab 
scale production  
3.1 Introduction 
Industrial production of complex transgenic glycoproteins such as therapeutic 
antibodies or Fc conjugates currently takes place in stably transfected mammalian 
cells. This ensures the correct structure and high expression of the protein required for 
therapy, as described in section 1.6.1. However, the process of stable clone selection 
is laborious and time consuming (Backliwal et al., 2008c) compared to transient gene 
expression  (TGE) which can provide significant advantages when rapid production is 
required (Wurm, 2004).  
TGE allows recombinant protein to be obtained a matter of days after transfection, 
rather than weeks as in the case of stable gene expression. Use of TGE early in 
protein development processes thereby provides a means for rapid protein expression 
with low cost and time constraints.  Assessment of pre-clinical performance can then 
be achieved using small amounts of recombinant protein. Furthermore, TGE can be 
used to predict recombinant protein expression levels in stable cells (Bentley et al., 
1998; Diepenbruck et al., 2012; Pybus et al., 2014b). TGE is therefore often used to 
produce the first quantities of novel proteins prior to committing to stable cell 
selection allowing more efficient product screening (Agrawal and Bal, 2012).  
The choice of host system for expression of recombinant proteins is important to 
ensure correct protein function and productivity. Suspension adapted Chinese 
Hamster Ovary (CHO) cells are currently the industry standard for recombinant 
glycoprotein production due to regulatory familiarity and high yields. It would 
therefore be advantageous to use CHO cells as both preliminary and endpoint 
expression systems for a seamless developmental transition from the lab bench. 
However, the Human Embryonic Kidney (HEK293) cell line has also been adapted to 
serum-free suspension growth and is preferentially utilised for TGE due to the higher 
transfection efficiencies (Sun et al., 2008).  
 78 
Both cell types can be transfected using a multitude of reagents and scales with 
varying limitations, associated cost and success. The scalable nature of TGE enables 
protein production at a range of volumes to meet requirements; however it is not yet 
clear what effects scale has on the subsequent cell growth, gene expression and 
protein stability.  
The work in this chapter was designed to develop a system for rapid, scalable and cost 
effective production of recombinant proteins using a previously described scFv-Fc as 
a production model (Table 2.1). Unlike whole monoclonal antibodies, which have 
complications in terms of heavy chain to light chain ratios and the co-transfection 
using multiple vectors, scFv-Fc vectors are simple constructs that easily model the 
transfection behaviour of their larger counter parts. Comparison of transient gene 
expression in suspension adapted CHO and HEK293 cells and further optimisation 
and comparison of the performance of two transfection reagents was utilised to assess 
performance during scale up and yield of recombinant protein. Characterisation of the 
scFv-Fc was carried out to investigate the effect of scale on protein stability and to 
evaluate the model protein as a potential therapeutic candidate.  
Aims  
Develop a transient mammalian expression system for rapid, scalable and cost 
effective production of recombinant proteins for use in laboratory scale production 
and characterise resulting products 
Objectives 
• Construct	  a	  plasmid	  for	  scFv-­‐Fc	  expression	  in	  mammalian	  cells	  	  
• 	  Develop	  a	  system	  for	  transient	  expression	  of	  scFv-­‐Fc	  comparing	  CHO-­‐S	  and	  HEK293F	  cells	  
• Optimise	  transfection	  protocols	  for	  cost	  efficient	  protein	  expression	  	  
• Establish	  the	  effects	  of	  transfection	  scale-­‐up	  on	  cell	  growth,	  productivity	  and	  protein	  stability	  
• Characterise	  the	  affinity	  and	  in	  vitro	  binding	  of	  scFv-­‐Fc	  to	  the	  target	  antigen	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3.2 Results 
3.2.1 Construct a plasmid for scFv-Fc expression in mammalian cells 
3.2.1.1 Design and cloning of SM3EL-Fc expression cassette 
Recombinant DNA coding for the single chain variable fragment, SM3E (Table 2.1), 
was kindly provided by Dr. Enrique Miranda Rota. The scFv was fused to the Fc 
portion of a murine IgG2a antibody using a pFUSE-mIgG2A plasmid vector from 
Invitrogen (Toulouse, Fr), also containing the interleukin 2 signal sequence ensuring 
secretion of the protein. PCR amplification primers were designed to amplify the scFv 
fragment (757bp) and add the restriction sites 5’ EcoRI and 3’ BglII to enable simple 
complementary end ligation into the multiple cloning site of the vector.  
Primer sequences;  
Sense (Fwd): GCATACGAGCTGAATTCGATGGCTCAGGTGAAGCTGGAACA 
Antisense (Rvs): CCTCTGGGAGATCTTTTGATCTCCAGCTTGGT 
N.b. Underlined letters indicate insertion of restriction sites. Sense (Fwd) inserts 
EcoRI and Antisense (Rvs) inserts BglII sites.  
The scFv fragment was amplified via PCR (Section 2.3.3) and double digested, along 
with the murine Fc expression vector, using BglII and EcoRI. The resulting fragments 
were resolved via agarose gel electrophoresis, excised and purified to obtain clean 
DNA. Ligation was successful using a 3:1 molar ratio (vector to insert) and the 
resulting plasmid DNA was transformed via electroporation into Top10 E. coli before 
incubation on 100µg/mL ampicillin-2TY selection plates overnight at 37°C. A total of 
12 colonies were selected and grown in 5mL ampicillin-2TY media overnight prior to 
isolation of plasmid DNA. An analytical restriction digest of pDNA was performed 
using BglII and EcoRI with expected fragment sizes of 4189bp and 751bp, clone 6 
produced DNA bands with the correct pattern (Figure 3.1Error! Reference source 
not found.). The scFv-Fc coding region of the plasmid was sequenced successfully 
and no mutations were incorporated during the cloning process.	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Figure 3.1 Restriction digest of pFUSE-SM3EL-Fc expression plasmid. DNA 
coding for an scFv was purified and ligated into an Fc fusion vector to produce an 
scFv-Fc conjugate. Successful ligation of the vector and insert was confirmed by 
analytical restriction digest and 1% agarose gel electrophoresis. A combination of 
EcoRI and BglII was used to cut the expression vector resulting in two bands at the 
expected sizes of 4189bp and 751bp. A 1Kb Hyperladder (Bioline) was included as a 
molecular weight marker. 
The plasmid DNA was amplified via growth of transformed TOP10 E. coli in a 
volume dependent on the quantity of DNA required.  For large-scale transfection 
purposes plasmid DNA was generated using an endotoxin-free Gigaprep kit from 
Qiagen using 2.5L bacterial cultures. After optimisation this yielded as much as 5mg 
of endotoxin free pDNA suitable for transfection at bioreactor scale.   
3.2.1.2 Preliminary transient expression of SM3EL-Fc in HEK293F and CHO 
cells 
HEK293F and CHO cells were transfected using polyethylenimine (PEI) in 30mL 
cultures that were maintained under incubation conditions for 7 days (Figure 3.2 
A/B).  Samples (0.5mL) were removed daily, centrifuged and the supernatant stored 
at -80°C. On day 7, cells were separated from the supernatant via centrifugation and 
filtration before a 1mL protein A mAbSelect chromatography column was used to 
capture scFv-Fc. The eluted protein was dialysed into PBS over night before being 
quantified by UV absorbance at 280nm using a nanodrop spectrophotometer as well 
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as separation and visualisation using 10% SDS-PAGE (Figure 3.2 D). Under reducing 
conditions the product resulted in a single band at the expected size (55 kDa) 
indicating that no product breakdown had occurred during expression and purification 
from either CHO or HEK293 cells. Secreted protein in the supernatants was 
quantified using a double antibody sandwich enzyme linked immunosorbant assay 
(DAS-ELISA) based on anti-kappa light chain and anti-murine Fc HRP conjugate 
antibodies. The ELISA was quantified against a standard curve generated with the 
purified scFv-Fc of known concentrations. Expression over the 7-day period reached 
a maximum of 8.65µg/mL in HEK293F cells and ~3.8ug/mL in CHO cells (Figure 
3.2 C), with a total yield of 0.27mgs and 0.19mgs respectively after dialyses into PBS.  
Preliminary expression of SM3EL-Fc confirmed that the plasmid construct 
successfully produced protein expression and that the product was quantifiable in 
supernatants by ELISA. Whilst expression of the protein was greater in HEK293F 
cells it remained low in both systems. 
 
Figure 3.2 Preliminary expression of SM3EL-Fc in suspension HEK293F and 
CHO cells. 30mL cultures of HEK293F and CHO-S cells were transfected at a cell 
density of 1x106 cells/mL using PEI. The cell growth and viability was assessed daily 
using the Trypan blue assay. Protein expression over 7 days was assayed using a 
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DAS-ELISA. Proteins from both flasks was resolved by 10% SDS-PAGE. A) 
HEK293F cell growth and viability B) CHO cell growth and viability C) Transient 
expression of SM3EL-Fc by HEK293F and CHO cells as determined by DAS-ELISA 
D) SDS-PAGE resolution of purified SM3EL-Fc showing CHO and HEK293 cell 
expressed SM3EL-Fc next to a PageRuler molecular weight marker. The molecular 
weight of the protein is 55 kDa. Error bars represent 1 standard deviation away from 
the mean (Biological and technical replicates = n3).  
 
3.2.2 Develop and optimise a system for transient expression in either CHO or 
HEK293 cells 
3.2.2.1 Polyethylenimine mediated transfection efficiency of HEK293F and 
CHO-S cells  
Maximal yield of a protein is dependant on the percentage of cells successfully 
transfected, hence the transfection efficiency of CHO and HEK293F cell lines was 
determined via expression of a green fluorescent protein (GFP) reporter gene.  
Analysis of GFP expression by cells was achieved via fluorescence associated cell 
sorting (FACS) at 24 and 48 h post transfection with PEI to allow for a full cell cycle 
to take place. The HEK293F cell line showed a greater GFP positive population than 
CHO cells at both time points (at 24 h HEK293F 23.4% vs CHO 0.25% and at 48 h 
HEK293F 24% vs CHO 1.63%) (Figure 3.3). These results confirmed previous 
findings in the literature and determined the choice of expression system used for 
further transient expression of the scFv-Fc.  
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Figure 3.3 Polyethylenimine-mediated transfection efficiency of CHO and 
HEK293F cells expressing green fluorescent protein. CHO and HEK293F cells 
were transfected with pDNA coding for Green fluorescent protein (GFP) using PEI. 
GFP expression was assayed after both 24 and 48 h post transfection and compared to 
non-transfected control cells. A) HEK293 non-transfected control B) HEK293F 24 h 
post transfection C) HEK293F 48 h post transfection D) CHO non-transfected control 
E) CHO 24 h post transfection F) CHO 48 h post transfection.  
3.2.2.2 Comparing efficiency of HEK293F transfection with polyethylenimine 
and 293Fectin 
The cost and performance of transfection reagents can vary substantially. Here two 
reagents based on a liposomal transfection method were compared for transfection 
efficiency. Polyethylenimine is one of the least expensive reagents whilst 293Fectin is 
at the top of the price spectrum. HEK293F cells were transfected with a red 
fluorescent reporter protein (RFP) in shake flask cultures of 30mL according to the 
manufactures instructions (293Fectin) or previously published methods (PEI –
Durocher et al., 2002). 293Fectin showed improved transfection efficiency compared 
to PEI mediated transfection after 24 h, 39.03% and 5.66% respectively. However 
there was also notable cytotoxicity and change in cell shape within hours of 293Fectin 
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addition compared to little change associated with PEI mediated transfection (Figure 
3.5). 
   
Figure 3.4 Comparison of PEI and 293Fectin transfection efficiency of HEK293F 
cells. HEK293F cells were transfected with pDNA coding for the DS red fluorescent 
protein (DS-RFP) as a reporter of transfection efficiency. The number of DS-RFP 
positive cells was compared between two transfection reagents, 293Fectin 
(LifeTechnologies) and PEI. Control conditions were exposed to transfection reagents 
alone (without DNA) whilst transfections were carried out according to manufacturers 
or published protocols for PEI (Durocher et al., 2002). A) HEK293F cells exposed to 
293Fectin alone. B) HEK293F cells transfected with 293Fectin. C) HEK293F cells 
exposed to PEI alone. D) HEK293 cells transfected with PEI. 
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Figure 3.5 HEK293F cells transiently expressing red fluorescent protein 24 h 
after transfection. HEK293F cells were transfected with pDNA coding for the DS 
red fluorescent protein (DS-RFP) as a reporter of transfection efficiency after 
transfection with either PEI or 293Fectin. The suspension HEK293F cells were plated 
on microscope slides after 24 h for fluorescence and cell morphology analysis. Cell in 
images A and C were transfected with 293Fectin. Cell in images B and D were 
transfected with PEI. Changes in cell morphology were observed after transfection 
with 293Fectin when compared to control and PEI transfected cells. These changes 
included cell clumping and enlargement as can be seen in image C.  
 
3.2.2.3 Optimisation of polyethylenimine to DNA ratio  
Whilst manufacturer’s guidelines are supplied with most commercial kits, published 
literature on optimum ratios of PEI to DNA for cell lines remains inconsistent. These 
factors have a significant effect not only on the transfection efficiency of cell cultures 
but also on recombinant protein expression. Compared to 293Fectin, PEI transfection 
efficiency was both lower and more variable (cells positive for the reporter protein 
were between 5.66-24%). Hence, the transfection protocol was optimised using a 
range of DNA:PEI ratios selected from the literature (Durocher et al., 2002; Akinc et 
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al., 2005; Pham et al., 2006; Backliwal et al., 2008b; Codamo et al., 2011; Longo et 
al., 2013).  
HEK293F cells were seeded at 0.5x106 cells/mL, in 30mL of Freestyle serum-free 
expression medium 24 h prior to transfection, to obtain a culture in log growth phase. 
Table 3.1 shows the DNA:PEI ratios investigated during the study and resulting GFP 
positive cells (%) in transfected populations 48 h later.  
DNA 
(µg/MVC) 
PEI 
(µg/MVC) 
Cells positive 
for GFP (%) 
0.5 1 23.55 
1 1 5.66 
1 2 38.34 
1 4 11.34 
1 8 2.58 
Table 3.1 Effect of DNA: PEI ratio on percentage of GFP expressing HEK293 
cells in 30mL suspension culture. HEK293F cells at a density of 1x106 cells/mL 
were transfected with plasmid DNA coding for GFP according to the above PEI:DNA 
ratios. The percentage of cells positive for GFP expression was analysed 48 h after 
incubation using flow cytometry as described previously. A DNA to PEI ratio of 1:2 
µg/ million viable cells (MVC) yielded the greatest percentage of GFP positive cells 
(38.34%).  
 
The results showed that a DNA:PEI ratio of 1:2 resulted in an improved transfection 
efficiency of over 30% compared to the worst performing ratios. These conditions 
were used for transfection of expression plasmids. Having established the optimum 
transfection ratios these parameters were used in future experiments and scale up of 
production.  
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3.2.3 Establish the effects of transfection scale-up on cell growth, productivity 
and protein stability 
Further characterisation of SM3EL-Fc, including in vitro and in vivo experiments, 
demanded increased production capacity from small shake flask based expression. 
Scale-up of transient transfection is often used as the simplest method for obtaining 
increased yields of recombinant protein (Derouazi et al., 2004). However scaling a 
transfection process does not necessarily maintain the same expression and growth 
characteristics as small-scale transfections.  
In this experiment HEK293F cells were transfected as above using a directly scaled 
transfection approach with 10fold increases in cell culture volume (30mL, 300mL 
shake flaks and a 3L bioreactor) and subsequent increases in transfection solutions. At 
30mL and 300mL scales the effect of PEI and 293Fectin was compared in shake 
flasks, however only PEI was used to transfect at 3L bioreactor scale due to cost 
limitations. The effect of transfection on cell growth characteristics was analysed 
immediately after addition of DNA complexes and over the successive culture period.  
3.2.3.1 Viability of transiently transfected HEK293F cells 
In preliminary experiments cytotoxicity was observed after exposure to both PEI and 
293Fectin, hence transfections were carried out alongside control conditions where no 
DNA was included in order to establish the effect of the two reagents on cell viability 
without the increased metabolic stress of expressing protein.  
Results showed that cells in 30mL and 300mL shake flasks subjected to either 
transfection reagent declined in viability at a greater rate than cells with no addition. 
Both reagents had a cytotoxic effect on cells within 24 h both with and without DNA 
included. However, the effect was less pronounced in cultures with PEI compared to 
293Fectin. Viability of transfected cells decreased more than mock-transfected cells 
in both PEI and 293Fectin conditions. There was no effect of DNA addition alone on 
cell density or viability when compared to control cells. The DNA only condition was 
therefore eliminated from further experiments.  
Scaling to the 300mL shake flask condition maintained similar viability profiles to 
30mL cultures without such a dramatic reduction in viability after day 5-6. Again, 
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exposure to transfection reagents reduced cell viability compared no addition controls. 
293Fectin reduced viability more than PEI in all shake flask conditions.  
Scale up of transfection to 3L bioreactor fermentation showed comparable results to 
shake flask cultures with a drop in viability after transfection as observed at smaller 
scales. Bioreactor based cultures recovered from transfection at a faster rate than 
those grown and transfected in shake flasks but produced a lower total cell density of 
only 2.8x106 cells/mL; substantially less than in shake flasks.
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Figure 3.6 Viability of HEK39F cell cultures after PEI and 293Fectin transient 
transfection. HEK293F cells cultures were transfected at 30mL, 300mL and 3L 
scales using either PEI according to the previously optimised protocol or 293Fectin 
according to the manufacturer’s instructions. Viability was determined via the 
Trypan blue exclusion assay using a Vi-Cell XR automated cell counter (Beckman 
Coulter, High Wycombe, UK). A) 30mL cultures with no DNA addition. B) 30mL 
cultures with DNA addition. C) 300mL cultures with no DNA addition D) 300mL 
cultures with DNA addition. E) 3L bioreactor culture transfected with PEI:DNA 
complex only.  Error bars represent 1 standard deviation away from the mean (n=3).  
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3.2.3.2  Growth of transiently transfected HEK293F cells 
Exposure of 30mL scale cultures to transfection reagents reduced total cell number 
achieved over the culture period compared no addition controls. Again, 293Fectin 
had a greater impact than PEI on total cell growth (Figure 3.7). There was also a 
marked reduction in total cell numbers when DNA was included in PEI mediated 
transfection complexes, supporting previous results. However, the same effect 
however was not observed in the 293Fectin transfected cells.  
Upon scale up to 300mL there was an increase in the total cell density of transfected 
conditions of almost double when compared to the 30mL transfections. The cell 
density of transfected and mock-transfected cells was not significantly reduced. In 
the 3L bioreactor transfection, a low cell growth rate was observed after transfection 
compared to shake flask growth. The reactor culture reached a maximum of 2.67x106 
cells/mL and began to reduce in density after a shorter growth period.  
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Figure 3.7 Total cell growth HEK39F cell cultures after PEI and 293Fectin 
transient transfection. HEK293F cells cultures were transfected at 30mL, 300mL 
and 3L scales using either PEI according to the previously optimised protocol or 
293Fectin according to the manufacturer’s instructions. Cell density was determined 
using a Vi-Cell XR automated cell counter. A) 30mL cultures with no DNA addition. 
B) 30mL cultures with DNA addition. C) 300mL cultures with no DNA addition D) 
300mL cultures with DNA addition. E) 3L bioreactor culture transfected with 
PEI:DNA complex only, arrow indicates transfection point.  Error bars represent 1 
standard deviation away from the mean (n=3).
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3.2.3.3 The effect of transfection scale on scFv-Fc expression 
Secretion of SM3EL-Fc facilitates simple quantification in the supernatant using a 
specific plate-trapped antigen enzyme linked immunosorbant assay (PTA-ELISA). 
ScFv-Fc titres were analysed by removing samples daily, separating solids and 
storing the supernatant at -80°C to ensure accurate analyses of sFv-Fc content.  
Although transfection efficiency was greater with 293Fectin (3.2.2.2), there was an 
increase of ~48% in scFv-Fc expression with PEI (60µg/mL and 38µg/mL 
respectively) at 30mL. Unsurprisingly, there was no expression of scFv-Fc detected 
in cells given DNA only. When scaled to 300mL there was an increase in the 
productivity over time as well as maximal scFv-Fc in the supernatant (PEI maximal - 
72µg/mL and 293Fectin maximal expression of 61µg/mL) (Figure 3.8). In the 3L 
bioreactor however, expression seemed to follow the expression profile of 30mL 
cultures with a stable period of around 3 days of high expression followed by a rapid 
decrease.  
In all conditions secreted scFv-Fc reached slightly less than the maximal level for 
each culture around 24 h (Figure 3.8) after transfection. This result correlates with 
the predicted cell cycle period for HEK293F cells in exponential growth, a 
prerequisite for the transfection process to take place. 
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Figure 3.8 Total SM3EL-Fc in supernatant of transiently transfected HEK293F cells. HEK293F cells cultures were transfected at 30mL, 
300mL and 3L scales using either PEI according to the previously optimised protocol or 293Fectin according to the manufacturer’s instructions. 
Samples were removed daily from cultures of each scale, centrifuged and the supernatant stored at -80°C until required. The supernatant was 
assayed for scFv-Fc content using a target specific PTA-ELISA. A) 30mL shake flask. B) 300mL shake flask. C) 3L pneumatic SUT bioreactor. 
Error bars represent 1 standard deviation away from the mean (n=3).
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3.2.3.4 The effect of transfection scale on scFv-Fc stability 
SM3EL-Fc was purified from shake flask and bioreactor cultures using protein A 
MabSelect chromatography (2.10.1). The purified protein from the different scales 
and transfection methods was assessed and compared by SDS-PAGE after the 
culture period (Figure 3.9). There was no difference in the breakdown of protein 
harvested from cells transfected with the different transfection reagents at each scale, 
even though the total numbers of cells, and therefore potential for protease activity, 
differed substantially.  
 
Figure 3.9 SDS-PAGE separation of transiently expressed SM3EL-Fc. Purified 
scFv-Fc resulting from transient expression at three different scales (30mL, 300mL 
and 3L) was diluted to 1mg/mL prior to addition of reducing buffer (see Table 2.2) 
and incubation at 100°c for 5 min. The proteins were resolved on a 10% SDS-PAGE 
gel and the number and size of bands compared between samples. There was no 
discernible difference between the products coming from the different scales.   
 
Analysis of temperature dependant protein stability was carried out via differential 
scanning fluorimetry (DSF). Proteins were incubated with SYPRO Orange, a 
fluorescent dye that binds to exposed hydrophobic protein regions, and subjected to a 
temperature ramp of 1°C per 15 seconds. As temperature increases the amount of 
unfolded protein also increases enabling greater binding of SYPRO orange to 
hydrophobic residues. The fluorescence of bound SYPRO was analysed after every 
degree increase to obtain an analysis of key temperature transitions and stability 
characteristics. Key transitions analysed include the onset of denaturation, peak 
fluorescence and the temperature at which 50% of the protein is denatured, the 
Tm50. The Tm50 can be calculated via a first derivative curve analysis of the raw 
64KDa&
50KDa&
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data and is most often used to compare the thermal stability of proteins (Figure 
3.10).  
As expected the DSF results showed that there was no difference between the Tm50 of  
scFv-Fc from cells transfected with PEI or 293Fectin (Tm50 =66.5°C and 66°c 
respectively) or between production scales (Figure 3.11). 
 
Figure 3.10 Temperature dependant stability of SM3EL-Fc from 30mL 
HEK293F cell transfection. SYPRO orange is a fluorophore that binds to 
hydrophobic protein regions allowing analysis of protein unfolding via differential 
scanning fluorimetry. SYPRO orange was diluted to a 1x concentration in 25µl of 
purified scFv -Fc (1mg/mL) in PBS buffer. Temperature dependant protein unfolding 
was assessed by heating from 20°C to 99°C at a rate of 1°C/15 s followed by a 
fluorescence read using excitation and emission of 480nm/568nm. The temperature 
of equilibrium between folded and unfolded protein (Tm50) was established using a 
first derivative curve analysis. This data shows Triangles indicate SYPRO 
fluorescence (RFU), squares indicate plot of first derivative function (ΔRFU/ΔT).  
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Figure 3.11 Comparison of temperature dependant stability of SM3EL-Fc 
produced at three different scales using two different transfection reagents. 
Differential scanning fluorimetry was used to analyse temperature dependant protein 
unfolding of scFv-Fc from the range of production scales and transfection reagents 
used in previous experiments. These include the reagents PEI and 293Fectin at scales 
30mL, 300mL and 3L (PEI only) transfections. There was no difference between the 
Tm50 values for the proteins.  Error bars represent 1 standard deviation distance 
from the mean (n=3).  
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3.2.4 Characterise the affinity and in vitro binding of scFv-Fc to the target 
antigen 
3.2.4.1 Determination of the affinity of SM3E-Fc to NA1 via association and 
disassociation curve fitting 
Kinetic association (Ka) and disassociation (Kd) constants of SM3EL-Fc were 
determined via surface plasmon resonance using a T200 enabled Biacore machine. A 
diagram depicting the assay designs used here can be seen in Figure 3.12. 
Equilibrium dissociation constants were established using this data according to 
Equation 4. The binding kinetics of SM3EL-Fc for NA1, the specific epitope of CEA 
to which it is targeted, were analysed using recombinant NA1 (Tolner et al., 2013). A 
literature review of SPR analysis protocols for antibody-antigen interactions 
recommended immobilisation of the antibody fragment with the ligand (antigen) 
passed over it, however during early stage experiments the amount of NA1 available 
proved a limiting factor in experimental design. Therefore, the epitope (NA1) was 
immobilised for SPR analysis rather than the scFv-Fc conjugate.  
𝐾!   = 𝑘!𝑘! = (Α𝑏)(𝐴𝑔)(𝐴𝑏𝐴𝑔)  
Equation 4 Equilibrium dissociation constant (KD). A dissociation constant 
describes the relationship between bound and unbound antibody and antigen; where 
Ab is antibody and Ag is antigen. ka represents kinetic association (Kon) and kd 
represents kinetic dissociation curves (koff).  
3.2.4.2 Immobilisation of the NA1 epitope of CEA to Streptavidin chip 
NA1 was covalently biotinylated using an EZ-Link Sulpho-NHS-LC-Biotinylation 
kit from Invitrogen (see methods) and desalted using a PD-10 column before 
immobilisation on a pre-prepared streptavidin coated (SA) Biacore chip from GE 
Healthcare (Buckinghamshire, UK) using the manufacturer’s protocol. A 10nM 
solution of NA1 was prepared and immobilised at 800RU (Figure 3.13) in cell 2 of 
the chip, leaving cell 1 blank as a negative control.  
3.2.4.3 Kinetic affinity analysis of SM3E-Fc on NA1 
SM3E-Fc was applied to the NA1-SA-chip at concentrations of 400, 200, 100, 50, 25 
and 12.5nM with subsequent regeneration of the chip carried out with 10mM glycine 
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at pH 2. Results indicated that there was excellent binding compared to negative 
control cells giving KD results that exceeded the detection limitations of the Biacore. 
Therefore only estimated reports could be generated, giving a KD (M) of 3.818x10-12 
(low picomolar range affinity) ( Table 3.2 and Figure 3.14). Whilst these results 
indicated an exceptionally high affinity of SM3EL-Fc for NA1 the experiment was 
repeated using immobilised scFv-Fc in order to achieve more accurate results. 
A.  
 
B.  
 
Figure 3.12 Diagram of typical surface plasmon resonance (Biacore) chip assay 
set up. An immobilised ligand (in this instance either the scFv-Fc (A) or the antigen 
(B)) is attached to the surface of the chip prior to measurement of binding of an 
analyte. Capture of proteins on the chip surface can be achieved using a range of 
methods, most commonly amine coupling (covalent binding), His-tag to Ni-NTA 
binding or biotin-avadin binding. Changes in laser-angle refraction are measured in 
relative fluorescence units (RFU) for binding analysis.  
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Figure 3.13 SPR sensorgram showing immobilisation of biotinylated NA1 on a streptavidin chip. The NA1 region of CEA was expressed 
and purified from Pichia pastoris. Immobilisation of NA1 for affinity analysis was carried out by biotinylation of the protein and binding to a 
streptavidin coated Biacore chip. Biotinylated NA1 was de-salted using a PD10 column (GE Healthcare) and immobilised on the chip at ~1000 
relative response units prior to affinity analyses via surface plasmon resonance.  
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Figure 3.14 Sensorgram showing SM3EL-Fc binding to immobilised NA1. 
Purified SM3EL-Fc was passed over immobilised NA1 at concentrations of 400nM 
(red), 200nM (green), 100nM (pink), 50nM (blue), 25nM (brown) and 12.5nM 
(purple) in HEPES-P buffer (see Table 2.3). Association (kon) and dissociation (koff) 
phases occurred over 120s and 300s respectively and the chip was regenerated using 
10mM Glycine-HCL, pH2.5. Binding kinetics and affinity constants were obtained 
using the BIAEvaluate software.  
Table 3.2 Affinity (KD) of SM3EL-Fc for immobilised NA1 antigen. Purified 
SM3EL-Fc was passed over immobilised NA1 at concentrations of 400nM, 200nM, 
100nM, 50nM, 25nM and 12.5nM in HEPES-P buffer (see Table 2.3). The KD was 
estimated to be 3.818x10-12M affinity.  
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3.2.4.4 Immobilisation of SM3EL-Fc to CM5 chip via EDC/NHS coupling 
Immobilisation of SM3EL-Fc was carried out using amine-coupling chemistry on a 
Biacore CM5 Amine chip according to the manufacturer’s instructions (see 2.16). 
However this method was unsuccessful under standard binding conditions. Binding 
buffer for the immobilisation was optimised between parameters of pH 4-5.5 in 
10mM Acetate (Figure 3.15). Results indicated that the binding response varied 
substantially depending on pH. A maximum relative response of 32695RU was 
possible at pH 4.5 compared to a minimum of 1150RU at pH 5.5. Subsequent binding 
cycle analysis confirmed results from pH scouting with a maximum relative response 
of 32540RU in cycle 3 correlating to pH 4.5 (Figure 3.16).  
EDC/NHS activation of the CM5 amine chip was carried out prior to SM3EL-Fc 
addition in 10mM acetate (pH4.5) binding buffer. Final immobilisation of SM3EL-Fc 
was reduced to 442.9 RU to ensure accuracy of kinetic analysis. As described 
previously a reference cell (1/4) was left blank on the chip (3.2.4.2). The same 
immobilisation technique was carried out with two different scFv-Fc constructs, one 
with affinity for NA1 and one without. Quality control of the chip was achieved by 
flowing a 200nM solution of NA1 over all cells of the chip. The results showed 
positive binding in the two cells with scFv-Fc’s that had affinity for NA1 and none in 
either the blank cell or the cell immobilised with a non-binding scFv-Fc (Figure 3.17, 
Figure 3.18 and Table 3.3).  
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Figure 3.15 Sensorgram showing relative response of SM3EL-Fc in binding 
buffers of different pH. Binding conditions for the immobilisation of SM3EL-Fc 
using amine-coupling were optimised using binding buffers of 10mM acetate from pH 
4 to 5.5. The relative binding response of the scFv-Fc in each buffer was measured to 
ensure the optimum buffers for immobilisation were used. Association phases of 
scFv-Fc in different buffers was analysed over 180s Ka rates were similar between 
buffers of pH 4 and 4.5 whilst lower binding was observed at pH5.5.  
 
Figure 3.16 Maximum binding (RU) of SM3EL-Fc to CM5 chip pH altered 
buffer. Consecutive cycle numbers relate to binding buffer 1) 10mM Acetate pH5.5. 
2) 10mM Acetate pH5.0. 3) 10mM Acetate pH4.5 4) 10mM Acetate pH4. Maximum 
relative response indicates that buffer composed of 10mM acetate pH 4.5 was optimal 
giving the highest RU of 32540 compared to the lowest of 1150RU at pH5.5. 
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Figure 3.17 Chip testing with binding of NA1 to immobilised SM3EL-Fc. 
SM3EL-Fc was described earlier as an anti-CEA scFv-Fc, it was predicted to bind 
with high affinity to the NA1 ligand. The NA1 epitope was passed over the 
immobilised scFv-Fc as a concentration of 200nM confirming activity of the 
immobilised construct at ~72 RU.  
 
Figure 3.18 Chip testing with binding of  NA1 to non-binding scFv-Fc. B6L-Fc is 
an scFv-Fc with no affinity for CEA/NA1. As predicted there was no binding of NA1 
to B6L-Fc confirming that there was no non-specific binding activity of NA1 to the 
chip surface.  
Immobilised 
Construct 
Ka 
(1/Ms) 
Kd (1/s) KD (M) Rmax 
(RU) 
Chi2 
SM3EL-Fc 
(Anti-NA1)  
2.32x104 3.68x10-6 1.586x10-10 97.81 0.0725 
B6L-Fc   
 
- - - - - 
Table 3.3 Binding of NA1 solution to immobilised scFv-Fc. SM3EL-Fc was 
immobilised on a CM5 amine Biacore chip (GE Healthcare). A 200nM solution of 
NA1 was passed over the chip with 
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3.2.4.5 Kinetic affinity analysis of NA1 on immobilised SM3EL-Fc 
The affinity of SM3EL-Fc to NA1 again resulted in the system being capable of 
calculating only a predictive KD, however this was no longer in the picomolar range 
dropping to 1.58x10-10. Having analysed the affinity of the scFv-Fc for the target 
when immobilised to a Biacore chip and passed over an NA1 immobilised chip, the 
predictive value had varied in terms of overall KD. In order to clarify the result and 
confirm binding to the whole molecule in a more biologically relevant fashion the 
assay was repeated using the whole CEA molecule.  
3.2.4.6 Kinetic affinity analysis of CEA on immobilised SM3EL-Fc 
CEA has previously proved a difficult protein to use in SPR analysis, possibly due to 
it’s heavily glycosylated structure, hence the use of the NA1 epitope in previous 
experiments. However for a further affinity analysis of SM3EL-Fc, CEA binding was 
tested using commercially available CEA from R&D. The same SM3EL-Fc 
immobilised chip was used for analysis of CEA binding and NA1 after regeneration. 
Results showed that the affinity of SM3EL-Fc for the whole CEA molecule was 
predicted to be in the same range as the NA1 region alone with a KD of 1.881x10-12 
compared to 3.818x10-12 on immobilised NA1. The correlation between these results 
increased confidence in the results suggesting that the affinity of SM3EL-Fc was in 
the picomolar range (Figure 3.19). 
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Figure 3.19 Sensorgram showing binding of CEA to immobilised SM3EL-Fc. 
Recombinant CEA was passed over the chip at 200nM (red), 100nM (blue), 50nM 
(pink x2), 25nM (green), 12.5nM (red), 6.125(dark green) and 3.125nM (dark blue) in 
HEPES-P buffer (see section 2.16). Association (kon) and dissociation (koff) phases 
occurred over 300s each and the chip was regenerated using 10mM Glycine-HCL, 
pH2.5. Binding kinetics and affinity constants were obtained using the BIAevaluate 
software.  
 
 
 
Table 3.4 Binding kinetics of immobilised SM3EL-Fc for recombinant CEA. 
Recombinant CEA was passed over the scFv-Fc immobilised to the chip at a 
concentrations of 200nM, 100nM, 50nM, 25nM, 12.5nM, 6.125 and 3.125nM. An 
estimated KD of 1.881x10-12M was calculated using ka and kd values with the 
BIAevaluate software.  
3.2.4.7 In vitro localisation of SM3EL-Fc in CEA expressing tissue 
Having assessed the binding of SM3EL-Fc to recombinant CEA, the in vitro targeting 
of SM3EL-Fc to CEA in the natural conformation was analysed by localisation to the 
target on Capan-1 cells at 4°C for 1 h (Figure 3.20). Bound SM3EL-Fc was stained 
with anti-murine IgG conjugated alexafluor 488 whilst the nucleus was stained with 
DAPI. Results showed a green florescence signal to be evident around the surface of 
the cell in the expected location of GPI-linked CEA whilst there was no comparative 
staining to on the CEA negative A375 cell line (Figure 3.21). In vitro localisation of 
SM3EL-Fc corroborated previous results and confirmed successful binding of the 
protein to CEA in its natural conformation on the cell surface with showed no off 
target activity.  
  106 
 
Figure 3.20 Localisation of SM3EL-Fc on CEA expressing Capan-1 cells after 1 
h. SM3EL-Fc was added to Capan-1 cells and incubated at 4°C for 1 h. Secondary 
staining of the scFv-Fc was achieved using an anti-murine IgG conjugated Alexafluor 
488 (green) whilst the nucleus is stained using DAPI (blue).  Image with help of Dr 
Enrique Miranda Rota.  
 
Figure 3.21 Localisation of SM3EL-Fc on A375 cell (CEA negative cell line). 
SM3EL-Fc was added to a CEA negative cell line (A375) and incubated for 1 h at 
4°C.  Secondary staining of the scFv-Fc was achieved using an anti-murine IgG 
conjugated Alexafluor 488 (green) whilst the nucleus is stained using DAPI (blue).  
Image with help of Dr Enrique Miranda Rota.  
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3.3 Discussion 
The aims of this chapter were to develop a mammalian expression system that worked 
in a rapid, scalable and cost effective fashion allowing production of recombinant 
proteins at lab scale. Many protein expression systems have substantially improved 
yields and lower costs, however mammalian cells have the advantage of being able to 
produce correctly glycosylated proteins that do not course immune responses due to 
post-translational modifications (Zhu, 2011) and retain functional characteristics. 
Despite this the cost and time of mammalian cell based protein expression can remain 
a barrier in some instances. 
TGE has a number of advantages over traditional stable cell based gene expression 
including no requirement for selection of stably integrated cells and thus no need to 
use reporter genes allowing for significantly reduced time between transfection to 
purification (Durocher et al., 2002). In practise this means that essential work on 
often-novel proteins can begin quickly allowing characterisation, without attributing 
time and costs to potentially unproductive stable gene selections. In-turn, this has led 
to its increased popularity, especially at lab scale (Geisse and Henke, 2005).  
CHO cells are the predominant mammalian system for recombinant protein 
expression usually in the form of stably transformed cells. Whilst HEK293 cells have 
advantages over CHO for TGE of r-proteins (Thomas and Smart, 2005) it would be 
advantages to use the final expression system for preliminary protein production in 
order to establish potential faults with the protein early rather than after stable cell 
selection and protein characterisation. For this reason both CHO and HEK293F cells 
were investigated as potential expression systems for the scFv-Fc. 
CHO cells yielded low quantities of protein after transient transfection, a maximum of 
3.84µg/mL, despite high numbers of viable cells and rapid growth whilst HEK293F 
cells expressed ~8.6 µg/mL. Analysis of the transfection efficiency of suspension 
CHO and HEK293F cells via GFP/RFP expression showed that the efficiency of 
CHO cell transfection with PEI was substantially lower than that of HEK293F cells 
(<2% and ~39% respectively) after optimisation. As a result the HEK293F system 
yielded a maximum yield of 72 µg scFv-Fc /mL meaning it was selected as the 
  108 
preferred expression system. Transfection of HEK293 cells can produce in the range 
of 50mg/L- 1g/L (Geisse and Henke, 2005; Baldi et al., 2007; Liu et al., 2008). TGE 
expression can be improved using a number of techniques are available to increase 
protein yield from TGE including the use of valproic acid (Backliwal et al., 2008c), 
cell cycle inhibitors (Tait et al., 2004) and apoptotic inhibition (Majors et al., 2008), 
however the range of expression yields present in the literature are indicative of the 
high variation in expression of even proteins of similar sequence (Pybus et al., 
2014b).  
Transfection reagents range hugely in price and productivity. Hence, a comparison of 
two different transfection reagents, PEI and 293Fectin, was carried out during scale 
up to investigate differences in the productivity, cell growth and stability of the 
resulting protein. PEI is a simple to make solution that has been used as a lipofection 
platform in many well cited studies (Backliwal et al., 2008b; Benjaminsen et al., 
2013; Codamo et al., 2011; Durocher et al., 2002; Longo et al., 2013) costing in 
region of £70/g, meanwhile 293Fectin (Life Technologies) has a price of £405/mL.  
The 293Fectin reagent outperformed PEI in terms of transfection efficiency as 
determined by RFP expression however also had greater cytotoxic effects on cells. 
The results shown here indicate that PEI out performed the more expensive reagent in 
terms of productivity. It should be noted that all there is greater potential for batch-to-
batch variation in the use of PEI solutions, as they are generally made in house.   
Direct scale up of the transfections to 300mL flasks produced an improved yield 
compared to small shake flasks using both reagents (PEI=72µg/mL and 293Fectin = 
61µg/mL). The hypothesis that improved maintenance of culture conditions in the 
bioreactor would produce an improved protein yield was not accepted after further 
scale up to a 3L bioreactor using PEI transfection produced a similar yield to the 
30mL shake flask condition. Whilst transfection appeared to reduce the total cell 
growth of cell cultures in the 30m and 3L conditions, the effect was less pronounced 
in the 300mL flasks potentially explaining the increase in protein yield.  
Analysis of protein stability was carried out as part of the product characterisation and 
to compare the stability of proteins resulting from different scales and reagents. The 
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scale effects of transfection have not been fully characterised, hence there was 
potential for protein stability to be affected by cell growth and lysis (Hutchinson et 
al., 2006). Results from differential scanning fluorimetry showed that the average 
Tm50 of SM3EL-Fc was 66.5°C and that there was no difference between the stability 
characteristics of proteins from the different scales and reagents analysed. Obtaining 
comparative stability data for other scFv-Fc constructs has proved difficult, (4 thesis 
examples in the range of 55-64°C) however when the assay was applied to whole 
antibodies the results conformed within 0.2-3°C of published results suggesting that 
the assay was accurate (King et al., 2011; Niesen et al., 2007). These data were 
corroborated by SDS-PAGE analysis of the proteins showing that there was no 
difference in the breakdown profile of the product after purification.  
Increased stability of antibodies and scFv-Fc constructs is often associated with 
improved affinities (Fennell et al., 2013). Dissociation constants of scFv-Fc constructs 
are usually in the nM range (Hashiguchi et al., 2003; Rochefort et al., 2014), however 
the predicted affinity of the scFv-Fc discussed here is in the 10-12 M (picomolar) 
region for both the whole CEA molecule and the specific epitope of the antigen. 
Whilst high affinity of constructs for targets does not always correlate with increased 
therapeutic efficacy in the context of solid tumour therapy (Adams et al., 2001; 
Rudnick et al., 2011; Vasalou et al., 2015), these results suggested that the scFv-Fc 
would be an effective binder.   
To assess localisation of SM3EL-Fc to its target in a biological context and test 
potential non-specific interactions of the scFv-Fc in vitro binding assays were 
completed. In vitro binding of SM3EL-Fc to CEA expressing cells was carried out on 
capan-1 cells with a375 cells used as a negative control. The results showed good 
localisation of the scFv-Fc to the target protein and no binding to the CEA negative 
cell line. These results confirmed the binding of the scFv-Fc to the target in its natural 
conformation and showed there were no non-specific interactions. The scFv-Fc was 
therefore validated as a functional model for use in further expression experiments.  
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3.3.1 Conclusions 
The aims of this chapter were to develop a cost effective transient expression system 
to produce quantities of recombinant protein sufficient for pre-clinical 
characterisation. These aims were achieved by establishing the HEK293F cell line 
along with PEI based transfection as a suitable expression platform that could be 
scaled up to 3L. The lower cost transfection reagent was shown to be as effective as 
the more expensive reagent after optimisation of the transfection methods.  
Analysis of the model protein produced using multiple scales and reagents showed 
that there was no difference in product quality. SPR affinity analysis and in vitro 
binding showed that the scFv-Fc bound to its target antigen specifically and with 
affinity predicted to be in the low picomolar range.  
The results in this chapter show that significant quantities of protein can successfully 
be produced by transient expression at multiple scales and analysed to short time 
scales using inexpensive reagents and techniques.  
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Chapter 4  Stable expression of SM3EL-Fc in a CHO cell 
population; yield and quality comparison with transiently 
expressed protein  
4.1 Introduction 
The work in this chapter focuses on the use of stable integration of transgenes to 
increase recombinant protein production capabilities without the need for clonal 
selection. Whilst TGE can reliably and rapidly produce sufficient amounts of protein 
for early protein characterisation studies, it faces a number of limiting factors for 
increased protein manufacture. This includes the need to re-transfect cells after each 
batch, synthesis of large amounts of recombinant DNA for scale up and potential for 
heterogeneity between batches. HEK293F cells have demonstrated improved 
transfection efficiency and productivity over CHO cells during TGE, however the 
literature points to CHO cells providing greater recombinant protein yields during 
stable expression thanks to increased cell densities of up to 1.5x107 cells/mL and the 
use of expression enhancing technology (Kim et al., 2011).  
Whilst the initial protocols for transient and stable-based transfection of cells for gene 
expression are the same, stable gene expression relies on serendipitous integration of 
transgenes into the host cell genome prior to selection.  The integration of exogenous 
DNA sequences occurs randomly within the genome of the host. The nuclear 
translocated plasmid DNA molecules (in either linear or circular form) are integrated 
into the host cell genome in nonhomologous recombination events during cell 
division (Finn et al., 1989). These recombination events can occur at multiple loci and 
with erratic frequency. Multiple copies of the transgene are often present at the same 
locus due to ligation of numerous copies of plasmid DNA to form a concatamer prior 
to recombination (Perucho et al., 1980).  
The heterogeneous protein expression and cell characteristics exhibited by transfected 
cell populations can there be apportioned to the lack of control over the locus or 
dosage of the transgene to the genome. During stable cell selection, these factors play 
an important role in determining the expression profile of the protein. Cells with the 
highest gene expression are usually selected based on resistance to antibiotic or 
metabolic stress. These highest expressers often have the transgene integrated into 
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highly expressed genomic areas such as those linked to ‘house keeping’ genes and 
may also have multiple transgene copies (Zhang et al., 2010).  
Rapid generation of high expressing cell populations is of particular relevance to 
therapeutic recombinant protein manufacture as stable cell line generation and 
selection of high expressing clones can take as long as 6 months. The ability to 
produce high expressing cell populations removes the need for clonal isolation and 
screening to obtain the best expressers, removing a significant step in cell line 
development.  In this chapter, two methods for improving simple, rapid generation of 
stable cells were explored; controlled locus of transgene integration and incorporation 
of a ubiquitous chromatin opening element (UCOE) based expression vector to 
enhance gene expression and reduce silencing.  
Transgene integration can be engineered to occur at specific recombination using a 
two-stage integration and selection process employing a DNA recombinase (Flp 
recombinase) derived from Saccharomyces cerevisiae that carries out site-specific 
recombination at previously defined binding and cleavage sites as shown in Figure 
4.5. When the number and locus of flp cloning sites in a cell line is known to be 
conducive to high expression, as assayed by a reporter gene, transfection can generate 
a high yielding population of cells quickly. Random integration of the scFv-Fc, 
SM3EL-Fc into Hela wild type cells was carried out in order to compare productivity 
with flp-mediated transfection. 
 The second method explored in this chapter is the enhancer-less ubiquitous 
chromatin-opening element (UCOE). In contrast to flp recombinase mediated 
transgene integration, the UCOE construct impacts directly on genomic structure at 
the locus of integration by almost completely stopping DNA methylation of the 
integrated transgene and generating a substantial increase in gene expression (Zhang 
et al., 2010). Whilst this technique is based on random integration, it generates high 
expressing cell lines in a single step using strong promoter activity and reduces gene 
silencing by regulation of heterochromatin structure via the heterogeneous nuclear 
ribonucleoproteins A2 B1/chromobox protein homolog 3 (HNRPA2B1-CBX3) house 
keeping gene locus (Williams et al., 2005).  
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This chapter aims to investigate methods to generate high expressing stable cell pools 
that do not require clonal selection for early production purposes. This was achieved 
using the model scFv-Fc described previously and either flp-targeted transgene 
recombination or UCOE based expression vectors. Both techniques aim to generate a 
high proportion of good expressers resulting in a more rapid cell line development 
process for early production needs. Increased production capacity was utilised for 
further work including assessment of in vivo and in vitro efficacy and distribution. 
This chapter also compares proteins from transient and stable cell systems in terms of 
stability and effector function to explore differences in scFv-Fcs produced in the 
different expression systems.  
Aims  
Investigate methods to generate stable cell pools for high expression of recombinant 
protein and to compare scFv-Fc produced in stable and transient systems  
Chapter objectives 
• Establish	  antibiotic	  selection	  conditions	  for	  Hela	  and	  flp	  site	  expressing	  H2Z	  cells	  (2.1.3)	  and	  generate	  randomly	  integrated	  scFv-­‐Fc	  expressing	  populations.	  
• Construct	  isogenic	  flp	  integrated	  Hela	  cell	  line	  expressing	  SM3EL-­‐Fc	  
• Construct	  stable	  CHO-­‐S	  cell	  line	  expressing	  SM3EL-­‐Fc	  in	  UCOE	  vector	  	  
• Develop	  media	  and	  feeding	  strategy	  for	  maximum	  protein	  expression	  in	  shake	  flasks	  culture	  	  
• Characterise	  and	  compare	  in	  vitro	  effector	  function	  and	  stability	  of	  transient	  and	  stably	  expressed	  scFv-­‐Fc.	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4.2 Results 
4.2.1 Zeocin and Hygromycin titration for Hela/H2Z-Flp selection 
The sensitivity of wild type Hela cells to zeocin and hygromycin was assessed in 
order to facilitate selection of stable cells. After transfection, the cells would be 
sensitive to either hygromycin or zeocin dependent on the locus of integration 
inserting the transgene after the ATG start signal (see Figure 4.5).  
Cells were exposed to zeocin concentrations of 0, 50, 100, 250, 500 or 1000µg/mL 
aiming for a selection period of between 4-5 days allowing time for expression of 
resistance genes and recovery from cytotoxic effects of transfection (Figure 4.1). 
Results showed that all zeocin concentrations affected the viability of cells, with those 
above 250 µg/mL reducing viability to below 20% after just 2 days. Cells subjected to 
50 and 100 µg/mL were respectively 20% and 22.5% viable after 5 days, therefore a 
selection concentration of 100 µg/mL was chosen for further work.  
Hygromycin concentrations of 0, 100, 250, 500, 750 and 1000 µg/mL µg/mL were 
also titrated in order to establish the appropriate selection concentration (Figure 4.2). 
The results indicate that a concentration of 250 µg/mL was sufficient to reduce cell 
viability of control cells to ≤ 20% at the desired time point of 5 days.  
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Figure 4.1 Titration of zeocin concentration required for selection of stable Hela 
cells. Zeocin selection was necessary as part of the integration of FRT sites into Hela 
cells. The cell lines was cultured to 70% confluence in 6–well plates and subjected to 
zeocin concentrations of 0, 50, 100, 250, 500 and 1000 µg/mL to establish selection 
concentrations for use in further experiments. A selection concentration of 100 µg/mL 
was chosen as the viability of Hela cells tested reduced to 20% over 4 days. Graph 
shows mean data and error bars show one standard deviation from the mean (n=3). 
 
Figure 4.2 Titration of hygromycin concentration required for selection of stable 
Hela cells. Hygromycin resistance was necessary for selection of flp-recombinase 
integrated cells. Hela cells were cultured to 70% in 6-well plates and subjected to 
hygromycin concentrations of 0, 100, 250, 500, 750 and 1000 µg/mL to establish the 
selection concentrations for use in further experiments. A selection concentration of 
250 µg/mL was chosen in order to obtain a viability of 20% over a period of 4 days. 
Graph shows mean data and error bars show 1 standard deviation from the mean 
(n=3).  
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4.2.2 Random integration and selection of SM3EL-Fc into Hela cells 
Random integration of SM3EL-Fc into Hela wild type cells was carried out in order 
to compare productivity with flp-mediated transfection. Transfection was performed 
in T25 tissue culture flasks using branched PEI (25 kDa) as described in 2.5. The 
pFUSE-SM3EL-Fc vector contains the gene sh ble, conferring resistance to zeocin 
exposure, hence transfected cells were selected for stable integration using 100 µg/mL 
zeocin as described above. After 7 days exposure to zeocin the viability of transfected 
cells had reduced to 63% whilst the control cell population was no longer viable 
(Figure 4.3). The transfected cells went on to recover to 100% viability after 12 days 
and were cryopreserved at low passage number.   
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Figure 4.3 Selection of stable Hela cells randomly integrated with pFUSE-
SM3EL-Fc. Adherent Hela cells were randomly transfected using branched form 25 
kDa PEI in T75 flasks with transgenic plasmid DNA encoding the gene for the scFv-
Fc as well as the sh ble gene conferring resistance to zeocin. After 24 h the cells were 
exposed to zeocin (100 µg/mL) and the viability determined by Trypan blue 
exclusion. Transfected cells (blue) remained over 60% viable whilst control cells 
(red) were 0% viable after day 7. Data shows mean viability and error bars indicated 
one standard deviation from it (n=3).  
4.2.3 Expression analysis of three randomly selected Hela cell populations 
Clonal selection of a number cell lines from the stable pool was carried out via single 
cell limited dilution in a 96-well tissue culture plate. Preliminary analysis of scFv-Fc 
expression by three clones showed the range of heterogeneity of randomly integrated 
Hela cells over the course of three weeks (Figure 4.4). After selection, cells were 
cultured in identical conditions (37°C, T75 flask, 5% CO2, seeded at 2x105 cells/mL 
in DMEM media) and passaged at ~90% confluence. The supernatant was removed 
after each week and analysed for expression of SM3EL-Fc via NA1 specific PTA-
ELISA (Methods 2.15.4). 
There was no difference in the recovery of cells or growth rates of the three clones 
analysed, however the results indicated that there was a wide range in the expression 
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profiles even in the small sample number analysed. These results illustrate the 
expression heterogeneity in populations when transgene integration is carried out via 
random integration techniques. 
 
Figure 4.4 Randomly integrated Hela cell populations expressing SM3EL-Fc. 
Zeocin selected Hela cells stably expressing SM3EL-Fc were cultured in three 
separate populations after clonal selection to asses the heterogeneity between different 
populations. Cells were cultured until ~90% confluent before passaging and the 
supernatant was retained each week. Expression of the secreted scFv-Fc was analysed 
by ELISA. Protein concentration observed in the supernatants differed between time 
points as cells recovered from selection and between the three populations illustrating 
heterogeneity. Data shows mean viability and error bars indicated one standard 
deviation from it (n=3).  
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4.2.4 Construction of a Flp mediated isogenic cell population 
The two-stage selection process for flp integration required cloning of DNA coding 
for SM3EL-Fc into a flp-site expression vector, transfection and selection procedures 
for cell integration and assessment of expression activity.  
 
Figure 4.5 Two stage flp recombinase meditated integration of SM3EL-Fc into 
Hela cells for isogenic expression. Stage one - the FRT (flp recombinase targeting 
site) is integrated, via zeocin selection, into the host cell genome. Activity of the 
integrated sites and selection of clonal selection can be carried out according to 
βgalactosidase actvity. Stage two - co-transfection of DNA coding for flp 
recombinase and the protein of interest in the pcDNA5/FRT vector results in 
integration of the hygromycin resistance gene and the protein expression cassette and 
re-sensitises cells to zeocin. Accronyms; SV40 is the simian vacuolating virus 40 
promoter, ATG is the start codon, FRT is DNA coding for the flp recombinase, lacZ 
sequence codes for β-galactosidase, Hygro-R is the hygromycin resistance gene, 
CMV is the cytomegalovirus promoter region, poly-A is the poly adenosine sequence 
and S signifies antibiotic sensitivity.  
 
4.2.5 H2Z-Flp β-galactosidase activity validation 
H2Z-Flp, a Hela cell line expressing flp recombinase targeting sites and the lacZ 
cassette (Figure 4.5, Stage 1), was kindly provided by Dr Darren Nesbeth, UCL. Cells 
were cultured in the presence of zeocin at a concentration of 100 µg/mL ensuring 
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antibiotic resistance was present. After 7 days of culture, β-galactosidase activity was 
analysed to confirm the presence of the promoter-linked flp-sites in cells.  
 
Figure 4.6 Confirmation of Beta-galactosidase activity by Hela cells with 
integrated FRT sites. Cells stably integrated with FRT-sites are also positive for β-
galactosidase activity. Hence β-gal activity was assessed by hydrolysis of the 
substrate ortho-Nitrophenyl-β-galactoside (ONPG) by FRT integrated cells (H2Z) and 
compared to wild type Hela cells. Cells were harvested and pelleted before being 
lysed. The supernatant was recovered, ONPG added and the reaction incubated at 
37°C for 30min allowing colour to develop. The assay was quantified using a 
microplate reader. Data represents the mean and error bars 1 standard deviation away 
from it (n=3). 
 
β-galactosidase activity was analysed using the β-Gal Assay Kit from Life 
Technologies (UK). A colorimetric assay based on hydrolyses of the β-galactosidase 
substrate ortho-Nitrophenyl-β-galactoside (ONPG). Hydrolyses of ONPG results in 
galactose and the yellow coloured orthonitrophenol that can be assayed by absorbance 
of light. The rate of hydrolysis was compared between wild type Hela and H2Z-Flp 
cells. The results, as expected, showed that the H2Z-Flp cell line had a substantially 
greater rate of ONPG hydrolysis than the wild type (background) Hela cells (23.5 nM 
hydrolysed ONPG compared to 7nMol respectively) (Figure 4.6). These results 
demonstrated that β-galactosidase activity of the H2Z-Flp cells was present; hence the 
FRT site was also present due its position as part of the same transgene insert.  
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4.2.6 Cloning of SM3EL-Fc into Flp transfection vector for isogenic cell 
integration 
Direct comparison of SM3EL-Fc expression between random and flp-mediated cell 
populations required use of identical protein expression cassettes (i.e. under the same 
promoter and control elements) in both conditions. To facilitate this the whole 
expression cassette for the protein, rather than just the scFv-Fc fragment, was cloned 
into the flp integration vector.Figure 4.7 shows a cloning strategy designed to achieve 
a direct comparison of expression. Restriction digest of the pFUSE-SM3EL-Fc 
expression fragment with NotI and BglI followed by electrophoresis and gel excision 
produced an insert of 3087bp after purification. The pCV01 vector encoding the flp 
recombination site (pCV01) was digested with SphI and HindIII, to remove the 
resident expression cassette including promoter and polyA region before also being 
gel excised to obtain a 4110bp backbone vector fragment. The vector and insert 
fragments were not complementary, therefore a blunt end ligation method was 
employed involving DNA polymerase I, large (Klenow) fragment blunting of both 
fragments, dephosphorylation of the vector with alkaline phosphatase (CIP – calf 
intestinal phosphatase) and phosphorylation of the insert via T4 polynucleotide kinase 
(PNK) (Figure 4.7). 
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Figure 4.7 Cloning strategy for insertion of SM3EL-Fc expression cassette into-
flp site encoding vector.  The flp site-encoding vector (pCV01) was digested using 
the restriction enzymes HindIII and SphI to remove the resident expression cassette, 
promoter and polyA regions. The whole expression cassette of the scFv-Fc in the 
pFUSE vector was separated via restriction digest with NotI and BglI. Both the 
backbone and insert fragments were isolated using electrophoresis and gel excision. 
The purified fragments were blunted using DNA polymerase 1, large fragment 
(Klenow) to blunt the non-complimentary fragment ends. Prior to ligation the 
fragments were either phosphorylated or dephosphorylated using CIP (Calf Intestinal 
Phosphatase).   
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Figure 4.8 Resolution of restriction digested Flp vector and ScFv-Fc insert. 
pDNA was isolated from 4 different TG1 E. coli colonies. Restriction digest showed 
colonies with the expected digestion pattern and allowed gel excision of the desired 
fragment for cloning. A) The flp-encoding vector was digested using HindIII and 
SphI enzymes to produce a 4110bp backbone fragment vector (white box). B) 
pFUSE-SM3E-Fc was digested using NotI and BglI restriction enzymes to produce 
multiple fragments; the 3087bp fragment (white box) contains the whole expression 
cassette of SM3EL-Fc. The molecular weight marker in lane 1 of both images is the 
1Kb ladder from NEB.  
 
Subsequent ligation of insert to vector (Figure 4.8) along with appropriate controls 
was carried out and purified using phenol-chloroform extraction prior to 
transformation of electrocompetent E. coli Top10 cells. Transformed cells were plated 
out on 100 µg/mL ampicillin 2TY agar selection plates before overnight incubation at 
37°C. The number of colony forming units was analysed to compare background 
vector re-ligation with ligated vector and insert as well as confirm ampicillin 
resistance in the uncut vector as positive control. The resulting colony ratios did not 
suggest that positive vector-insert ligations were present.  
Multiple cloning attempts were carried out using this strategy including varying 
ligation reactions, vector:insert ratios, strains of E. coli, (de) phosphorylating 
fragments and PCR colony screening methods. This cloning strategy did not result in 
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cloned insert, however parallel cloning of SM3EL-Fc into a UCOE based expression 
vector had been successful therefore the decision was made to proceed with this 
system for expression of SM3EL-Fc in further experiments.  
4.2.7 Cloning of SM3EL-Fc into UCOE vector 
Sequence analysis of pFUSE-SM3EL-Fc showed that it lacked compatible restriction 
sites for cloning into the UCOE expression vector, hence the simplest method of 
cloning was to PCR amplify the murine SM3EL-Fc expression cassette and insert 
compatible (sticky end) restriction sites whilst maintaining the activity of the IL2 
secretion signal. Primers were designed to extend the SM3EL-Fc cassette and insert 
the restriction sites 5’Bstb1 and 3’ Xba1 (See Figure 4.9). The resulting 1543bp PCR 
fragment was gel extracted, purified and digested along with the vector using BstBI 
and XbaI restriction enzymes to create complementary ends. Ligation of the digested 
fragment into the 3.2Kb murine UCOE expression vector was carried out at room 
temp for 10 minutes before phenol-chloroform extraction. See Figure 4.10 for final 
plasmid construction map.  
 
 
Figure 4.9 Extension primers for addition of BstBI and XbaI restriction sites to 
SM3EL-Fc for cloning into the UCOE vector. Cloning of SM3EL-Fc into the 
UCOE expression vector required extension of the expression cassette and addition of 
complimentary restriction sites for simple ligation into the MCS. The forward (sense) 
primer added the restriction site for BstBI whilst the reverse (anti-sense) primer added 
the XbaI site. Both restriction sites are indicated in the primers in red with ‘^’ 
denoting the cutting site yielding an expected PCR amplicon of 1543bp. 
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The ligated plasmid was transformed via electroporation into Top10 Escherichia coli, 
plated on 100µg/mL ampicillin 2TY agar plates and incubated over night at 37°C. 
There were a greater number of colonies in the vector + insert conditions compared to 
control plates indicating increased likelihood of colonies positive for the ligated 
insert.  Colonies were selected and grown in liquid 2TY media (Amp 100µg/mL). 
Plasmid DNA was recovered from 6 colonies and analysed via restriction digest with 
BglII. Clone 6 showed the correct digestion pattern (6670bp and 2632bp) (Figure 
4.11). Sequencing (UCL sequencing service) was carried out using primers designed 
to provide data across the insert and Fc portion of the construct. This confirmed that 
no mutations had occurred during the cloning process 
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 Figure 4.10 Plasmid map of pSM3EL-Fc-UCOE. The expression plasmid map 
shows the SM3E scFv (blue), hinge region (pink) and mouse Fc (red) under the 
control of the hCMV promoter and IL2 signal sequence as well as the ubiquitous 
chromatin-opening element (UCOE) that utilises house keeping promoter genes to 
reduce methylation based silencing and increase expression. The plasmid confers 
resistance to puromycin under the mPGK promoter for mammalian cell selection and 
ampicillin under the Amp promoter for bacterial selection purposes.  
         
Figure 4.11 Restriction digest of pSM3EL-Fc-UCOE using BglII. Top10 E. coli 
were transformed with pSM3EL-Fc-UCOE via electroporation. Transformed cells 
were plated on 2TY-ampicillin agar plates and incubated overnight at 37°C. 10 CFUs 
were selected and transferred to liquid ampicillin selection 2TY media before pDNA 
was isolated and presence of the insert analysed. The pDNA was digested using BglII 
restriction enzyme. Clone 6 had the expected DNA fragment sizes of 6670bp and 
232bp. Negative control was uncut DNA. The molecular weight marker was the 
Hyperladder 1 from Bioline.
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4.2.8 Titration of puromycin for stable cell selection 
The necessary concentration of puromycin to apply sufficient selection pressure for 
stable cell line generation was titrated prior to selections. Puromycin was added to 
untransfected CHO-S cells at a density of 1x106 cells/mL at a concentration of 0, 5, 
7.5, 10, 12.5, 15 and 20µg/mL (Figure 4.12). After 48 h of puromycin exposure 
cultures supplemented with either 10 or 12.5µg/mL reduced in viability dramatically 
to around 40% whilst those ≥15 µg/mL were below 5% viable. Cells with 5 µg/mL 
puromycin were unchanged compared to control whilst 7.5µg/mL showed a mild 
reduction in viability.  In selection conditions of 7.5µg/mL and above there was a 
distinct morphological change in a proportion of the population, developing non-
circular profiles compared to healthy cells. Whilst these cells maintained exclusion 
of Trypan Blue there was a correlation between the numbers of these non-circular 
cells and a reduction in viability (Figure 4.13). Viability was recorded using the total 
of dead cells determined by the Trypan Blue exclusion assay and using the number 
of non-circular cells and added to that figure to ensure accurate viability counts. 
Analysis of data using both counting parameters arrived at the same results. 
Puromycin selection pressure was set at 12.5µg/mL in order to kill non-transfected 
cells within 72-96 h as opposed to 10µg/mL that would take up to 120 h.  
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Figure 4.12 Viability of CHO-S cells under puromycin exposure – cells 
excluding Trypan Blue. Selection of stably transfected CHO cells required the use 
of puromycin antibiotic; hence it was necessary to titrate the appropriate 
concentration to kill non-stable cells. Suspension adapted CHO-S cells were cultured 
to 1x106 cells/mL and 100% viability in 30mL of CD-CHO media. Cultures were 
exposed to puromycin at concentrations of 0, 5, 10, 12.5, 15 and 20 µg/mL and the 
viability of cultures determined by the Trypan Blue exclusion assay. Data shows a 
single data set. Cells excluding Trypan Blue were counted as viable.  
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Figure 4.13 Viability of CHO-S cells under puromycin exposure – cells 
exhibiting normal morphology. It was noted in a previous titration that cell 
morphology was impacted during selection procedures and that those cultures with 
high percentages of non-circular cells had a reduced viability in the following days. 
Here viability was determined by counting both Trypan blue positive cells (blue 
cells) and deformed cells (non-circular) as non-viable cells to compare against the 
Trypan blue exclusion assay alone. The results were very similar to the Trypan blue 
assay alone.  Data shows a single data set. 
 
4.2.9 CHO-S transfection with SM3EL-Fc-UCOE and stable cell selection   
CHO-S cells were passaged to 0.5x106 cells/mL 24 h prior to transfection in 30mL of 
serum free Freestyle media to obtain an exponential phase culture at a density of 
1x106 cells/mL on the day of transfection. Transfection was carried out using linear 
25 kDa PEI, using a PEI to DNA ratio of 1:2, as described in Chapter 3. Cells were 
counted every 24 h and the percentage viability determined via the Trypan Blue 
assay. As observed previously, cell growth rate reduced after transfection compared 
to non-transfected controls. 48 h post transfection the control population had a 
greater cell density than transfected cells (2.8 and 1.97x106 cells/mL respectively) 
whilst viability was 100% compared to ~95% (Figure 4.14 A and B). The culture 
was centrifuged at 150x g and suspended in fresh media supplemented with 12.5 
µg/mL puromycin. The effects of puromycin incubation were observed 24 h after 
0	  
20	  
40	  
60	  
80	  
100	  
0	   2	   4	   6	   8	  
Vi
ab
ili
ty
	  (%
)	  
Time	  (Days)	  
0	  μg/mL	  
5	  μg/mL	  
10	  μg/mL	  
12.5	  μg/mL	  
15	  μg/mL	  
20	  μg/mL	  
  131 
addition. The viability of in both groups dropped to ~80% even as cells continued to 
divide for a further 24-48 h. The viability of control and transfected cultures 
decreased rapidly after Day 4 and all cells were non-viable at Day 7. Puromycin 
selection pressure of 12.5µg/mL resulted in unsuccessful stable cell selection.   
 
  132 
 
 
 
Figure 4.14 Selection of CHO cells transfected with pSM3EL-Fc-UCOE. CHO-S 
cells at a density of 1x106 cells/mL were transfected using 25 kDa linear PEI with 
plasmid DNA coding of the scFv-Fc under the control for the UCOE expression 
vector. After 24 h puromycin selection reagent was added to a final concentration of 
12.5 µg/mL to both the transfected cells and a non-transfected control culture. After 
6 days post-transfection both control and transfected cells were dead despite 
maintaining growth up to day 3. A) Cell viability was determined using the Trypan 
Blue exclusion assay. B) Cell density was determined by counting cells plated in a 
haemocytometer. 
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4.2.10 Stable cell selection using a graduated puromycin selection ramp 
A gradual increase of the selection concentration was employed after communications 
with the manufacturer. Using a graduated increase in selection pressure was 
hypothesized to allow cells to adapt to puromycin conditions without immediately 
being exposed to the upper limit of puromycin tolerance before sufficient expression 
of the resistance gene or recovery after transfection. Cells were cultured and 
transfected as described previously. After a recovery period of 24 h puromycin was 
added at 5 µg/mL, with subsequent addition of 2.5 µg/mL every 24 h until a final 
concentration of 12.5 µg/mL. Control cells maintained greater viability and cell 
division rates compared to transfected cells during the recovery phase, however upon 
graduated puromycin addition cell division slowed. There was a slower decrease in 
viability compared to higher puromycin concentrations (Figure 4.14 and 4.15). 
Nonetheless, both cultures rapidly decreased in viability after concentration reached 
24 h exposure to 12.5 µg/mL puromycin. At Day 9 there was no difference between 
transfected and control cell populations and the selection was terminated.  
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Figure 4.15 CHO cells under graduated puromycin selection after transfection 
with pSM3EL-Fc-UCOE. CHO-S cells at a density of 1x106 cells/mL were 
transfected using 25 kDa linear PEI with plasmid DNA coding for the scFv-Fc. After 
48 h puromycin selection reagent was added to a final concentration of 5 µg/mL to 
both the transfected cells and a non-transfected control culture. The selection 
concentration was increased every 24 h by 2.5µg/mL until reaching a final 
concentration of 12.5µg/mL on day 5. Cell cultures were suspended in fresh selection 
12.5 µg/mL selection media on day 7 after which cell viability in both control and 
transfected cultures rapidly declined. A) Cell viability was determined using the 
Trypan Blue exclusion assay. B) Cell density was determined by counting cells plated 
in a haemocytometer. 
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4.2.11 Analyses of SM3EL-Fc expression by CHO cells after transfection using 
PEI or Freestyle MAX transfection reagent 
After unsuccessful selection attempts using the PEI and CHO-S cells the amount of 
scFv-Fc produced by cultures was analysed by ELISA. These results showed that a 
small amount of scFv-Fc was detectable after 24 and 48 h (both <3µg/mL) from 
cultures transfected with PEI. However the minimal amount of protein expression 
suggested that low transfection efficiencies might have affected the number of 
potential integration events and as such potential for stable selection. A comparison 
between transfection efficiency of PEI and the more expensive Freestyle MAX 
reagent from Invitrogen was carried out as well as an assessment of protein 
expression.  
Cell cultures were co-transfected with separate plasmids coding for the scFv-Fc and a 
Green Fluorescent Protein using either PEI as per the previous protocol or with 
Freestyle MAX according to the manufacturer’s instructions. Initial (transient) 
expression of SM3EL-Fc was greater in cells transfected via Freestyle max reagent 
after 24 and 48 h (Figure 4.16A) showing substantially improved expression in the 
Freestyle MAX condition over PEI (16µg/mL vs. ~ 2.4µg/mL respectively). Further 
to this there was an increase in GFP positive cells of over 40% in the Freestyle 
transfected condition as determined by flow cytometry (Figure 4.16B). As a result 
Freestyle MAX was used for transfection of CHO cells for stable selection.  
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Figure 4.16 Expression of SM3EL-Fc and GFP by CHO-S cells after transfection 
with either PEI or Freestyle MAX. CHO-S cells at a density of 1x106- cells/mL 
were co-transfected with the scFv-Fc expression plasmid and a GFP expression 
plasmid using either PEI (as described previously) or Freestyle MAX (Life 
Technologies) (as per the manufactures instructions). A) Expression of the scFv-Fc 
was analysed by PTA-ELISA at 24 and 48 h post transfection. Cultures transfected 
with the Freestyle MAX reagent produced substantially more scFv-Fc than those 
transfected with PEI (16 µg/mL and ~2.4 µg/mL respectively). Data shows mean 
scFv-Fc in supernatant and error bars represents one standard deviation away from the 
mean (n=3). B) Analysis of Green Fluorescent Protein expression in transfected cells 
as determined by flow cytometry shows that there was an increase of over 40% in 
GFP positive cells in the Freestyle transfected condition.  
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4.2.12 Stable cell selection after transfection with Freestyle MAX  
CHO cells were transfected according to the manufacturer’s instructions and a 
graduated selection pressure was applied as previously described (Section 1.2.4.3) 
after a 48 h recovery period. Control cells divided at a substantially greater rate and 
had improved viability compared to transfected cells immediately after transfection 
(Figure 4.17). However, after 10 days under selection pressure control cells were non-
viable and the viability of transfected cells was ~15% in transfected cultures 
indicating a stable cell population had potentially been selected. 
Transfected cells rapidly recovered despite being maintained under selection pressure 
and after Day 21 were 100% viable and dividing at a sufficient rate for 
cryopreservation. Cells were cryogenically frozen at low passage number (P3/4).  
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Figure 4.17 CHO cells under graduated puromycin selection after transfection 
with Freestyle MAX reagent. CHO cells were transfected with plasmid coding for 
the scFv-Fc as described previously using the Freestyle MAX reagent. Puromycin 
selection was increased gradually from 5µg/mL after 48 h increasing by 2.5µg/mL 
every 24 h until reaching a final concentration of 12.5 µg/mL. Transfected cells 
dropped in viability initially after transfection showing similar results to previous data 
with improved transfection efficiency. After 13 days under puromycin selection the 
non-transfected control cells were all dead whilst the transfected culture remained 
>10% viable. These cells rapidly recovered to 100% viability 5 days after the control 
cells reached 0% viable cells.  
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4.2.13 Selecting media for shake flask based, batch mode expression   
A number of serum free cell growth media are available for batch based protein 
expression by CHO cells. In this study media of 3 different compositions were 
compared for cell growth, viability and expression of SM3EL-Fc. The stable cell line 
was thawed out and allowed to grow to between 1-2x106 cells/mL in CD-CHO media 
from Invitrogen (the media used during cryopreservation) before three passages in 
ether CD-CHO (Invitrogen), CD-CHO3 (Ex cell) or a 50:50 mix of the two (Mix 6).   
Cells were grown in 30mL of each of the selected media in shake flask cultures from 
a starting density of 0.3x106 cells/mL. Both growth rate and average protein 
expression were analysed every 24 h. Cells grown in CD-CHO reached the highest 
cell density (6.57x106 cells/mL) despite a longer lag period, whilst cells grown in Mix 
6 reached the lowest maximum cell density (5.5x106 cells/mL) Figure 4.18. There was 
no significant difference (P=0.207) in the growth of cells between the media 
conditions. Despite this, expression of SM3EL-Fc, as analysed by ELISA, showed 
that cells grown in the Mix 6 condition were the highest expressers (~24µg/mL) on 
day 7. The Mix 6 media was therefore selected for further production processes in 
shake flasks. 
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Figure 4.18 Shake flask based growth of CHO-S cells expressing SM3EL-Fc in 
media of three different compositions.  Stably selected CHO-S cells expressing 
SM3EL-Fc were seeded at 0.3x106 cells/mL in different media compositions and the 
growth and productivity analysed over time. Three media compositions were 
compared consisting of CD-CHO (Life Technologies), ExCell CD-CHO (Sigma 
Aldrich) or a 1:1 mix of both media (Mix6). There was no significant difference 
between the growth of cells (P= 0.207) but cells grown in Mix6 yielded the highest 
overall scFv-Fc expression. A) Cell density (x106 cells/mL). B) scFv-Fc secreted in 
supernatant as determined by PTA-ELISA. Data represents the mean and error bars 
show one standard deviation away from it (n=3).  
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Figure 4.19 Shake flask-based batch-culture of CHO-S cells expressing SM3EL-
Fc. CHO-S cells selected for stable expression of SM3EL-Fc were seeded at 0.5x106 
cells/mL in Mix6 media. Cells were cultured until viability dropped below 80% (day 
8). The growth and viability of cells was analysed over time using the Trypan Blue 
exclusion assay. The cultures reached an average of 8.6x106 cells/mL on day 6 and 
viability remained at or above 90% until day 7 after which the viability dropped 
dramatically to ~10%.  
Shake flask culture of CHO cells stably expressing SM3EL-Fc 
Shake flask culture of SM3EL-Fc expressing cells was carried out in 300mL flasks to 
compare maximal expression of the protein between fed-batch and batch-based 
expression. Cells were seeded in Mix 6 media at a density of 0.5x106 cells/mL and 
after Day 3 were either given EfficientFeed B (3% of total volume per 24 h) or no 
addition (control).  
Both cultures entered log phase on Day 3 reaching ~3.7x106 cells/mL at 100% 
viability. Batch cultured cells reached a maximum of 8.6x106 cells/mL (Figure 4.19) 
before viability dropped rapidly after day 6. Cells supplemented with feed remained 
over 90% viable for a further 4 days reaching a maximum viable cell density of 
1.28x107 cells/mL (Figure 4.20). Specific growth rate was higher during log phase in 
fed batch cultures compared to batch cultures (0.56 to 0.5/day respectively) whilst 
specific productivity was also higher in the fed batch culture (2.96 compared to 4.41 
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pg/cell/day). Supplemented cultures not only reached a higher cell density but also 
produced more scFv-Fc compared to the control producing a maximum of 86.6µg/mL 
(Figure 4.21) compared to 34.3 µg/mL in batch based culture.  
Protein from fed-batch cultures was purified via protein A MabSelect 
chromatography after centrifugation and filtration before concentration and dialysis 
into PBS overnight (see Methods) for further analysis.  
 
Figure 4.20 Fed-Batch culture of CHO-S cells expressing SM3EL-Fc. CHO-S 
cells stably expressing SM3EL-Fc were grown in 300mL Mix6 media in shake-flasks. 
On day 4 cultures were supplemented with 3% final volume of CD-CHO 
EfficientFeed B (Invitrogen) or a necessary to obtain media with greater than 4g/L 
glucose. Cell density and viability were determined using the Trypan Blue exclusion 
assay. Cells reached a maximum density of 10.28x106 cells/mL and remained above 
88% viability throughout the culture period.  
 
Protein from stable CHO and HEK293F transient expression was compared to assess 
difference in protein stability and in vitro efficacy. The stability of proteins from 
transient and stable expression in the two host systems was analysed using SDS-
PAGE, repeated freeze-thaw analysis and differential scanning fluorimetry as well as 
an in vitro complement-dependent cytotoxicity assay to assess effector function.   
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Figure 4.21 Expression of SM3EL-Fc by batch and fed-batch cultured CHO 
cells. CHO-S cells stably expressing SM3EL-Fc were cultured in 300mL of Mix6 
media in shake flasks. After day 4 fed-batch flasks were given 3% final volume 
supplement of CD-CHO EfficientFeed B whilst batch culture flasks were not 
supplemented. Daily samples were removed and solids separated before storage of the 
supernatant at -80°C for analysis of scFv-Fc content by ELISA. Batch based culture 
reached a maximum of 34.4µg/mL compared to maximal expression of 86.6µg/mL in 
the fed-batch condition.  
 
4.2.14 SDS-PAGE freeze thaw analysis 
ScFv-Fc was diluted to 1mg/mL in PBS buffer prior to freeze-thaw analysis. Protein 
was frozen to -80°C and thawed out at room temperature over 24 h cycles. Samples 
were removed and boiled in reducing buffer before storage at -20°C. Protein 
resolution using a 10% SDS-PAGE gel ( ) showed that there was no difference 
between the samples of scFv-Fc from transient or stable cells. Furthermore there was 
also no difference between the sizes of bands resulting from repeated freeze-thaw 
cycles in either transiently expressed or stably expressed samples.  
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4.2.15 Stability comparison of scFv-Fc from CHO and HEK293f cells 
DSF was utilised to assess and compare the Tm50 of proteins from the various 
expression systems (Figure 4.23). There was no difference found between the Tm50 of 
proteins assessed, including the peak heights and Tm50°C. This result further 
corroborated previous findings suggesting that the characteristics of protein from 
transient systems was a good indicator of final performance of the product after stable 
cell expression. 
 
  
Figure 4.22 SDS-PAGE separation of scFv-Fc from transient HEK293F and 
stable CHO-S expression. scFv-Fc was transiently expressed by HEK293F cells and 
stable CHO-S cells in shake flask conditions. Protein was purified using protein A 
MabSelect chromatography (GE Healthcare) and dialysed into PBS and diluted to 1 
mg/mL. Samples were frozen at -80°c and thawed out at room temperature in cycles 
of 24 h. After each cycle samples were removed and heated to 100°c for 5 min in 
reducing buffer before storage at -20°C. There was no difference in the size of 
resolved bands of scFv-Fc from either condition using 10% SDS-PAGE resolution, 
and no breakdown observed after consecutive freeze-thaw cycles. FT refers to freeze-
thaw cycle number. Ladder shows 50 kDa band of a SeeBlue Ladder from 
ThermoFisher (UK). 
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Figure 4.23 Thermal stability of SM3EL-Fc produced by transient expression in 
HEK293F cells and stable expression in CHO cells. Purified scFv-Fc from each 
scale was diluted to 1mg/mL and SYPRO orange added as described previously. 
Temperature-dependent protein unfolding was assessed via differential scanning 
fluorimetry. Comparing the Tm50 (°C) showed that there was no difference in protein 
stability from the different expression systems. Data shows mean and error bars of 
one standard deviation (n=3).  
 
4.2.16 Comparison of functional in vitro activity of SM3EL-Fc from CHO stable 
and transient HEK293F cells 
Comparative analysis of the structural integrity and thermal stability of scFv-Fc 
showed that proteins from both sources of expression behaved in a very similar way 
with no differences in characterisation assays. However these assays do not 
necessarily translate into good efficacy in a therapeutic setting. In order to further 
assess the effector function of the constructs the complement dependent cytotoxicity 
(CDC) activity was compared using the MTS Tetrazolium assay utilising cells both 
positive and negative for the target and rabbit complement.  
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Capan-1 cells (expressing CEA) and Hela cells (negative control) were plated out in 
6-well plates (1x105 cells). 24 h after seeding, SM3EL-Fc was added to the cells at a 
final concentration of 1µg/mL and the plate was incubated at 4°C to stop 
internalisation. After 1 h, baby rabbit complement was added at a concentration of 
1µg/mL and the complement mediated cell killing allowed to take place under normal 
incubation conditions for 1 h. Cell viability was analysed via the reduction of MTS 
Tetrazolium to form a yellow coloured substrate in the media. This was analysed 
using a 6 well plate reader via absorbance at (490) nm.  
The results showed that when either transient or stably expressed SM3EL-Fc and 
complement were added to cells the viability of CEA expressing capan-1 cells was 
reduced by over 50%. There was no reduction in the viability of Hela cells suggesting 
that SM3EL-Fc did not have off target affects and that it successfully mediated CDC 
activity. When either transient or stably expressed SM3EL-Fc and not complement 
was added to the cells there was a slight reduction in viability compared to control 
cells with no addition.  However, this effect is enhanced when complement only is 
added (Figure 4.24).  
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Figure 4.24 In vitro complement mediated cytotoxicity (CDC) activity of 
transient and stably expressed SM3EL-Fc. CEA-expressing capan-1 cells and 
CEA-negative Hela cells were plated out in a 96-well tissue culture plate (10,000 
cells/well). After 24 h 1µg of SM3EL-Fc was added to each well and the plate was 
incubated at 4°C for 1 h. Rabbit complement (AbD Sertech) was added (11µL/well) 
and the plate incubated for a further 1 h at 37°C followed by MTS (Cell Titre 96 
Aqueous One Solution, Promega) assay substrate (12µL/well) and an incubation for 
30min at 37°C. Analysis of colour was carried out using by absorbance at 490nm in a 
Varioskan Flash 96well plate reader. There was a reduction in the viability of capan-1 
cells of ~52% with both transiently expressed (HEK293F) or stably expressed (CHO-
S) scFv-Fc, showing no difference between the two samples. There was also no 
reduction in the viability of Hela cells further confirming no off-target effects of the 
protein. Figure shows mean data and error bars are one standard deviation (n=3).  
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4.3 Discussion  
Clonal selection of stable cells is often used to obtain high expression of a 
recombinant protein. However this is a laborious process that can take several months 
creating a bottleneck in the development process. The aim of this chapter was to 
achieve increased expression of the model scFv-Fc by generating a pool of high 
expressing stable cells that could be cultured for protein production after primary 
selection. Two different transgene integration techniques were investigated relying on 
either targeted transgene integration or manipulation of heterochromatin structure and 
promoter activity rather than standard random integration. Media selection and 
feeding strategies were also used to maximise recombinant protein expression within 
the lab environment.  
Random integration of transgenic DNA into host cells is currently the standard 
method of obtaining stable mammalian cell lines. Whilst this method does generate 
stable integrants, it has a number of draw backs for rapid expression such as 
producing a pool of highly heterogeneous cells with a wide variety of transgene copy 
number, integration loci and gene silencing levels (Liu et al., 2005). This 
heterogeneity was illustrated here using random transgene integration into Hela cells 
resulting in sub-cloned populations with a range of protein expression, growth and 
recovery characteristics.  
High expressing cells are usually obtained from a pool of stable integrants using 
antibiotic or metabolic selection procedures; however these methods are often labour 
intensive, costly and inefficient. Indeed the use of antibiotic selection methods may, 
in itself, effect transgenic protein expression (Kaufman et al., 2008). During early 
developmental research of recombinant therapeutics a number of candidates are 
investigated and characterised without the need for cGMP based clonal production. 
However screening of huge numbers of cells is still a primary method for isolating 
high expressers at this stage. As such, a system for rapid generation of a pool of high 
expressing cells that can be used to produce substantial quantities of recombinant 
proteins at pre-GMP stages is highly desirable.  
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A number of approaches have been developed that go someway to addressing these 
issues; these include synchronisation of cells prior to transfection using mimosine 
(Grosjean et al., 2002a), aphidicolin or butyrate (Golzio et al., 2002) in order to 
achieve improved transfection rates, use of weak or attenuated antibiotic promoters to 
ensure selection of only very high expressers (Chin et al., 2015; Hitoshi et al., 1991) 
and codon-usage optimisation (Inouye et al., 2015). However, whilst these methods 
do enhance protein expression they do not actively address the issue of transgene 
integration.  
The use of recombinase-mediated site specific integration technology (a.k.a 
recombinase mediated cassette exchange) has been reported as far back as 1988 
(Wirth et al., 1988). The proposed advantages of using this system are that, in cells 
with well-characterised integration sites, transfected populations have the transgene 
integrated in the same locus, with the same expression profile. Hence, the resulting 
stable integrants are isogenic for the transgene negating the need for further selection 
once stable cells are obtained. The Flp recombinase system in particular has been 
used with success in the development and study of isogenic hosts in a number of cell 
lines (Liu et al., 2005). Alternative genetic engineering techniques have also been 
developed that may allow this approach to mature fully in high expressing cell 
development including the use of Cre recombinase and CRISPR mediated genetic 
modifications (Lee et al., 2015).  
In this chapter Hela cells were used as a model system to study flp-recombinase 
mediated generation of isogenic cells. Hela cells are a widely used cell line that was 
used here to model expression characteristics with the intention of developing the 
system into other suspension cell lines. Whilst Hela is a readily accessible cell line, 
and the modified H2Z version described here was made in house, there are a number 
of commercially available Flp-In cell lines with well characterised integration sites 
specifically for generation of high expressing cells including CHO, BHK and 293 
cells (Life Technologies).  
The second technique investigated in this chapter was the use of a ubiquitous 
chromatin opening element-based (UCOE) vector. The UCOE element utilises a 
composite set of promoters for ‘house keeping’ genes that not only maintain a high 
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level of expression but are also resistant to heterochromatin-mediated gene silencing 
(Antoniou et al., 2003) to generate cells with stable high production of the target 
protein. The combination of an extended CpG island along with a composite dual 
promoter consisting of those for house keeping genes and the hCMV promoter has 
been shown to have significant improvements of protein expression irrespective of the 
location of transgene integration (Williams et al., 2005). In previous work transgene 
expression levels in cell pools have been shown to increase significantly when 
compared to other expression vectors (Boscolo et al., 2011).  
In this chapter the model scFv-Fc was incorporated into the UCOE system and used 
in conjunction with suspension adapted CHO cells. As discussed previously CHO 
cells are the industry standard for recombinant protein expression and, without the 
need for transient expression, were chose as the final host system. In order to remain a 
cost effective expression system PEI was initially used as the transfection reagent, 
however selection of cells proved unsuccessful. After analysis and comparison of 
transfection efficiency of PEI and Freestyle MAX (Life Technologies), the more 
expensive FreestyleMAX reagent was used instead resulting in both improved 
transfection and successful selection of stable cells.  
Having established a pool of stable transfectants, maximal expression was analysed in 
shake flasks using batch-based culture of cells. The results from transfected cell pools 
in this chapter yielded an expression level of up to 34µg/mL in batch operation rising 
to ~86 µg/mL in fed-batch mode. Clonal selection of cells with UCOE enhanced 
scFv-Fc expression has previously indicated that pooled cells and monoclonal cells 
expression levels were comparable (Boscolo et al., 2011).  Therefore in early 
biopharmaceutical development stages, when monoclonal expression is not a 
necessity, a polyclonal population would carry out the same production role without 
the time and costs associated with clonal selection.  
Further increases in protein production can be easily achieved using extended cell 
culture practises such as fed-batch or perfusion-based techniques. However whilst 
perfusion can provide exceptionally high yields of protein (Lee et al., 2012), it also 
requires significant outlay in terms of specialist equipment and limited scalability. In 
contrast, fed-batch based culture requires only the addition of an enriched feed media 
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making it an accessible technique for many laboratories. The results in this chapter 
showed that that the amount of recombinant protein in fed batch-based culture was 
almost 40% greater than that of batch-based culture, even without process 
optimisation. Further to this, the stable pool yielded an increase of over 12% 
compared to transient based expression.  
The use of TGE to express the first quantities of recombinant proteins prior to 
committing to stable expression relies on the product accurately represent the 
characteristics of protein from the intended final expression system. Transient and 
stable expression of recombinant proteins, especially antibody based fragments, has 
been investigated previously showing that there is good correlation between the 
stability, effector function and expression profile of protein from both systems 
(Diepenbruck et al., 2012). However the relationship between the characteristics of 
the same protein expressed in different systems has not been fully investigated, save 
for glycosylation differences and yield.  
Here, scFv-Fc from the transient and stable expression systems described in chapters 
3 and 4 were compared in terms of stability and effector function. The respective cell 
lines are of Human or Chinese Hamster origins; however both are routinely used at 
for protein expression purposes. Protein stability as determined by differential 
scanning fluorimetry and repeated freeze-thaw cycle SDS-PAGE showed that there 
was no difference between proteins expressed by either system at scales up to 300mL. 
Assessment of effector function, a key determinant of protein performance, indicated 
that the difference in CDC activity of the proteins was not significant (p> 0.1). The 
results presented here suggest that, whilst there may be differences in terms of 
glycosylation structure (Croset et al., 2012), the stability and effector function of the 
model protein was unchanged between the two systems. Hence, there is potential for 
early recombinant protein work to be carried out rapidly in a transient expression 
system with the results remaining relevant to a different final expression system 
allowing a more rapid and flexible approach to early protein expression.  
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Conclusion 
The aims of this chapter were to develop a system that would rapidly establish high 
expressing stable cells for use in early protein production and to compare products 
from transient and stable expression. This was achieved using a combination of a 
UCOE expression vector, fed-batch feeding and selection of an efficient transfection 
reagent to enable commencement of production within 2 weeks.  
A comparison of the scFv-Fc produced in both transient and stable cell based systems 
established that there was no difference in the stability or effector function of the 
respective proteins. These results show that the characteristics of a transiently 
expressed scFv-Fc from HEK293 cells can be generalised to the same protein 
expressed in stable CHO cells reducing the necessity for stable cell protein screening.  
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Chapter 5 Primary recovery of recombinant proteins from 
unclarified mammalian cell feed streams using radial flow 
chromatography and large bead IMAC resin*.  
5.1 Introduction  
Current methods for the capture of recombinant proteins require the separation of 
solids from liquids to remove cells and debris prior to capture based on ion exchange 
or affinity. The work in this chapter describes a new method developed to address 
these issues. The method exploits large bead diameter chromatography resins utilising 
a stationary phase made of agarose beads typically between 300-500µm in diameter 
packed into a radial flow column.  
Solid-liquid separation is the crucial first step in most mammalian cell bioprocesses 
and has been impacted significantly by recent improvements in upstream 
technological advances.  Primary processing of high cell density feed streams requires 
particular consideration to avoid such cell stresses and shearing that could result in 
protein aggregation and cell lysis (Hutchinson et al., 2006; Kiese et al., 2008). The 
latter affects the quantity and quality of product through contamination with host cell 
protein (HCP), protease and DNA (Sandberg et al., 2006).  
The capture method proposed here is hypothesized to facilitate recovery from 
unclarified feed, thus negating traditional solid-liquid separation stages prior to 
chromatographic capture. Large diameter resins create a semi-porous packed bed 
enabling simultaneous protein capture and concentration whilst allowing cells to pass 
through. As with many resins, a generic scaffold such as agarose can be 
functionalized in a number of ways meaning that affinity capture, IMAC or ion 
exchange chromatography can be used making this processing technique widely 
applicable to many recombinant proteins.  
The traditional axial flow column, where feed and pressure are both perpendicular to 
the packed bed, is used in most recovery processes. However bed height at scale can 
affect performance meaning that significant footfalls and high-pressure drops are 
necessary. An alternative to axial flow is radial flow chromatography. In contrast to 
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axial flow, RFC consists of two concentric cylindrical porous frits holding a 
stationary phase between them. In RFC, feed flows from the outer to the inner surface 
across the radius of the column (Figure 5.1) providing a minimal pressure drop. 
Improved elution peak resolution due to the trapezoidal column geometry and greater 
operational flow rates are reported as advantages (Besselink et al., 2013). In this 
chapter large diameter immobilized metal affinity chromatography (IMAC) beads 
were packed into a scale down RFC system.  
                                             
Figure 5.1 Schematic of axial and radial flow chromatography systems. Axial and 
radial flow columns with respective directions of feed flow from top to bottom or 
outer surface to inner surface.  
 
Unlike proteins with Fc fragments, which have a natural affinity for Protein A from 
Staphlycocuss aureus, most recombinant proteins require addition of a molecular tag 
to facilitate affinity capture. Many tags are available to facilitate capture however the 
polyhistidine repeat tag remains the major workhorse for tag-based purification due to 
the simplicity of amino or carboxy terminal fusion and purification of proteins that 
lack a natural purification tag (Terpe, 2003).  
In this chapter a His-tagged glycoprotein, the CEA, was expressed in CHO cells using 
the UCOE expression system discussed in Chapter 4. CEA is a clinically relevant 
glycoprotein used in many diagnostic and therapeutic applications (Chester et al., 
2000; Francis et al., 2002; Graff et al., 2004; Li et al., 2010, Miranda-Rota., in 
preparation) as well as the molecular target of SM3EL-Fc as expressed in previous 
chapters.  
Axial&ﬂow& Radial&ﬂow&
Indicates*direc,on*of*ﬂow**
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Here, a process for protein recovery from unclarified mammalian cell fermentation 
streams was developed using a RFC packed with a large diameter resin to obtain an 
integrated primary capture step.  
 The method was developed using suspension-adapted CHO cells grown in shake 
flask culture. The process was then scaled up to a 3L bioreactor whilst maintaining 
chromatography bed height. The study forms the basis of a primary recovery step 
applicable to the recovery of many recombinant proteins from unclarified mammalian 
cell feed streams.  
Aims  
Develop a process for protein recovery directly from unclarified mammalian cell feed 
streams and demonstrate reactor harvest integration 
Chapter objectives 
• Show	  that	  CHO	  cells	  can	  survive	  passage	  through	  a	  scale	  down	  radial	  flow	  column	  packed	  with	  large	  diameter	  beads.	  
• Optimise	  conditions	  for	  IMAC	  protein	  capture	  from	  model	  and	  cell	  containing	  feed	  streams.	  	  	  
• Compare	  recovery	  of	  HIS-­‐tagged	  CEA	  from	  unclarified	  and	  clarified	  feeds.	  	  
• Integrate	  primary	  recovery	  into	  reactor	  harvesting	  and	  assess	  robustness.	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5.2 Results 
5.2.1 Design of Scale Down Radial Flow Column  
Colum design was influenced by a number of factors such as frit porosity and scale 
down ratio (Fig 2.1). The average diameter of CHO cells (14.02µm -15.21µm (Han et 
al., 2006)) and the diameter of the beads were both limiting factors on frit pore size. 
Pores over 300µm would allow the resin to escape whilst pores too small would not 
let individual or aggregated cells pass through the column causing fouling. CHO cell 
aggregates in shake flask cultures did not exceed 30µm in previous shake flask 
cultures hence pores of 40µm and 200µm were chosen for pilot experiments using 
shake flask feed stocks of CHO-S at a density of 1x106 cells/mL (97.4% viable). 
Whilst both these pore sizes would theoretically allow for cell passage it was 
hypothesized that the 40µm pores would create areas of high shear and thus cell 
disruption. Results from these experiments showed that feed passed through the 40µm 
pore size frit dropped in terms of cell density and had a reduced (19.38% +/-2.3%) 
viability indicating cell shearing during column passage as determined by the Trypan 
blue exclusion assay. The average size of particles in the column flow through and the 
total count was also substantially reduced in comparison to the original feedstock 
(Figure 5.2). In contrast, cells remained viable (97% +/-2.2%) when the feed was 
passed through a 200µm porous frit accompanied by an increase in the average size of 
particles in the flow through. In light of these pilot results all further experiments 
were carried out using the 200µm porous frit. 
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Figure 5.2 Column flow through particle size distribution of CHO cells passed 
through a scale down radial flow column. CHO-S cells were cultured in 300mL of 
CD-CHO media in shake flasks to generate a model feed stream of cell density 1x106 
cells/mL and viability >95%. The CHO cell feed stream was applied to the column, 
whilst maintaining agitation of the shake flask, at a flow rate of 1CV/min through a 
scale down radial flow 5mL column packed with CellThru large diameter bead resin 
and fitted with frits of either 40µm or 200µm pore size. The particle size distribution 
was analysed both prior to application of the feed stream and in column flow through 
samples using a CASY Cell Counter Analyser System (Roche) with appropriate 
dilutions.   
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5.2.2 Packing of scale down radial flow column and resin charging 
Column packing was carried out according to the manufacture’s instructions. 
Packing of a radial flow bed requires careful monitoring of conditions to ensure the 
resin is not over pressured. Due to the trapezoidal geometry pressure characteristics 
are different to packing an axial column with a very rapid increase in pressure after a 
shorter period of low pressure as the column is progressively loaded with resin. In 
this chapter a micro-RFC column with 6cm bed height was loaded with Sterogene 
CellThru Bigbead IMAC resin. 
5.2.3 CHO cell passage through radial flow column  
Having established that the 200µm frits allowed an acceptable cell survival rate 
(97% +/- 2.2%) using a feedstock that contained a maximum of 1x106 cells/mL, the 
effect of increased cell density was assessed. Feed streams generated in shake flask 
cultures were diluted to a range of cell densities from 0.5 – 8.5x106 cells/mL at 100% 
viability reflecting the highest cell densities achieved with the stable CEA expressing 
cell line during previous work. Greater than 98% of cells remained viable in flow 
from feed streams with >1x106 cells/mL (Figure 5.3 A). This data was confirmed via 
analysis of cell lysis indicators including host cell DNA (hDNA) and proteolytic 
activity using qPCR and FRET protease assay respectively. These markers showed 
no significant difference between pre/post column samples (P>0.05) (Figure 5.3).  
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Figure 5.3 Analysis of unclarified feed streams containing different densities of 
CHO cells before and after passage through a scale down radial flow column 
with BigBead resin. CHO cells were cultured as described previously in shake flaks 
and re-suspended to a final cell density of 0.5, 1, 2, 3, or 8.5x106 cells/mL. The 
model feed streams were passed through the scale down column using the 200µm 
pore frits and flow rates of 1CV/min. Samples of each feed stream and a media only 
control were taken prior to and after column flow and the cell viability, CHO cell 
DNA and protease content of the feeds analysed. A) Percentage cell viability of 
unclarified feed stream in pre-column, flow through and washing conditions as 
determined by Trypan Blue exclusion. B) qPCR quantification of host cell DNA in 
pre-column and flow through conditions. C) Quantification of supernatant protease 
activity in unclarified feed stream and maximum cell lyses samples using a FRET 
assay (Life Technologies). Analysis of column flow through from different cell 
density showed that there was a small reduction in cell viability in the 0.5x106 
cell/mL feed stream but no such reduction in the at higher densities. There was also 
no change in the amount of protease activity or host DNA in pre and post column 
samples. Figures show mean data and error bars one standard deviation (n=3).   
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Although cell density and viability were measured with using the Trypan blue assay 
this did not control for lysed cells or, importantly, any aggregated matter from cell 
lysis or resin particles escaping in the flow through. Cell integrity and aggregate 
presence was assayed via examination of the particle size distribution of feed streams 
pre and post column. Counts of particulate matter from cell lysis and protein 
aggregation (<6.7µm) and larger particles such as cell aggregates (>22µm) increased 
in proportion with cell density. There was no significant difference at cell densities 
of 0.5, 1, 2 and 8.5x106 cells/mL. These data verified that CHO cells survived 
passage through the column without significant detrimental effects when feed with 
up to 8.5x106 cells/mL was applied to the column. 
Column washing is important to ensure the eluted product is as free of potential 
contaminants as possible prior to further down stream processing steps. In this case, 
as the solid-liquid separation steps are combined, there is potential for an increased 
amount of contamination as cells, the cause of most contaminating factors, are 
present during product capture. The column was washed with 10CV resulting in 
effective DNA clearance (zero detection), a decrease in proteolytic activity to <0.15 
units/mL and a low particulate count (Figure 5.3, Figure 5.4). Furthermore, although 
cells were found in the first 2 column volumes of column washing there was 
complete clearance of cells by column volume 5. These results reinforced previous 
results showing that cell passage through the column did not create extreme shear 
environments that affected contamination of product, including at increased cell 
densities.
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Figure 5.4 Particle size distribution of crude feed streams applied to a scale 
down radial-flow column packed with BigBead resin. CHO-S cells were cultured 
as described previously (Figure 5.3). Samples were removed from both pre and post-
column feed streams as well as from column washes and the particle size distribution 
analysed. Feed stream cell density: A) Media only B) 0.5x106 cells/mL C) 1x106 
cells/mL D) 2x106 cells/mL E) 3x106 cells/mL F) 8.5x106 cells/mL. Blue indicates 
pre-column sample, red flow through and green PBS wash.  
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5.2.4 Model protein binding to IMAC resin in media modelling fermentation 
conditions  
Recovery of His-tagged protein is dependent on the composition of media from 
which it is purified; accordingly, media is usually buffered to favour IMAC binding 
conditions prior to purification. In order to simulate IMAC capture at the end of 
CHO-S fermentation, a 12 day-old non-transfected shake flask culture that had been 
clarified and spiked with 1mg/mL His-tagged ScFv (His-SHMFE) was used to model 
binding of His tagged protein in buffered and non-buffered conditions. Protein was 
recovered using the scale down radial flow bed packed with large bead resin as 
previously discussed. Binding was analysed from both un-buffered and buffered 
media conditions using UV absorbance and SDS-PAGE. Un-buffered media received 
no addition prior to chromatography whilst buffered media was adjusted to 150mM 
NaCl, pH >7.5 and 20mM imidazole. Total product recovery was improved in 
buffered media, 83% versus 61%, as determined by absorbance at 280nm (data not 
shown). UV conductivity and SDS-PAGE resolution of protein captured from 
buffered media showed that the main protein fraction was eluted in CV3 and CV4. 
There was no visible protein band in the column flow through suggesting adequate 
binding to the IMAC matrix (Figure 5.5). The model protein was successfully 
recovered from media conditioned to simulate typical harvest conditions, showing 
that His-tag recovery was feasible using the combination of large bead resin and 
scaled down radial flow column.
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Figure 5.5 UV absorbance and SDS-PAGE resolution of eluted fractions of a 
model His-tagged single-chain variable fragment from conditioned media 
buffered to IMAC binding conditions. Simulated capture of a His-tagged protein 
from media at the end fermentation was achieved using spent growth media that was 
buffered to 150mM NaCl, pH >7.5 and 20mM imidazole and spiked with a model 
scFv (His6-tagged SHMFE) at a concentration of 1mg/mL. The media was run 
through the column at a rate of 1CV/min and capture by the large diameter IMAC 
resin was analysed by UV absorbance and SDS-PAGE resolution. Blue line indicates 
UV absorbance and red line shows conductivity (change from running buffer to 
elution buffer). Red numbers indicate 1mL fraction collection points. Results show 
that there is no protein band visible in the early fractions and a set of bands from 
fractions around the main peak of elution.  
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5.2.5 Buffer Optimisation for His-tagged CEA recovery 
Having established that His-tagged proteins could be recovered from buffered media 
using the model protein, His-tagged CEA purification was optimized after expression 
in stably selected CHO cells. Column application buffer optimisation was performed 
in order to achieve maximum recovery of the target protein from clarified shake flask 
supernatant. There are a number of processes and buffers that would need to be 
optimized in the purification process for CEA (i.e. feeding strategy, column velocity 
and cell density). However the most relevant to this study was the column application 
buffer in order to improve recovery of expressed product without destroying cells. For 
instance cells exposed to excessive NaCl concentrations can undergo lysis and initiate 
protein denaturation due to the presence of proteolytic enzymes.  
Three main factors were investigated as part of an experimental design incorporating 
a central composite, two-level, three-factorial optimisation to investigate the effects of 
pH, NaCl and imidazole concentration on product recovery using a 5mL HisTrap 
column. DesignExpert8 (Shukla et al., 2001) was used to determine the necessary 
experimental grid for optimising buffer composition. One significant factor 
interaction was found between pH and NaCl concentration (P<0.05) (Figure 5.6 A 
and B). Percentage recovery ranged between ~36%-73%. Reducing NaCl 
concentration at high pH and increasing it at lower pH showed equally improved 
recovery of CEA (Figure 5.6 C and D). The lower pH of 7.5 was selected for further 
experiments to reduce cell stress whilst imidazole was maintained at 20mM after no 
effect was found on CEA yield. However purification at pH 7.5 meant that a high 
concentration of NaCl was required (500mM) with potential negative effects on cell 
integrity.   
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Table 5.1 Design of experiments matrix for optimisation of IMAC binding buffer 
for capture of His-tagged CEA from unclarified CHO feed streams. IMAC buffer 
optimisation was carried out using DesingExpert8 to design an experimental matrix 
using a two-level, three factorial, central composite model.  
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Figure 5.6 Design of Experiments based optimisation of buffer composition for 
IMAC capture of His-tagged CEA. CHO cells stably expressing His-tagged CEA 
were cultured in shake flasks to a density of 8x106 cells/mL. Subsequently, the 
supernatant was centrifuged and filtered prior to buffering to the appropriate pH, 
imidazole and NaCl concentrations as specified in table 5.1. The buffered supernatant 
was passed through a 5mL HisTrap column, eluted and the protein capture analysed 
by ELISA. A) Pareto Chart indicates significant factor interactions above 1 value 
limit (black line). Blue indicates negative effects, orange positive effects and hollow 
significant effects (Factor labels; a = pH, b= NaCl, c= imidazole). B) Factor 
interaction of NaCl and pH (Red = 500mM NaCl, Black = no NaCl addition). C) 2D, 
and D) 3D surface response curve (heat map) of His-tagged CEA capture. 
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5.2.6 Cell survival under IMAC buffering conditions 
Whilst buffer optimization had been shown to increase the percentage recovery of 
CEA from supernatant, the resulting exposure of cells to the high NaCl concentration 
required was anticipated to affect the viability and robustness.  
The effect of high salt concentration and IMAC buffering on cell viability and feed 
characteristics were determined over an hour-long incubation. Viability of cells 
reduced by ~2% and 5% respectively in shake flasks with 200mM and 500mM NaCl, 
whilst feeds exposed to higher NaCl concentrations lost a much greater proportion of 
viable cells; up to 34% (Figure 5.7 A). Microscope observations indicated that above 
750mM NaCl there was a build up cell aggregation as well as reduced viability.  
Consequently binding buffer composed of 500mM NaCl, pH 7.5 and 20mM 
imidazole was selected for use in further experiments. The impact of IMAC buffer on 
cell robustness during column passage was tested by passing CHO-S cells in buffered 
media through the column to determine the impact on column passage.  
Percentage viability in the flow through remained >98% whilst host contaminants 
remained low, with protease activity < 1units/mL and 2ng/µL hDNA (Figure 5.7 B 
and C). Particle size distributions corroborated these results showing no significant 
difference (P>0.05) between pre-column and flow through samples (Figure 5.7 D) as 
seen previously with scFv. The results indicated that the optimised IMAC buffer did 
not substantially affect cell characteristics, nor negatively affect protease levels in the 
feed or eluted fractions.  
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Figure 5.7 Cell survival and column flow characteristics of feed stream under 
optimised buffer conditions. CHO-S cells were cultured to 8.5x 106 cells/mL in 
shake flask cultures (>95% viability) before being buffered to the appropriate NaCl 
concentration in 300mL. A) The survival of CHO cells in buffered media with 
increasing NaCl concentration was analysed at 10-minute intervals over the course of 
60min whilst being maintained under incubation conditions using an automated cell 
counter and Trypan Blue exclusion assay. The results showed that CHO-S cells 
survived up to 500mM NaCl with little effect on viability. B) Protease activity in 
unclarified CHO-S feed streams compared to maximum cell lyses samples after 
column flow buffered with 500mM NaCl, 20mM imidazole and pH 8.5. C) Host cell 
DNA in pre-column, flow through and wash samples cells passed through the radial 
flow column when buffered to optimum IMAC binding conditions. D) Particle size 
distribution (PSD) of feed stream passed through the column buffered with 500mM 
NaCl, 20mM imidazole and pH 8.5. These results show that the optimised IMAC 
binding buffer does not negatively affect the amount of host cell contaminants or 
amount of cell damage during column passage. Results show mean data with error 
bars one standard deviation (n=3).  
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5.2.7 Comparing recovery of His-tagged CEA from unclarified and clarified 
shake flask feed streams  
The effect of media clarification on CEA-His recovery was investigated in the radial 
flow column and compared with recovery from a packed-bed, axial flow column 
(HisTrap). Recovery using the HisTrap column was hypothesised to be greater than 
the large bead IMAC resin in part due to the advantages of packed bed over large 
bead resin (i.e. greater surface area), however this column was used as a bench mark 
for comparison purposes.  
CHO cells expressing CEA-His were cultivated in fed-batch shake flask conditions 
for 12 days (Figure 5.8 A). Feed was buffered and applied to the column either 
clarified or unclarified. Cells from the unclarified feed remained ~97% viable in 
column flow-through with low contamination levels of  >1 unit/mL protease activity 
and >2ng/µL hDNA (Figure 5.8 B and C) and a particle size distribution that was 
indistinguishable from results with the scFv model protein (Figure 5.4). No difference 
in proteolytic activity was observed between unclarified and clarified feeds (Figure 
5.8 B), however the hDNA quantity decreased in both clarified feeds, (1.95ng/µL 
from radial flow and 0.78ng/µL from HisTrap columns compared to 2.77ng/µL from 
unclarified feed). Protein recovery was higher from clarified media than from 
unclarified media (Figure 5.8 C), with the standard packed-bed HisTrap column 
achieving ~89% recovery, the radial flow ~78% and unclarified feed ~71% (Figure 
5.8 D).  
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Figure 5.8 Comparison of crude and processed feed applied to RFC system 
packed with large diameter resin. HIS-CEA expressing CHO-S cells were cultured 
in shake flasks over a period of 12 days using fed-batch mode culture. The feed was 
separated into 3x300mL final volume and applied to the radial flow column in either 
an unclarified or clarified state or to an axial flow HisTrap column of the same 
volume after being buffered to optimised IMAC conditions or to the manufactures 
instructions. A) Fed-batch shake flask growth of CHO cells expressing His-tagged 
CEA. B) Viable cells/mL before and after passage through column. C) Protease 
activity in crude and processed feed streams after column flow through. D) 
Percentage recovery of His-tagged CEA from crude and processed feed streams as 
determined by ELISA. These results showed that recovery was improved in the 
HisTrap column as expected and that there was also an improved recovery in the 
radial flow column from clarified feed. Graphs show average data with error bars 
representing one standard deviation (n=3).   
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5.2.8 Generating a feed stream using bioreactor based fed-batch culture of 
CHO cells stably expressing recombinant CEA 
A feed with increased volume, cell density and productivity was generated using a 
PBS3L single-use technology bioreactor. Cells were inoculated at a density of 0.3x106 
cell/mL with feed addition commencing 3 Days into fermentation. Once cells reached 
~10x106 cells/mL the fermentation temperature was reduced to 35°c in order to 
improve glycoprotein expression and extend viability of the culture. The bioreactor 
feed had an increased cell density and product titre compared to shake flask growth 
(11.8x106 cells/mL and 7.2µg/mL CEA) (Figure 5.9 A and B).  
 
Figure 5.9 His-tagged CEA expression in a 3L fed-batch bioreactor 
fermentation. HIS-tagged CEA expressing CHO-S cells were cultured in a PBS-3L 
single use technology pneumatic bioreactor system (PBS Biotechnology, CA) under 
fed-batch conditions. Cells were seeded at 0.3x106 cells/mL and reactor conditions set 
to 37°C, 25RPM vertical pneumatic wheel agitation, pH 7.2 and DO>30% via PID 
control. Feeding was started at 3% total volume (v/v) /day using CD-CHO Efficient 
Feed B as described previously after Day 4. On day 6 temperature and agitation were 
reduced to increase the length of fermentation and amount of glycosylated protein as 
described by (Nam et al., 2008). A) Fed batch fermentation of CEA-expressing CHO 
cells in SUT-3L PBS bioreactor.  B) Time course of CEA expression in bioreactor 
fermentation as determined by ELISA.  
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5.2.9 Integrated recovery of His-tagged CEA via radial flow chromatography 
direct from bioreactor fermentation 
A significant advantage of removing the requirement for solid liquid separation is that 
primary capture can be integrated directly into bioreactor harvest. As such a system of 
pumps and valves was designed to allow the multiple steps of primary capture to be 
carried out whilst the column remained in situ (see Figure 5.10). The inclusion of 
multiple buffer holding tanks and DSP process end points (i.e. elution, waste, washing 
and further DSP) enable simple charging, recovery and washing of the column.  
Feed was harvested via passage directly through the column in 1L batches with 
subsequent regeneration to ensure consistency (see Methods 2.11). Cell viability and 
feed stream characteristics were not significantly different to previous experiments. 
Average product recovery was 69% (+/-6%) giving a final pooled sample yield of 
14.6mg of His-tagged CEA as determined by ELISA. Fractions from individual 
purifications were diluted to 1µg/mL for Western blotting and were visualised using 
both anti-CEA and anti-His antibodies (Figure 5.11 C and D). There was no visible 
difference between subsequent purifications. CEA, but no His-tag, was identified in 
flow-through from the column indicating that His-tag recovery was efficient and the 
apparent lower yield compared to equivalent shake flask material was due to untagged 
or degraded CEA passing through the column.  
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Figure 5.10 Process flow diagram of integrated radial flow chromatography 
control system. Integration of the radial flow system directly into the reactor harvest 
line was achieved using a combination of buffer storage tanks, pumps and control 
valves. Primary harvesting of the reactor in 1L batches (valves 1 and 3 open) was 
followed by washing (valves 2 and 3 open) and then elution (valves 2 and 4 open). 
Integration of the radial flow unit was carried out using a sterile Masterflex C-FLEX 
tube-welding unit to allow for cell culture to remain sterile at all times.  
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Figure 5.11 Western blotting of eluted fractions from reactor purification via 
radial flow chromatography. Samples removed from the bioreactor culture, column 
flow through and elutions were probed using an anti-CEA antibody (made in house) 
or an anti-HIS antibody (Qiagen, Netherlands) in order to asses the purity and success 
of CEA capture before both antibodies were detected using an HRP-conjugated anti-
mouse antibody (R&D, UK). A) Anti-CEA western blot of radial flow column eluate. 
B) Anti-His western blot of radial flow column eluate. All elutions and positive 
controls were diluted to 1µg/mL prior to western blotting. Elution refers to separate 
experiments NOT fractions. The results suggest that whilst there is a substantial 
amount of CEA remaining in the flow through after column passage there is a good 
concentration rate of the HIS tag from the supernatant. Neither figure shows any 
staining activity in washing samples.  
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5.3 Discussion 
The aim of this chapter was to develop and evaluate a system for primary recovery of 
recombinant proteins from unclarified CHO cell feed streams. Primary recovery 
techniques for recombinant proteins expressed in mammalian cells currently requires 
laborious solid-liquid separation prior to chromatographic capture. This process has 
been estimated to account for between 50-80% of the cost of production for some 
proteins (Levy et al., 2014). Process efficiency can be achieved by the better 
integration of steps directly following the bioreactor stage as these currently have 
large impacts on cost (Warikoo et al., 2012), with the added benefit of  reducing 
process volumes, CAPEX, operator costs and consumables.  
 In this chapter an integrated primary capture step for recovery of secreted, 
recombinant proteins from unclarified mammalian cell feeds was developed using 
scale-down radial flow chromatography operated with large diameter resins.  
Previous chapters in this thesis have focussed on methods for rapid production of an 
Fc conjugated scFv (scFv-Fc), however here the target antigen from previous 
chapters, recombinant HIS-tagged CEA, was chosen to illustrate the procedure. CEA 
is a heavily glycosylated molecule that is up regulated and secreted in a number of 
cancers and is therefore of interest as a therapeutic target of interest. CEA has 
previously been produced either by recovery from ascetic fluids (Hammarström, 
1999., Sigma Aldrich) or in the yeast Pichia pastoris. However yeast expression has 
only achieved truncated forms of the protein (Hellwig et al., 1999; Sainz-Pastor et al., 
2006; Tolner et al., 2013). Consequently CEA remains an expensive protein to work 
with requiring expression in mammalian or glyco-engineered insect cells to ensure 
correct glycosylation for structure and function.  
As with other proteins that lack a natural purification tag primary capture can be 
facilitated by the addition of an affinity based capture method. The application of a 
His fusion tag is a simple and convenient purification technique for many proteins 
including CEA and IMAC capture offers a comparatively inexpensive, robust and 
versatile alternative to protein A/G based chromatography (Young et al., 2012). 
Whilst concerns have been raised about the potential of therapeutically redundant 
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purification tags to affect in vivo half life and therapuetic function of proteins, many 
tags are cleavable post-purification (Waugh, 2011) and His tags have been used in a 
number of clinical products without adverse effects (Tolner et al., 2013, Table 37.1).   
The development of the integrated process discussed here took into account a number 
of feed stream factors that could have affected the performance of future process steps 
and recovery. Cell damage plays an important role in the characteristics of feed 
streams (Anspach et al., 1999; Salte et al., 2006) and has been shown to vary widely 
across bioprocess operations (Hogwood et al., 2013; Kim et al., 2013). Here the focus 
was particularly on proteolytic activity and hDNA contamination. Proteases directly 
affect product stability and affinity tag cleavage (Gao et al., 2011) and hDNA 
contamination significantly affects feed viscosity (Balasundaram et al., 2009) and 
must be at minimal levels to meet regulatory standards (Nissom, 2007). Previous 
studies in the area have focussed on host cell protein (HCP) content however this is 
not directly linked to product degradation (Cordoba et al., 2005).  
In this process, cell damage was predicted to occur during column passage, especially 
as the cells traversed the relatively high shear regions of the porous frit. The results 
showed between 2-4% loss of viability and no significant difference (p= <0.05) 
between particle size distribution, protease activity or hDNA content in pre and post 
column samples. By comparison, previous results of direct capture using expanded 
bed adsorption (EBA) from hybridoma cells showed an increase in hDNA 
contamination of up to 54% (Feuser et al., 1999).  
The current benchmark for primary protein recovery is axial packed-bed 
chromatography (as used in most industrial operations); these results demonstrated 
that percentage recovery of CEA was 17.9% greater in an axial packed-bed column 
(89.16%) compared to capture from unclarified feed using the large diameter resin in 
radial flow format (71.6%). In industrial processes His-tag recovery can be as high as 
90% (Saraswat et al., 2013). In this chapter three factors (pH, imidazole, and NaCl 
concentration) were optimised for product capture, therefore a broader optimisation of 
process factors (bead diameter, bed height, load mass, flow rate, cell density, 
temperature etc) would be expected to improve yield.   
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5.3.1 Conclusions 
This chapter shows that primary recovery of recombinant proteins from unclarified 
media is a functional processing technique that can integrate easily with current 
bioprocess tools. Whilst the data presented here demonstrates primary capture of a 
heavily glycosylated, His-tagged CEA molecule, the generic use of CHO cells as an 
expression host suggests that this approach is applicable to the recovery of many 
different proteins using other modes of chromatographic interactions.  
 
 
 
 
 
 
 
 
 
 
 
*The	  work	  presented	  in	  this	  chapter	  has	  been	  published	  as;	  Kinna	  et	  al.,	  2015	  	  
 
 
  179 
 
 
  180 
Chapter 6 Conclusions and future work 
This chapter aims to review and summarise the results of this thesis and provide 
recommendations for the future direction of related work.  
6.1 Development of a rapid and cost effective transient gene expression system 
in mammalian cells for use in lab scale production 
The use of transient expression in mammalian cells to produce recombinant proteins 
at small scale is well documented (Durocher et al., 2002; Wurm, 2004; Ye et al., 
2009; Longo et al., 2013). However, transient expression systems can be cumbersome 
and difficult to scale in order to meet increased demand. They can also be 
prohibitively expensive in the small lab environment leading to submaximal 
screening. In chapter 3 a recombinant protein expression system was developed and 
optimised for rapid, scalable and cost effective production of recombinant proteins in 
suspension adapted 293 cells. The system was used to express the first quantities of a 
model scFv-Fc fusion protein targeted against CEA, which were then characterised 
with an aim to further develop it.  
ScFv-Fc constructs are encoded on a single plasmid and therefore make good model 
proteins for investigating transfection and expression unlike proteins that require co-
transfection of multiple plasmids, such as the light and heavy chains of an antibody 
(Pybus et al., 2014a), which adds a further complication in studying transfection 
efficiency and expression.  
Preliminary transfection efficiency data generated using fluorescent reporter proteins 
showed that the HEK293F cell line was transfected more efficiently with PEI than 
CHO cell lines contributing to greater protein expression. The cytotoxic effects of 
transfection has been shown previously (Jain et al., 2013), and this was evident in all 
transfection conditions investigated here. As high transfection efficiency plays a 
significant role in transient gene expression the combination of the HEK293 cell line 
and PEI reagent was optimised in terms of DNA: PEI ratios to improve expression. 
Previous optimisations of PEI to DNA ratios in transfection of cell lines have varied 
from 1:1 to 5:1 dependant on cell lines (Fang and Shen, 2010; Thompson et al., 2012; 
Xie et al., 2013; Longo et al., 2013), however these figures may differ significantly 
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based on batch-batch variation when PEI solutions are made in-house and could 
therefore require optimisation on a ‘per-batch’ basis. The results presented here show 
that the optimum ratio was 2:1 (PEI:DNA) for transfections. Using linear 25 kDa PEI 
solutions made in-house cost in the region of £0.70/mL compared to £405.00/mL for 
the commercial reagents tested and is used in similar quantities during transfection 
(prices correct as of Feb 2016 – suppliers Polyscience, Germany and ThermoFisher 
Scientific, UK).  
Scale up of transient gene expression was carried out using a linear 10-fold increase 
of culture volume and transfection solution from 30mL-300mL-3L including the use 
of shake flasks and a pneumatic SUT bioreactor. Scale-able transient transfection has 
been carried out using a number of methods including transfection and electroporation 
of high cell density cultures prior to expansion (Backliwal et al., 2008b; Baldi et al., 
2007) and linear increases in transfection solutions such as those used in most 
commercial kit reagents. The results shown here indicated that there was an 
improvement in yield at a scale of 300mL, however all conditions were comparable in 
terms of cell growth and protein yield. The simplicity of a linear increase in 
transfection solution and no requirement for further process optimisation at increased 
capacity are the main advantage of this scaling method compared to a number of other 
techniques.  
Stability characterisation of scFv-Fc produced using the different scales and reagent 
combinations tested showed there was no difference in the quality of the proteins. The 
DSF assay is now well established in determining and comparing stability between 
similar proteins including those with aggregation potentials and is also routinely used 
in screening ligand interactions involved with protein stability (Niesen et al., 2007; 
Menzen and Friess, 2013). DSF has been directly compared with differential scanning 
calorimetry (Wen et al., 2012; Shi et al., 2013) showing comparable results, however 
the DSF assay does not carry the cost of DSC in equipment outlay, time or protein 
required for the assay. Combined with more standard protein stability analyses 
techniques the profile presented suggests that the protein was highly stable.  
The scFv-Fc was also analysed by surface plasmin resonance in a Biacore T200 
resulting in very high estimations of binding affinity. This was confirmed by in vitro 
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binding indicating that the construct had both a high affinity and selectivity for CEA. 
The results shown contributed significantly to continued development of this protein 
candidate and to methods used for the production of a number of other recombinant 
proteins.  
The cost of commercial transfection reagents and protein analysis assays can prove 
limiting when factors such as scale and multiple transfections are considered, 
especially in the small lab environment. This work shows that comparatively 
inexpensive reagents and techniques can be used to great effect without reducing 
quality of results or productivity of recombinant proteins.  
6.2 Stable integration and expression of SM3EL-Fc in CHO-S cells and 
comparison of product stability 
The scFv-Fc investigated in chapter 3 produced promising results during 
characterisation. A production system with greater capacity was required to increase 
yield and further reduce costs for larger quantities of recombinant protein for further 
investigation. In chapter 4 methods to rapidly obtain a stably expressing population to 
increase protein yield were assessed.  
During characterisation and preclinical phases of development clonal populations are 
not necessary unlike for clinical grade use. Whilst heterogeneity should be avoided 
when characterising products, there is a level of heterogeneity even in clonally 
produced proteins (Pilbrough et al., 2009). The application of stable cell based protein 
expression to rapid protein production has been discussed previously (Ye et al., 2010), 
as has the difference in transient and stably expressed glycoproteins (Ye et al., 2009) 
suggesting that there is no difference in the activity of proteins due to their 
glycoprofiles after expression in different systems. Stable cell pools used in early 
production stages provide all the benefits of stable cell expression as well as reduce 
mass DNA production and variability between transfections.   
Two DNA integration systems designed to increase expression in stable cells and to 
allow for rapid selection and cell line developments were investigated in chapter 4. 
Whilst flp-mediated stable cell generation was unsuccessful, cloning the model scFv-
Fc into a UCOE expression vector did allow for stable cell selection. Isogenic cell 
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technologies have generally been used for research purposes as opposed to production 
in the literature, however site-specific recombination has been used for high 
expressing cell line generation (Codamo et al., 2011)   Unlike flp-mediated 
integration, which yields an isogenic population, expression using the UCOE vector 
produces a variable population. However any variability in genomic insertions does 
not negatively effect the characterisation or activity of the protein during early stage 
development (Ye et al., 2010).  Similar vector-based techniques for ensuring active 
chromatin regions at transgene insertions include scaffold/matrix (S/MAR) and, 
alternatively, bacterial artificial chromosomes (BACs) (Kunert and Casanova, 2013).  
Comparing transiently expressed protein, which has associated heterogeneity, with 
protein from stable cell pools showed no difference in stability or effector function in 
this study. Previous comparisons of protein activity have often focussed on 
differences between transient and stably produced proteins or HEK293 vs. CHO 
expressed proteins (Geisse and Voedisch, 2012). These results indicate that 
characterisation data from transiently expressed protein in HEK293 cells is directly 
comparable to stably produced protein using non-clonal CHO populations and that 
stable cell pools can be used effectively in the production of recombinant protein for 
early development.  
6.3 Primary recovery of recombinant proteins from unclarified mammalian 
cell feed streams using radial flow chromatography and large bead IMAC 
resin. 
Primary capture of recombinant proteins from mammalian cells is both a costly and 
lengthy process, as discussed in chapters 1 and 5. Here this challenge has been 
addressed by developing an integrated primary capture step for recovery of secreted, 
His-tagged recombinant proteins from unclarified mammalian cell feeds using RFC 
operated with large diameter resins. As yield is a function of the number of processes 
(Farid, 2011), it is advantageous to remove process steps where possible.  
The improvement in process efficiency yielded from using an integrated capture step 
would result in a reduction in COG/g and has been shown previously with capture 
techniques from unclarified feeds (Schügerl and Hubbuch, 2005). EBA, a format with 
similar process advantages to large-bead resins, has been compared with standard 
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bioprocess techniques resulting in reduced COG/g and simplified recovery in 
microbial and mammalian cell downstream processing (Willoughby et al., 2004; 
Chhatre et al., 2006; Tolner et al., 2013). Similar efficiency gains from the removal of 
clarification steps could be expected with large bead diameter resins. Uptake of novel 
techniques can be affected by concerns over regulatory compliance however the 
combination of RFC and EBA has been applied to unclarified microbial fermentation 
broths using His-tagged proteins previously in cGMP-compliant processes (Tolner et 
al., 2013), showing that adoption of similar approaches does not necessarily introduce 
regulatory hurdles.   
In this thesis the radial flow column has been used with maximum volumes of 1L 
batches and a viable cell density of ~12x106 cells/mL whilst fully integrated into the 
harvest system. Industrial feed volumes, cell densities and protein titers can far 
exceed those used here however ultimately the data presented here shows that there is 
potential for this system to be integrated into larger scale production chains after 
optimization. Whilst further work must be carried out in order to investigate the 
effects of factors such as cell density and protein concentration as well as flow 
velocity on product capture, this primary capture technique has obvious industrial 
applications given that it can reduce the number of processing steps and volumes 
involved in protein purification potentially reducing costs and time for protein 
recovery at many scales.   
6.4 Reducing the cost of recombinant protein expression and purification 
A key part of each of the chapters in this thesis has been to underline the cost 
effectiveness of the techniques used.  
Transient gene expression enables production of recombinant proteins at a far greater 
speed without the associated costs and time of stable cell selection. Transiently 
expressed proteins can also predict the behaviour of those from stable expression 
saving costs on screening proteins. Using PEI, a significantly cheaper transfection 
reagent than those in commercially available kits, reduced the cost of transfection and 
is available as a GMP compliant reagent permitting its use in early and late stage 
clinically relevant transfection.  
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Stable cell based expression using a UCOE expression facilitated larger scale 
production of recombinant protein without the need to produce DNA and transfect on 
multiple occasions. This simulated selection of a lead candidate after screening many 
proteins by transient expression. In order to produce large quantities of protein, high 
expressing stably selected cells and an optimised feeding and growth strategy proved 
the most efficient production method.   
Chromatographic capture of proteins and primary recovery is often the most 
expensive part of protein separation. In chapter 5 a method is proposed that can 
remove the need for solid liquid separation entirely saving all associated costs. Some 
estimates put this cost as high as 80% of total process cost that could be partially 
saved. 
 The methods for production, purification and analysis of recombinant proteins in 
suspension adapted HEK293 and CHO cell lines discussed here can be used by many 
labs engaged in early stage screening of drug candidates. The protocols and 
techniques have been selected to address the necessity for rapid, simple and 
inexpensive production at lab and preclinical stages of development and can therefore 
form a methodology for those aiming to complete similar projects. 
6.5 Future work  
The results presented in this thesis show that a simple, cost effective and rapid 
expression system can be used to produce sufficient recombinant proteins (both 
antigen target and targeting antibody) for early screening of novel drugs. 
Characterisation of proteins from transient expression in HEK293 cells provided a 
reliable platform for the selection of candidates of interest and subsequent scale up of 
production.  
Whilst the yield of the model scFv-Fc construct used here was sufficient for 
characterisation and further study, there is significant variability in the expression of 
even highly similar proteins. Hence, more difficult to express proteins can require 
further improvement to obtain sufficient protein expression. This can sometimes be 
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achieved using engineered tags to improve expression and solubility levels of the 
target (Young 2012). Glycosylation of recombinant proteins and its importance has 
been discussed here however was not analysed as part of this data, future work should 
include analysis of the variability of these systems in terms of glycosylation effect.  
Recombinant protein expression has been shown to increase when rates of cellular 
division are inhibited, either to slow it or to halt it (Dietmair et al., 2012; Dinnis and 
James, 2005). Techniques that have been used to induce a stalled cell cycle include; 
nutrient limitation, reduced pH, reduced temperature or hyper osmotic pressure 
(Dinnis and James, 2005) as well as cell cycle inhibitors, such as the P53 regulated-
Gadd45 protein (Kim et al., 2014, p. 45) or P21/27 (Ibarra et al., 2003), in 
combination with cells adapted to high cell density culture.  Cell cycle control 
techniques have also been used in combination with electroporation methods as well 
as lipofection based methods (Golzio et al., 2002). 
Biphasic (two phased) culture of cells uses these findings to create a high cell density 
in the first phase of growth with rapid cell division, followed by a secondary phase 
with division inhibited but growth enhanced. Thus the primary growth stage is shorter 
than usual and the secondary production phase enables a greater titre than single-
phase growth. Research has been carried out that incorporates numerous methods for 
increasing expression including those discussed above to great effect (Codamo et al., 
2011).  
Further work may include establishing a simple method to transfect cells at an 
increased cell density and optimisation of the recovery time prior to cell cycle 
inhibition. Of particular interest is reduction in temperature to induce cell cycle 
inhibition as this represents the lowest costs.  
Other reported methods to increase transfection efficiency include synchronisation of 
cell cultures prior to transfection as discussed by Grosjean et al (2002) and since in 
some commercial kits. This enables the addition of the transgenic DNA within the 
optimum cell cycle stage for efficient transfection yet has not been widely revisited 
These techniques alone or in combination may well provide further increases in 
transfection efficiency for both transient and stable based protein expression.  
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The use of transiently expressed scFv-Fc has been shown here to be a good model of 
stably expressed product however; the variable expression performance of numerous 
protein scaffolds suggests that this may not be true for all proteins. It would therefore 
be advantageous to characterise the effects of cross-cell and expression type variation 
based on protein scaffold.  
In chapter 5 a technique was developed to capture His-tagged protein from unclarified 
mammalian cell feed streams. The process utilised IDA chelating agarose beads of 
between 300-500µm in diameter forming a packed resin charged with nickel. 
However, a range of resins are available differing in construction, functional groups, 
bead size and packing density (Hochulial., 1987; Bornhorst and Falke, 2000; Warren 
and Bettadapura, 2005; Saraswat et al., 2013). These variables are expected to have a 
significant impact on performance and feed stream characteristics e.g. bead diameter 
will directly affect interparticle porosity affecting cell travel through the column, fluid 
dynamics and the shear rate experienced by the cells thus affecting protein yield.  
Initially a protein A based resin was imagined for capturing proteins from unclarified 
feeds, however its associated costs proved prohibitive. It would therefore be worthy 
of further investigation for the recovery of high value Fc containing proteins which 
make up a huge portion of the biopharmaceuticals industry. Whilst HIS-tag based 
capture has been used in GMP settings, protein A based capture has the advantage of 
being routinely used in GMP compliant processes. This being said, IMAC capture of 
proteins with naturally occurring histidine rich regions has also been demonstrated, 
including in antibodies and antibody fragments (Todorova-Balvay et al., 2004; 
Cheung et al., 2012). Hence, another area for further investigation could be the 
possibility of utilising comparatively inexpensive IMAC resin for large scale primary 
capture of antibody based molecules prior to polishing using the more expensive 
protein A resin.  
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Cluster alignment of 3 affinity matured scFv constructs targeting CEA. shMFE23 –
humanised version of MFE23, shMFE- shmfe23 with further stabilising 
modifications, SM3E stabilised and humanised with G4S linker.   
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